var title_f9_25_9616="Interincisal distance";
var content_f9_25_9616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Measurement of interincisal distance",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 577px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tongue is placed at the posterior edge of the upper teeth, and the mouth is opened as widely as possible. Measurement (in millimeters) is taken between the teeth, as illustrated above.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9616=[""].join("\n");
var outline_f9_25_9616=null;
var title_f9_25_9617="Pediatric spine board";
var content_f9_25_9617=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59634&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Immobilization on spine board",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9617=[""].join("\n");
var outline_f9_25_9617=null;
var title_f9_25_9618="Biotin (vitamin H): Pediatric drug information";
var content_f9_25_9618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Biotin (vitamin H): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1056859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Biotinidase Deficiency, Treatment Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Water Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate intake (AI): 5 mcg/day (~0.7 mcg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Biotinidase deficiency: 5-10 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1056858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adequate intake (AI): Infants, Children, and Adults: There is no official RDA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1 to &lt;6 months: 5 mcg/day (~0.7 mcg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-12 months: 6 mcg/day (~0.7 mcg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     1-3 years: 8 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     4-8 years: 12 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-13 years: 20 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     14-18 years: 25 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 30 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Biotinidase deficiency: Infants, Children, and Adults: 5-10 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Biotin deficiency: Children and Adults: 5-20 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F238960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capsule: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1056863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be administered without regard to meals",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1056862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of primary biotinidase deficiency; nutritional biotin deficiency; component of the vitamin B complex",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1056865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to biotin or any component",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1056867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Large amounts of raw egg whites prevent biotin absorption",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1056861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum biotinidase activity",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1056857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A member of the B-complex group of vitamins; biotin is required for various metabolic functions such as gluconeogenesis, lipogenesis, fatty acid biosynthesis, propionate metabolism, and the catabolism of branched-chain amino acids; there are 9 known biotin-dependent enzymes; the enzyme biotinidase regenerates biotin in the body and is also required for the release of dietary protein-bound biotin.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Biotinidase deficiency is an autosomal recessively inherited metabolic disorder characterized by deficient activity of the enzyme in serum. Children with the disorder usually exhibit seizures, hypotonia, ataxia, skin rash, alopecia, metabolic ketoacidosis, and organic aciduria.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      McVoy JR, Levy HL, Lawler M, et al, &ldquo;Partial Biotinidase Deficiency: Clinical and Biochemical Features,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1990, 116(1):78-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9618/abstract-text/2295967 /pubmed\" id=\"2295967 \" target=\"_blank\">",
"        2295967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salbert BA, Pellock JM, and Wolf B, &ldquo;Characterization of Seizures Associated With Biotinidase Deficiency,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1993, 43(7):1351-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9618/abstract-text/8327137/pubmed\" id=\"8327137\" target=\"_blank\">",
"        8327137",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine, &ldquo;Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B",
"      <sub>",
"       6",
"      </sub>",
"      , Folate, Vitamin B",
"      <sub>",
"       12",
"      </sub>",
"      , Pantothenic Acid, Biotin and Choline,&rdquo;",
"      <i>",
"       National Academy of Sciences",
"      </i>",
"      , Washington, DC: National Academy Press, 1999. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wastell HJ, Bartlett K, Dale G, et al, &ldquo;Biotinidase Deficiency: A Survey of 10 Cases,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1988, 63(10):1244-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9618/abstract-text/3196050/pubmed\" id=\"3196050\" target=\"_blank\">",
"        3196050",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13071 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-4F5D24ED7D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9618=[""].join("\n");
var outline_f9_25_9618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056859\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442086\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056858\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F238960\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056863\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056862\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056865\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056867\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056861\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1056857\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13071\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13071|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_25_9619="Three types of holoprosencephaly";
var content_f9_25_9619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Three types of holoprosencephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 203px; height: 600px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJYAMsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6C8feMrPwVplpeX1lf3ourkWscVkqM+7y3kyd7qMbY27+nFcC37QWgKhY+HvEuB/0ztf/AI/Vv9o64NroHhmZcZXWl6/9elyK4zV7Xw94a+Cvge70rwR4Z1bxVrNrp9raR3emxSefNJErO7nAJ4zklhywJNAHSx/tD+HZG2poHiUn08u2/wDj9OH7Qvh4sVHh/wASZ9PLtf8A4/XI69D4U179nZPFmm+FtA0zVvNtFmazsI4ngmW8iSQKQNyg88ZztbkmvJFTdJ5/8Ibn6UAfRn/C/wDQgoY+HvEmD0+S1/8Aj9QS/tFeG4vv6D4kH/bO1P8A7Xrwy12TyvGWGFGU965K+lMV60Ug+UE0AfTv/DR3hnZv/sLxLt6Z8q2/+P0f8NH+GMA/2F4kwf8Aplbf/H6+W45iY2UdAcii4lVPLYdGGCKAPqBP2lPCr526J4kOOv7q2/8Aj9N/4aY8J5x/YviTP/XG3/8Aj9fKKtmYheN1EsRjOTQB9W/8NM+Es4/sXxJn/rjb/wDx6lP7TPhIEg6L4k/782//AMer5QVcsQRyelRvnJLdelAH1n/w0x4Sxn+xfEuP+uNv/wDHqkP7SPhcIH/sLxLtPQ+Tbf8Ax+vlKSBhApx8rDIq7Yy7tPZCMlOPwoA+nG/aX8JqwB0XxJk/9Mbf/wCP1qXHx50a3s4rqbw34lW3l+4+y1Ofynr4+mhZBuxxnrXeWmsxXfg+K2lI3wtxmgD3aP8AaQ8MSkhNC8Skjk/ubb/4/Ulv+0V4buJCkOg+JGYdvKth/wC16+Wkuo7e+OB8pyKtaXdpBdTZ9Mg0AfTbftF+G1zu0HxLwcH91bf/AB+nR/tD+HZJhEmgeJTJjOPLten/AH/r5fs71JZ7hZDw5yKuWFwrXgfPKDFAH0sv7Qnh9iQPD/iUkf8ATO1/+P02X9ofw7Eu6Tw/4lA/652x/wDa9eDaTCkxlmz8oNJeWqvdLEMYNAHu6/tGeGmQMNB8S7Txnyrb/wCP1JD+0N4emJEXh/xKxHX91bf/AB+vnxbIIl2g6LytS28Qt1jkXo+CaAPpXwp8aNE8R+KtP0CDSNctLy+LiKS6jgEY2RtIclJWPRD264r1Cvkf4VyrN8Z/CLKMYmuR/wCSk9fXFAHkH7S9rLe+GPDsFuMytrAIH0tLk/0rjNJ1j4aanongKXxjd6lPd+HtJitTpk+k3Etr5phVJC6+QQ5BXghsfKDzXcftHzy2vh7w3LBnzF1njHvZ3QP6GvC0kUuTMBtcYbPagDqvFGr/AA9sPh54j0LwXqepSNrOp296ljLYTxwwEXMTOIiYVCIETOCT90AV5k1wI0mtx8yHoataqqNHiHkRt19qrrAttcBpeY3G4UAVbaOdYopo2O+NsMPajUYoriUs+BIRStdrC8hi+6cgVRWZ7i9QnoRigCnqEaw+UYz94YYVXeGSZQwBwK2r3TGjltzLwHatbUbaC307fAASB82KAOQSzk8kzAfdPNT3UamFcn5q19NieeAj+FlPFZt2iqsZY9iKALN3DCkdrIgGeN1Y+oogu3CfdPNWftKmFOelU7yRXnLLyMUAXFuRLaRxAfMnNSWNvIolAXgisy2l8p9xHFdBbapDEwGBhkwaAI7u0ZdMSTbway7XzPKYJ93PNbl/qcbacsK+pxVPRWjkW5Q4yVyPrQBkSKTMc0qAsSVPOK1pLNfJ8w/eYVnJA6TKV5HegCqCynIyDnrUkNzJFIWB69auyW6lXUDmqa2zPEzAcqeaANjSNZaCCSMnhq0P7Y3XiSZHC4rkCCGxT0cgEg0AdtFqkclrM2fmzVi2mElvBn7pbArhFmYIwBPPat2y1JU06JWPzq1AHp3wmgC/F3wrIOn2q4X/AMk7ivravkn4LXK3PxE8KNkbvt0/5fYrmvragDy34+mIaX4V+0ECL+2sMT2/0O6r508UOjapILMkRKMDHeveP2ot3/CIeH9md39srjH/AF63NeDWsSxkrdD5gucmgCtLbyxWpmcfKcA1mT3R2FZSDjlfpVjWdWMtuIoj+6U4asBS99dRKgPpQBJv+0lFj4wea27a0W2mQMMn71U7GGK3V45BiUGtC3u0d3lfoF2gUAQXE8l9O8bcGIZWq8OoIBLbytlZB+RrHn1CRL2SSM4ySKz3kLuWJ9+KANZtRa1uCsLfIARWdPcNKAD61BnPJOaQd6AFyccUhzmgdKOMUALRSCl75oAUkkYJ6U+3meF9y9aiNHOcGgC6b+RtoPQGp7C8X7Qd4G08Vl9qBxzQB0hi3yxuvRjzSm0MV/JABw4yKzrG/wBhRW6Cu10lYLvVllbGFQZ/KgDjtQ05omk+U8DNZI4BFeu3OlQ6na3c0AGVXGK891zRZtPn2yIVGM8igDDwcA0oYgEVMFxHUUi4UYoA9J/Z5uHb4weFoSfl864b/wAlJx/Wvtyvhz9nf/ktfhb/AH7n/wBJJq+46APIv2lM/wDCNeHCoyRrAOP+3S5r5w1bUyGPmgbiMEV9GftNSmHwt4ekXqusD/0kua+StVupJLuUk/eoAsXd0jKYYFyX610eg20Gm2LXF0n7wrlMisTw5ZCectJxtGa7C/MVzaW1uE+ZDyfUUAULq0iuLaS/A2/L+dcbc3TJuVDjJzXU6/qIgtPskPEanJ964i5k3zFhwD2oAa7FmJPXNNPWg/rR3oAB0pR0pKBQAEUH3oPX2o7UALSEelAzml9aAE9Pal7UlHUdKACg0e1H1oABkGtXSdUltLgsWOCuKyiKM89aAPUfAOsAajBDK2YZZF3A+ma9M+MPhW2v9LGp6SgZEAD7e3FfPOi3ht5ocHDBuK+kvhXrqaj4Z1KxuyH3/IoPqRQB80XNu0avn+FqqXH3EIrvPFGgy2rXybCNkhHT3ribmLbCPUHFAHcfs7/8ls8LY6b7n/0kmr7jr4c/Z3/5LX4W/wB+5/8ASSavuOgDw/8Aa5laHwBorocMNZQfnbXAr5T09Dc3yK+Tk819Uftf/wDJPNF/7DUf/pPcV88/DrT01DxHZxP9wtyfagD0vwj4Hl1oLFYR8vGGLdhisXxvZnQtW+xtw0fyE+pr6R8FafF4e0HULlR8gJZTjsBXz/4zt5df8SRJIuJXJf8AWgDybWZ2LmI8kHk1k5rZ8V2b6frM1vICCDWKevWgA7UfzoA4oxQAUdqUnikoAMij0HejgUUAHuBS0dqTtQAd8UcUoo+vSgBMflQaB0o6UAHagelHpRQA6FykisOoOa9b+DWplNaSJmxGXVmryLHSur8EX5sb2SQHB28UAfTvizwzaar4J1PUraMGYyNKMf3RXy/fWgj8wOMc5Ar7I+GzR6n8O4lf5lkR1b8a+XfiTpLadqOAMJuIH50AQfs+DHxv8Mf9dLn/ANJZq+4a+JPgGgX43eGD/wBNLn/0knr7boA8M/a//wCSeaL/ANhmP/0nuK8q+D2i+ZN9qK8pjH1Neq/tff8AJPdE/wCw1H/6T3Fch8FwzeXGi5R3RSaAPfvFUyad4QkUADKLEB9a8x8KeHotc8di5B/0a3iyxHr0FehfEl2XRoY8ZR3Cn61D4B02HTNQ1KNDlgqHPtigD5L+Ltv5XjnUUIwscjLXD3KbCgHUjNdx8XboXfjnVXU/L9ob+dcXe/60ewFAFYjGBSH9KfK2589sUBcR5PegBnalFJzijnFABRnnHWnBGIyAaQ8e9AB+FBHajt0p0SF3CryTQA0CnBGIJANdRpfhee4wdhORmussvBJKhHTBaIsKAPKdpAzikNdzd+HQltNhfnVsCuc1PSZrW58vaegNAGTR3pzqVODxim+tACHvV7TJWWc4PaqPXirdgP3px6UAfVnwN8SvHocVi43Ru+0exNcf+0XaC01WONEwuNwPrVf4R6lHaS6ZE3/PYFq7H9prTvMtLC+QcMChoA8j+BWP+F3eFSO73P8A6ST19q18TfAM5+NPhUHqJbkf+Sk1fbNAHhf7YHHw80X/ALDUf/pPcVz37OjFoo1kTdukBz6V0f7XgB+H2ig/9BlP/Sa4rgfgJqM8OqafZwdHlBegD6E+IdxBDpIWY/Ox+TPqK8+8P+Nktb7WJZRkmHap9wOK7j4n2ouNPt2dgqRsWJr5ov8AUVTUL2OE4X5ufWgDgvFty1zq08xPzPIzH86xmcyMWbrVjUpfNmYnruPNQogKD1NAFfP6Uu4njsKRsZOKfHGz52DNADeh61esdOluY94U7ScZq34e0WXVbjYinAGa9M8LaAgsJYpVwYwTn3FAGJH4Zhi0GVzgyqBXGXmlvGmQp3F8CvYbTT5DpV2ZMl3cKq1HqekWCQaR0M8sh8wDtQB5O2jTLp7SlDhTjOKu+ANH/tPxHHbOvavWdTsbEeH2gUAStPj8Kx/h7ZQ2fjXzONqo1AHQ6fp72d3JCsecZUcelVtS1OWG9jK8CNTHXRaFrkEnid/NUGKNHB+tcTqU/ma4YscSOW+nNAGvrmmLbaTZXbLxcjd+NZuqaFFdXKMoHEIJ/Kt3xBfR3Nhp1mWBEKHj0rPaWWHSUmYHcxK/hQB5f4k8Pm3nwi8nFczqFo1pOY2Br2TVYVmvbWWQZQ4Nea+Mthu5XUdXIoA5k+ta/he1N5qiQgZyM1kd8V0XguYW2ovL1IXA+tAHpHw6tlOsQozfMLhVUfjXuvxv0w33hWDaMiJ/6V4D4LeWDxJZkE584EfUmvq/xHpzapoZt2xuIDH6igD5H+CkPkfHjw3FjG2a6H/kpPX2jXyN8PLP7J+0VoK/9PF0P/JWevrmgDxX9q1Fk8E6Cj/dOsp/6TXFeUfBG+jsvFVsJF+RZRk16v8AtWsqeCdBZz8o1lCf/AW5r558C3RGswhGKvJMAPzoA+tPirHPcWVjFFxE7kO3YcV8neLUOn63c26vnk819k+KLD7d4WSJ5ApQIzOT6YzXyX8QdMRfE940T+ZCOjetAHms4O/8zSREgE9sVNepidsdKaACCqjoKAKwBOMda6zwnpL3KurRkljjpWb4U0/+0NZgiYZUsM19VfDPwdpk2k3UyqhnIKLnt70AeY+HNGj07UALdAUjQM5rUvdRt7K3RVADyuSRWvdW50q/vLZedw25rzrWVmfUELHhTx9aAOn07U8A78MzZ2L71XhijDzzXTgtbv8AKCa5q6uZdOWKd+u7C1lXmtyuk2WI8xs0AdLfakl3cRlGwpfpmqen3y2N7dzhvnXI61x9nfMql9x+VqovqT75wScsc0Adrp2vRxKXLfvHY5Oabbast5rEkwxwMLXn0Vwxfk8E1u6JOkd6AT/DigDro783FxI7t8qELXVx3S6rb/ZYwBtOBj0rzKGUxh153SS8V1fhq5a1lnkkONoxQBPrN4iQLGOsLYzXmXih91wBnknca6LW9TDM4Q5LEsa5i+UzlJG6mgDJxjpXReFbbe6uehbmst7cLB5h7tiui0dhFaRBPvHNAHovwytf7U8b6fEq7gsodh7Dmvq26yLWXb1CHH5V86fs3WPm+KL26dciGHg+hNfR0uPLfPoaAPlHwJIZP2htALfeFzdZ/wDASevrCvkf4fSb/wBpHSMHK/bLvB/7dZ6+uKAPDP2vjj4e6KR/0GY//Se4r5q8MXBTVLdl42ndmvpX9r7/AJJ7ov8A2GY//Se4r5e06UQyqe+aAPsqz1S98T/DiVbddtwsYVueWAr598XltvkyIUkzhs9a9U/Z38Qtd3NzYynIMYKg+1aHxS+Hj3F3d6vZgNGVLsg7GgD5g1ax8lc/3jxWbawlpiuevFdPrllcCIPKpAB4rl0doXZj1BNAHReBbi303W3luDlEBx9a92+EXiJU1ZjLNiBlZiue3avmBJnG4qep5r2f9njTZNd8Sv5zkW1um5/celAHZ+LNatHjnuIwRcM5/LPFce4TUJbdV++uXc1r/GWxi0TVDChAMv7wKOwrzbT9Zlt2ldTyw2igDf8AFdhcTWMN0R/o6ZArzrUJ2GWHFevCWfU/BEyMoCphQ3vXkOuQG3lMR7HmgAsebBvUnNUZ4237vWp7WURQMT0PAr2X4eXS6n8K/GepXmmaHNf6bHCLSZtItcx5yDn93hjx1bNAHhqqeD6Vat7gxSF/4qmu5ZLq4luJ1hWSRtxWGJIkH0RAFUewAqmyMzlux6UAdhosZuLqzeQfJu3GpNY1IxPeLAflZsAilWX7NosDKMSAYFZjpv0R5TzIWNAFTTf9KS4aQ/cWgwM0cP8AtHArPtpjBbuAcbzg1uRTo8luP4Y1z+NAGfrcLW8ccXvmtTSIWiiiMgPK5Gar3n+m6mqkfLWxd4aWNI/uxJg/WgD6K/Z409Lfw/e6gePOYLn2Ar0Wwvhe6ReXqn923mbPoARXmXgDXbbRvhCuXH2hy0arnks1a/i7XU8HfCeLcwFzLb+Wg75Ycn9aAPC/hPIJPj54ebOS11dkn/t1nr7Dr4r+BM/n/Gvwyx5YzXJ/8lJ6+1KAPDP2v+Ph5ov/AGGo/wD0nuK+U4X2nd37V9WftfjPw80XP/Qaj/8ASe4r5RCHBf8AhFAHqHwm15tI8Q2cwbG1hu56ivsNJINX0gtGQ0NxGRx7ivgTSp3hljkUkc8V9ZfC/wAZWcHh6xsrp8Mq/ez1JoA8s+LNpb2FylhGgVoASx9TXkttpzXbsir83XFfQnxn8MzSXX9tMy+ROeF7149pc0el3t3LIoJ2HH1oA5tNGkW1lYocBsZ967z4dapL4VhmmjbYJMB/celYlzrEL2EUIAB3Fm9zUNml1qt3bWkCt+8boO9AGr4t1q48T61JeXTHLnao9FFZNvYNJdxrt+UN0q5qkcWjao6TnmIYx703StYjneaQL2OD6UAdKNUVNPXT4sCMPuI9a4bxbZl5dyj5mO6ui8FIt7dXU1w3yqCF+tUtZw95cEkbU/SgDz+aNosK/wCVdj4W8YXuieFNc0a3itmtNVVFmeRWLrtzjaQQB17g1ykxN1dnb05xVqSArbLGo5HWgCGRi6SOBwBUlrtZYIyPmJpJP3UIixyxqewhG8yH+HpQB2Wq2iJYwEfc8vj61zbttsJIge+AKu65rXmWFvCp4QYrCFyA67zwPmNAFG8jMUixjrVy2YmcKOw5qS0tZNRlknVSQozVjSYAb1Vbv1oA3NN00mTzmB5WnLHshZ27k4roComgsba0GZZMg4rH8UlbO5S2U8R8N9aAOm8ISS6rrWlaKjEoHViKl/aV8TC51uLR4HBgs0CYB745rG+Gup/2Zrs2rSnHlISpP0rzzxfqb6xr93eSsWMshbJoA679nli3xq8Lk/8APS5/9JJ6+4a+HP2d/wDktXhb/fuf/SSavuOgDwv9sD/knejf9hmP/wBJ7ivk4SnaFPIzX1j+2B/yTvRf+wzH/wCk9xXyXQBrWk8e0bTyOcV1+la1Nbww/OV5GK88Viuf5irtnqLxSo0nzovY0Aex+KfHV7qujw207/u4RhR+FcfeywnSU43XEvJqjpc0eqOyIwLY3FWqxp6D7UZJRlEOOegFAGdZWaG9iW4bA6mvUvAk+n6fq8uouimK2iKoD/exXndzCbm/Msa4UnCgVfvbltP0iRAxGTg+9AGL4zvH1HU7i56CVzj8667TPDkOm/D2TUrjiWXhAa88e6a7uYEI+QHJruvEGqXes6dY6daqVt41C7RQBzOm6q1pGY4zjJyTVe81JmScZ5kJJNFxp8kUrIQQR1rMkiKMS/fpmgCbQo1e6JfoBXW+FNOhvl1C6nIEUAOM9zXCQTtDv2nk8V0EN+1j4eeNXIabkgd6AMjVJlbUGMf3QeKjW+KRuq9zVIkkknrSDpxQBZMrTyID0zSOGklKjuaLVcbnPQVf063LTLkZJoA9S8EaVaWXw31O/udpuX+WMHrXnqA2zo54Z8139mCnhpoZWxGgzj3rhNWXMqn+FRgUAd54BljW8W5mwRChIz61yetb77VZGbOZZSfwq7pTy2+nNJkqCtWPDVqdSvJbkrmOAEk4oAo6n/xL9HkC/KWG0V57KcuSa6XxZftNIyZ+UsSBXMnmgD0X9nf/AJLX4W/66XP/AKSTV9x18Ofs7/8AJa/C3+/c/wDpJNX3HQB4X+2D/wAk70b/ALDMf/pPcV8jsSG9q+uP2wP+Sd6L/wBhmP8A9J7ivknANADQWHIqXO4c8GkH0oJwQAOKAHpI8Th42KsO4Na1jrksUYinG+POSR1rG7c0D9aAO+0/VLdoS8TBm7A/w1V1K5W6tGQnJXk1xsbshyrEH1FXrS/2ZWYEqe4oAu2UQibzGGW6AV6V4Rs5IXimuo8HZuUEVh/DrTbbXPEFssrD7NGwLZr0z4kTWejymW2KhPL2qBQBw93bQT3ZjON8khyfauD8UIqajJFB9xOM1oza06ymcdcHFZcIa+85j99zQBg55FT3k5lCL/Coqd7IrOy44WqcikMfrQAzFX9EsG1C/SFeneqB4rrfB6C2JmxmR+B7UAQ3WleXeLAg4ziup03RY11G3hQBmxzj1pl9AYw90R8w6fWtfwY32eRdSvPug5Ge9AFbxd5mmqtq3yr1auFMzX9/HCvTdz9K2/H+vtrGsuYwACe1T+ENFUaVeapcYAQYXPrQBNqF2n9mNbwjkfLWpoF1HpvhW6Ax51wdo+lc9Aqtbu7HjljUN1cPDpodjgYO0UAczr0okvmA6LxWdntTpXMkjMeSxyab3oA9H/Z2H/F5vC7f9Nbkf+Sk9fcNfD/7PHHxm8LD/prc/wDpJPX3BQB5N+0n4U1zxh4K0yy8NWBv7uDU0uHiEscZEYhmUnLso6uvGc8186/8KS+I/wD0K0n/AIHWn/x2vq74p+JNU8N2GjHRDZLc3+oC0Z7yB5kRfImkyFV0OcxAde5rldL8c69qGn295Fq8TQzxrLG8XgLVpEdWGQysJcEEHII60AfPf/Ck/iPx/wAUtL/4HWn/AMdo/wCFJfEf/oVpP/A60/8AjtfRNz431m0jWS81+2tYmkSLzbnwLqkEYZ2CqGd5wq5ZgMkgc1xvi740eItCk2Wmp+HL/wB/7Jmj/wDbo0AeT/8ACkviP28LS/8Agdaf/HaU/BL4j5/5FaX/AMDrT/47XQXX7TfjKB9otPDbt/15zj/2vTLf9pzxvPIEXT/DeT/06z//AB6gDC/4Un8SP+hWk/8AA60/+O0f8KT+I/8A0K0v/gdaf/Ha6K7/AGlvG8BASx8NyOews5x/7Xrd0L43/EjV2QR6Z4cTeMj/AEOc/wDtegDidP8AhD8UdPuFns/DlxFKpyCt/a//AB2tnXfh/wDFbXI4xf8AhiQsowSt9aDP/kWu/b4j/ExYWka18NBR/wBOE/P/AJHrl9Q+PHxCsr020mn+Gy2M5FnP/wDH6AOcb4Q+PfswQeE7oydyb2zx/wCjqdpnwl+IFrKpl8J3JUHJC3tp/wDHq37X48/ES43H+zfDagetpPz/AOR6uL8a/iKQpNh4cAY4H+hT/wDx+gDmZvhR48kuXkHhK6CnoPttn/8AHqybr4MfEWSYsnhWYL6G+tP/AI7XuFn4u+J8+mi8kj8MRKRuCmwnJx/4EVlR/Ej4jvu2xeGMhtv/AB4z/n/x8UAePf8ACk/iPn/kVpf/AAOtP/jtdD4f+FnjyxlDXnhK7ZQOBHe2Z/nMK75PiT8SppXjtbfwxMV9LGf/AOP1Yi8b/F6a1kuI9H8OMidf9Cn5/wDI9AHF6l8PvHl2dq+Eb1Ys5wbyzz/6PqXVPAvj2eyitrTwheRpGuPmvbMZP4TVFrfx4+JmkSMl3ovh1WHY2k4/9rVzj/tUeOY2KvpPhsEf9O0//wAeoALf4P8AxCE7Sz+FbhiemL20P/tauim8AePxoQ0638JXiqTlib2z5/8AI1c4v7VXjYsN2l+GwO5FtOf/AGtW0v7Rvja6sTcaZa+GbplGXhNpOjr+HnnNK9gKS/Cz4hfKreFLry++L20z/wCjqNd+FfxBvokjtvCdyiqMfPe2g/lNVJv2qfHKsVbSfDYI6g20/wD8epP+Gq/HH/QK8N/+A8//AMepgZ//AApL4kf9CtL/AOB1p/8AHaenwT+Io+94Wlz7X1p/8dq8n7VPjh2CjSvDWT/07z//AB6lf9qjxyjYbSvDef8Ar3n/APj1AHUfBr4W+NdA+KGg6rrOgSWenWrztNM13bvt3W8qD5UkLHLMo4HevqqvmL4M/H7xT43+I2j6BqtjokNneGYSNbQSrINkMkgwWkI6oOx4zX07QB5L+0berp2geGbtzhYtaBP/AICXI/rXHaxc6t/YHwJ03Sbm6VL/AE9EmtotTnsEuAtpEQHlhywA5IwD+taH7Z0rQ/DHSZEOGGsx4/8AAecV5Rp/x/0UeEtA0XXvhxp2trpFnFaRS3t0kmSkaoWVWgbbu2g4B/E0AdnrGt395+y74vTU7+6vtS0nVls5Z55DL80d5CQElJJkUAgBjyfQcV8xSanLcgmV2YDnk1694/8Aj1ZeJvhvf+D9L8F2+iWlz5YRre8UpDslSTiNYlHO3HUdc14dErSEInUmgAd3lm3AkseldT4Z0S7uJFaJGZ244Fdt8KfhLf8Aia4jnMLCDqWI4r6a8G/DHS/DyJcXaofJbcdwoGeQ+EfgxMyQX2rIVDDdtbtXsvh7w5pUF5Da2ix7kTDEDpVjXdam1aWa000YiT5QVrChafSHRF3G7ujs560AVfiZ4gs7WZdL0qNSVIUlR1NZOi+A0urh9U1cKqiPdtNbPjXwxB4ds7bWLgecyvukz61g2Os6r4xjup4A1vpyDYuOM0AZ2haHHrWr3bWkQFjbkglR1xXT2WgrM/mtAiW8f3Sw9K1/Ba2PhvwjcqzqbiZ+c9TXH+LfGE15qcenWTCKKJfmxxmgDrZtVnk0iaJFG0fKGA4rkpNL1ALGI1by5CWLY7V0fhrULR9ISK4wsasCzHvV7xD410dmiht3SO3gGC3rQBm+BTBpzyNIuRuw5YV7Dp15a3UI+yshXH3R2r5m8Q+J22JNHHJb6fcSMIpWUhZduM7T3xkVe8NfEL7DeQSRTAop2kE8EUAe6eKPBmjeJI8ahaoZAMB1GCK+cvHX7Ol4bm5udKZJIACyjPP5V9SaPqEWqabBeW5zHKuRVw80CPzJ8SeG73Q7tobiF1K8EkVkWl1PZzrNbyNHIp4Ir9FvH/w40fxfaFZ4UiuBnbIqjk+9fG3xU+F+oeFNXkVoiYDyrqOCKAOWW60/xCoivUSz1E8LOvCOf9qsLVdMutLuDFdRle6sOQw9Qabc2TwLvzxWlpeuhIfsmqxfa7M8AMfmT3BqbW2GYaMVYFetDsWbLda6O+0NfI+2aO5urLq3Hzx+xFc+0ZL88CmmmI9Q/Zc/5Lt4Z/7ev/SWWvv+vgH9l3j47+Gf+3r/ANJZa+/qYHgH7an/ACS3Sv8AsNRf+iJ6+K/avtT9tb/klmlf9hqL/wBET18Yqn7vkde9AENeqfBX4d3ni3URMsTG3RhubHArznSbJtQ1KG2iBZ3IH41+gnwT8MReE/AdpCyBZ5B5krY5oGdb4c0a00DSILK0jVEiQAkDqfWuc1xb3VrySxtZCImbLY7Csbxn4zngmljtsrChxkd6xdG8fR2MMjHDXM2cEnpQB6F4Z0W20SK4aZlYj7ztWfJd6Pca9HdzlCqf6s9ga8X8Q+ONXuTcxecywk5JBrgNV+IElviETn5fegD6j+LRivvCy20ZEhuJFVNvP40ab4RXSvAyWNgB5+3ex9TXg/hX4mpcWtst65cxtldxzivfPBvji18SGO2tU+fbhmz2oA8N8WapLpdpcGeXc6OcLnpXkVz4te51GSZMq7cZFetfHbw5d2N9euMvC/zLj3q54I+EGiaR8L79/Gl7aWeu6siTKtxdpbNbxK6usW9gdhfA3Ng4yOPl5APL9G8Ta9ratpejQS3DhS8jAhUiQdWdzhUUd2YgVBq3jDStACxwPF4h1hOsjA/YLc+wODOw9ThPZxzXIeLvEmoXDzaHbR2mnaRBLgWOmyiSGRlPDvIpPnt/tsze2BxWdY+GtSv0DQW8rE+imgCxqnizU9Z1Vr7Vrya5m2hQXPCgdFUdFUdgMAVJp+uSAkmQjnpUNx4P1e3GZbSVR6lDWNc2s9pLtlRlYdsUAfUfgP40tpGkWtjIA4Rcc16J4G+MEWta39ivAiiRtqEHHNfEFtqDpIpYkYre0nWp7O+jltpD5g5yD0oA/SRWDDKkEe1ZHifw7YeI9NltNQhRwykK5HKmvmT4SfGK5stXS21i4eW3lO1t5ztr6utLiK7to7iBw8UihlYdxQI+KPjD8LbjwvKxRd1s+SrjvXhtzCYJSh7V+k3xC8M2viXw/cQXAPmKhMbDsa+B/iD4YuNE1CQSRsBk9RQM5jS9TutMnEtpIVPcdmHuK6Ew2HiNDJbslnqeMmI8JIfb0Ncl35q1E4RQycEdx1qWuqEeo/s0Wk9n8fPDcNzG0cg+1cMP+nWWvvivhb9m3WZ9Q+MfhW3ugskkb3JWY/e2/ZJvlJ/L8q+6aaA8D/bPGfhhpI6/8TmL/wBET18YSOThAPpX2j+2Zz8M9I/7DMf/AKTz18g6Rp7X2qQQgZ3MBTGev/s4eB4dR8QLqepLi0tRvJPc19K614khto/sttNlZPuqOwrnfhj4ZFjp8FrGm0SoN4HpWjc+FFbxeXUErFGcL2oA5PxFf2sumzIWAkOSc15bqbuqW08OSAx/Gu3+Iei3FjFuwczOcfSvPdZmNpYszHalshH1Y0Ac94r8StBC8St879QO1eY3M7yysWcnJzVjUrl7q4aRzkEmqFAGpaak9vsRGIA6mvpf9nXxFZWdyj3cvzv8gGa+Va2dB1y70u4SSCRgw+7QB9q/tDS2lz4Qd7aaMzj+JT2r4i1FZJr8qCWcnr616Df+LL2+0hLa6mdg5y2T1rU+GPgOXxfr8KRrtjzlmI4AoAv/AAN+Dk/iq+S/1BTHp0TAsWH3vYV9gaR4R0PSYUjs9PgUIMAlcmrvh/SbbQ9Jt7CzjVIoUC8DGT61o0CMu90DS72Bop7KBlb/AGBXlni/4D6NrV49xasISw+7jivZ6KAPh74v/BLUvDBiuNOiM9q3BZBnBrziTwjremwpczWsqo/QlTX6STwRXEZjnjWRD1VhkVmat4c0vVLNba7tI2iXlQFxigZ+bEl1NaMflZZVbr0r7G/Zu+IUepeG4dL1SdVni4jZj1HpXBfGj4Tx2NtczadAS24uNo7V4P4f1m+0C7IR3Qo3TpQB+lnDL2INePftAeBLfWfDFxf2Vsv2yFSTtHJFWvgN8QB4s0UWt2+byFRj3WvVZo1mieNwCrggg96BH5a3sD291JFIpVlYgg0kLKRtYV698e/BEmh+KL2SNAIXcspHoa8fjjYyYHUUDPWf2YY9nxw8MkDjdc/+ks1fe9fDH7M9q8fxZ8LzMpw09wN3b/j0n4r7noEeC/tmHHwz0g/9RmL/ANJ56+cPhJpxv/FVmCMgMCa+j/2zBn4Z6QP+o1F/6Inrzv8AZY0KO88YTTuoaK2h38+tAz6u0jT4bOCMxLhiig1zDaylvf6ndyofkfyVrs7iVLe3klkO1EUsT7CvM9Tnin8JXUkWDPdTs6euM0AV/Hd/Z6hZx7FViowPrXzZ8bbefSbeOHpHcfP9a9iKPDAn2l8hTubJryn9oC+GqrayRKBEi4B9aAPD2OIwM5zTEUscCjPGDV61tjIwEeT3NAFiw07zp44gNxNev+Cvghq+stZ3s0JjtZGHJHaq3wB8Kv4i8XRRSwlreI75GI4Ar7htYIrWCOCBQkaKFVR2FAHhmp/s+2FxJZiG52xpjzcjk/SvU/BXg3TPCVo0OnR/M3VyOa6WigQVFJcRRsFZwGJxjNSgYHNc/q2nSFL+5VjvKZQUAdACCMg5FFea/DnxfJfXNzp14rh43wGPYV6UCCMjkUAFAGBiijNAGbqo0+VDZ3xT9+CAGr5b+M3wotNN86/sJAEbc2K93u7Ntf8AEs9xJOY7e0+VQD3rD8feHLm+0aXzJHMIBCn1oGfLXwX8Yz+EvF0UgbMW7Yyn0r730y9i1Cwgu4GDRyoGBHvX5weJNGvNA8QMJY3VWfKnHXmvtH9nPXl1bwNFAzEzW5w2T2oAy/2lvC66j4aOowxZeLiQj07V8ZaXaCXV3t2HU4r9HPG9oL7wnqkG0MWgYgY9BX57aKjN46EWPmNxtx+NAH1b4J8GWvhi6+Gk8QxcXN/MX47GwujXvFeZa7cpB41+FumggP59xKV9hYzj/wBmr02gR4V+2CA3w60YHp/bUf8A6T3Fcv8Asdsrza2T9/AA+ma6X9sc4+Gujn/qMx/+k9xXD/shT7davIVPDRkmgD6S8c3y6f4YvpWGSUKge5rzjw6yy+CpL2U4FsT19K9B+IFsl34auYn64yPrXjumX1wvg2401EJkllK4HpQNHJaj4jTU5ruGJ9oxxXHfFTypdE063gG5wuWIrpH0D+zdWlglGJCuTmud8QxotzbifBTOKAPKrXRpbqbZGhJHtXpXhb4b6jJapc+Sx80hQoHNdt4L8GhtWtX8rdDcEfNivp/Q9GtdOhCRRJtGAvHSgDB+Ffgm08GaAkUaL9rmAeaTHOfSq0/ja3TxY9qz/uoDtYjpXT+LNQ/szRJ51O1vug/WvlzxbrTabf3ex8mX585oA+rJ9XsoLUTvOpQjcMHOaoaV4osNRaQRvsVOrPwK+V/DnjW+mtG+0O7x52jnoK1vFfiOWDQHFk5R5OMKecUAfT1trmmXNwYLe9hkkAyQrZri/EHj+K313+yxGdjHbv8AWvkzwZ4m1LTvE8SS3EgMzgHJ7E17H4mEs2vWNwi/ukUHd/eNAG2PEVroGq3KxoDNcMW/Cu2+HfjCLVJ1tHl3SvnCk8ivDfEd75Pi60aQBgRivQvhvoY03XIdWmbaZmIVSeBmgD3GUsyssZAfHX0qtcSz2/2aONPMLth29PesJ9ba015rcqXi2lpHHOKdofjfR9XvmtIZwk4JAV+M4oA04dKjhvpHRB5Uoy/+9Vy/gWayki2BsrhQfWrIIIyDkU13VF3NwB60CPmj4x+C7ubSXvLiBN0WSuBzXLfs0eLH0rxodIuQywz/ACc/3u1fSl3a/wBu3JWZDJbl8EdgK+ep9ItNJ+OzCxULBE+do9aBn1ddRCe2liPR0K/mK+IdI8ObfjrFZCMhVveTjsDX25YzC4tIpR/EoNeA6n4alg+OzXETbYSPOLY6cc0AXNf1Rbz9qDwdZwHMVilxG3sxtJ/8K95r5W+H839ofHyyvyxfOqTRKx9BZXX+FfVNAjwT9s3/AJJlpOP+gzF/6Inrzj9kS5WLxfPD3eI16R+2YcfDLSP+wzF/6Tz14n+zLffYviJahjgS/J+dAz7U8Q2v2vSbhM4IUnNeZeA9PguIZWYBn87Cj8a9ckQSROjdGBH4V5x4Shi0HxdeWErYjJzHnuTQBw3xjsf7O8RNdIMGSPjFeJ3073t3bxSjDO4x+dfQvx6tme8tJicL5ZH1rwC8UfaraRVw0coB/OgD6oh06HRfh/ZSIim6jjVlbHc1N4G8STXt3Pb37gFRleaja4/tD4ZpLkGSOIfnXlekXN1Z3xuJHYPnKqP4hQB7x4us4r/SGim+4Tmvl/4ieFJ31QNCf9Gx1r6FttUl8ReE3uohskiyCPXFeYmO41G+a2ZCSmW570AecWOlG00T7OsX7wneWx0p+h6d9t8wXDBgvODXoumaet28qSIFKghhTfDPhFPNlZ3x8/AoA8f1XwrcpdjVxGVjhbOAOwr1bw7d/wBuaRDLgDy1wAfWt/4gzeH9E0R7LUdRsbSeSPMcc0yIzj1AJya5bwhf6JDbx2+manZXkhTcyW86yFPqFJxQBzOpNFDqzz3nzSxNwD3rTu/Gl01xZBRshBAXB6Vj/EiAxD7Snr8xHrXN/aS+mwkk7twJPpQB9T3esxw6DBdWcayPJEEkY8nmvHPGdpNo7W+vWbhcPhgp6V6P8ILa21rR/wB5IZoowA6E965T4qWSaVql9ZTBvsEyb4l7A4oA9Y+HXiQ69ocExAwqAO2e9afi+/is9ClnZ8JkDcDXzT8MPFV1p9rcWELkxO+0YPSvTvjNfNpPwxskRmMszqD6kd6ALOrfFOx026t7CwjwpQbnPc15trNmT40GuCQhJ13bveuJ1Qzapd6a0eY0UAE+tdP4hnmNlZ2ETkkYG7vQB9JeAZjN4bt2aQOeeQa88+JlxJofiW+1GQ4WW12x/lXQfBpnj0m4tpGJMRXr7iq3xq8MT6/pvmW+Q0UZAI+tAHA/CPRorM+C9Sdgbq+1ydj67fsF5/8AWr6MrxHwzYNpuqfDm0lUrLFfzAj62F3Xt1AjwX9swZ+GekA/9BmP/wBJ56+cfhHcG08Z6ZJnaBKCT+NfSP7YqeZ8N9HUd9Zj/wDSe4r5U0id7DULWWM4YMKBo/R+Fw8KOOQyg1xHxDtUtJ7LVEGHWVVY+vNS/CrxA2ueHIvOOZolAJ9q0PiJYtfeFrtYxmWMCRPqKAOJ+O67/D9jefwrgn8a+friNhLDcTDEDOGFeyfFe/nu/hpp8so4yEY/SvJL+RLnwrhP9bEcge1AHsuhTXFz8P7xrdj5eVCisa7UaVe2zXa7t8BK5/vGrfw/vvtXgOK3DCI8A+5q/wCL7FGWymlcMsTKKAO0+Fca/wDCPSRPyWJLD61LfeHRaakbm3T90VOT71P8PLYw2FxJ/A7/AC/SurlRZEKMODQB4BdGXT9Sv4Q5BzuNRW91dTTwfZZtqkgtW7440CW38VTXDki2lh4PbNcpqPlaNoL3CSkNjrQBX+M17Jf+HtYi3ZjhsnJx3O2mfBixN94e0Z5UDpDZKV9uKk0xrfXdGG9I5vPUiRZFDKw9CDwRVjwTqv8AYmtGyihjjgK7FRFCqq+gA4AoAd400Z5dDmmEJZGbk4rzaLTjIEiVdqdcGvpPVEik0q6to9rRuN49s14Xr+n3dpexyIu2AkrmgDovgNrr6H4tudKlYG2uO5P3T2r27x5oOn65Ybb0osgU7GPWvnzwv4fm1HUbm+03KtCgJPqRXuMV5Hq+kaej7vtSLhwfWgDxTwv4Tj0TWpWWQSkzYRM+9ek/G22/tS00zTbfaZQu5l/uivN7eebRfjFHDfl2tVffjtio/jj4zig8Vebo0rbXjAkOf5UAWNZ8PwaObISMCqRh9w6VyevX6y+IoJrNitsuB+NPi8VyeI7G2soeuQjM3WtXUvCxgu0gD5kIBIHagD2f4LzmRb7Lh94VvpXpF7IiRfvF3g/w+tecfDm2g0MQMx4nUJu969JuIBM0bZ+4d31oA4PWCsvinwRMyhJTrEq7fRf7PvK9CrzDXp3PxS8JQt0Gpytjt/x4Xden0CPCf2xG2/DnRj0/4nUf/pPcV8lBh9oUhulfV37aRI+F+klev9tRf+iJ6+NFu2XB/ioGfZv7MutRTWlzaySDzWA2qT1xXvFxEJoJI2+66lTXwd8GvFLaR4i0+6LlUEoDjPavu+1nS5top4iGSRQwI9DQBwni3wsl/wCBnsAN5hcuBjrzXz7Jpv2K7ngcZSQYC+lfXWwrcNuIMbjp714V8UvD7WGvy3NumIZVJ+hoA84tNZk05YbSGTCRPk4PavTNL1O08WWttaRuBKZlBGa8Y1K2aFZX2tuwSa5fwh4tvfDvimO5eRhGj7sUAfoBZW0dpbRwwqFRRjAqBrrGoGPBKhcHHY185a5+0YRawJYRqsx++2K9Z+C3iJvFHhqXUJn3zvKd3tQB2es6bbana+RdAYPQ964Hxj8M01W0aKyk2qqYVGPU10nxEa4g0MXVnIUkgkVuO4rV8P3clxpFvPdyKZJBnNAHzPYWl34UupdJlQ+eWwgPvUhtbqGYTbf3qZzXuPxF8N2d7bHVfLAvLcZVh3ryW7v2uJceXsaPIYY60ALJrstv4cw0pMshxn0qDxDqtvf2FpBGgJjj+Y+9VF0yS90d3Q5ZWLbfasnRrG9vPtLeU2EGDx0oA3fAviM6NczW7xgRMDub2r2XwKbXUrbz0AwpJGK8CfQLu4uo44HyHHJ9K6HQPFc3hbRJLQT/AL4uVZqAOy+JtrpUPiiC6mjUSNGFZx2ryzxxoej32qZt5VdWTJINYnxG8YS3gYQyM3HBJzzXGaFqN5O0IZnMpfGfagDb8KaWdN1C7uWRjaQNkH3r1DQri71aC61WONRGV2Lurt5fDWnRfB+9leBVnlt/MZyOcjpXnHwo1v7ZpkWlwR7nBbcfpQB6XpFz5fg62F38ssdwGVj1PNemreJI1vGrDMih+vavm7VfFbvrEVlMp8iFiNg4wfWu18DX1xfoztdt94+WSeg9KANXWL+K6+KXhBI12sNTnP1xY3Qr1WvFzZXEXxR8HXEzbkfUJwG9/sN1/hXtFAjwP9s4FvhjpIH/AEGYv/RE9fFbxODypr7w/aZ0tta8MeHNPQZM2tLx9LW5b+leFXXwouGhJWPleOlAzxbQ7iSG4VUJBBzX3T8AvF41/wALxWk7g3FsoUZPJFfKOteAr3RyXMRDkZHFb3wz13UPCmqxKzMhYhj70AfbOqxSTWTiA4lHzL9RXDa0yarELTURtuW9fauo8J+IbfX7BJYWHmBQXFcx8TIZLfUNPvbZcuMhgKAPNfGOixmzBt4gSrbG4rxr4i+FPs1tHcwDDPwcV9PLcWd69hZ3KqjzHLGsbxN8On1a/vLO3YFFAdKAPkDRvDF9qV4IFDbyMivp/wCCK6h4Xs/7NAYtP/D6Gqtn4Kl8OpNqVxEN1qdpGOor2LwJplle2VnrMa4Z1yBjpQBB4t1C4XwzNb36bXY43e1czouo39xDp9sVdbXzQFmHQgdq9C8ZaYdY082KAb5AcH0rmzANA8JWVlc4+0QyAigDrPFLINIMb9JCFrwjxnZ3Fj4lUQr8rDJFdT8QvFV20mmRKuFDhzjuRWXr2qJqGb+ePaQgUZ7mgDD0S8lg1OeN0/dbcj0r2zwtp2n6f4Y+0NFHtkQyyMRXz++rRQQmYyrk5yO61a8W/F+3X4ZXGmWTEXe3yt4POKAMnxr4xg0jVbi706VTEXYKoPSvP73xPb3+njc2ZpJCzc15jdalc3Y2u7Nk+td/8MPh7qXia/gIikFsGBZsUAaeneH73XbiGK1R33kcAZr17Q/hXcaRNZTX0QEO9dxPvXtXgrwVpnhqyiW3gVp9o3Ow5qx47uIoNFPm8guvA60AcZ8c9Yj0DwNFp1vhftWIsDqF9a+cfBmuN4U16Rox+7IJBPvXqHxpNxNqOmSagxeARbkXtivIdatvttw9xF8qKRtHtQA+71ltQa+v5CUcMcY75r1n4OzeZBpnmSFopn2ba8Y12UWGlmIIAZRmvd/gdaJL8PbHUAmZobsAfiaAPT/EllHaeJPAoX/oMyhT3x/Z95Xb1x3jPefF3gA/wf2rNn6/2fd//XrsaBHF/EaNJdT8FrJjYdYkJz7afeGuan1e2WBowo8wPjH0rofiajS33gyOPO5tYkAx/wBg+8rgJtDu7fxAn2lHWEnOT3oGiXxFFb67qdkkUaldoVwB0rC+L/w3ltfst3o0RZdmG2joa7XwXp8EOvX085/0fgr9c16jKIbiDZIquh4waAPm74K+KJNI1gWWob1LHy2z2r0/4neIbfTb6yRwHWVcfnUnjbwdp0Fqb2wt1juCwBIHOa5n4leG7yXTdIvpVLCMqsg7gUASeIWie60w2i/MVHzDtXV+CZ559dmWVyxjjwSe9c1ZpbvOqxciJQQK1tB1KOx8aLE3CXEe38aANXxzFH9kezlABupODVbw/wCILDw1ocVjcE7omKgCpPiLIsscan5Z7c71x3Feb+OrSYQ2syZ8yXliKAPaLLU4NS1G2mtJN0JQ/nXMeObS7v8AWRFCheDaPu9jVP4SwyvaCKZtkkDbseorstNWSPxJfo5BjKh1BoA4228Fz6nfLJefLHEuBkd6wfi34dl0PwpHc2p8xY2/eYH5V7dWfr2mwavpVxZ3aB4pFwQaAufnlrer3zTzeWzfOT8oqvpGiahqltLvV9uN3SvpXWvhFBZXa3EcStHMTgGvR9A+Hmlx6LGr26ROV5bFAHzN8HvhjBruqwtqPyQBwGB719meHvD2m6BZpbabbJEiqBkDk18x/EDxda+C9Qns9LdQ8b8bexFdx8GfjPN4q1GDStQRTcPwHHFAHX+OviHLoGsSabHb4cplJG6ZrzjTfGN9e6hdT6xvmtHO0eimu88b6NB4t8UvbHEUlrCcsf0rgr6zPhzwzJHfKrDecNQBz3jHxYfEE32Vo8vB8kZPcVi/Yf8AQZWeMhBweOhqbwxo8ms+IIjtxCZMlq9X+KGlaPoXgN4RMn24sNhXqaAPmfxGrzSGMtlUGK+iP2fbqP8A4VrJbBgJIrlW57814Rqtpv0+eSNT5m3JzXY/A/W3h0K5t+cxzKTj60AfTHi993iXwBxw2rytn/uH3ldfXGeJn3658PCOjarIf/Kdd12dAjlPGgB8Q+BM9P7akP8A5T7ytfX9MXUrIouFlXlWrJ8Zf8jH4E/7DUn/AKbryuqoA4iLQ5fsh2KUduCPoa2rK2uo5rcOSUTrW265XjGaVRj60DuYnim3lmggKH92j7nHr6VYvmtLrSN0+DBgfhU17tmt7gddvHFQXNor6MYoh8hTOPegDzXV9Lk0jXftVmGeylG4mtLQoYZPElrdzKNmzgn1rutOtI59GhhuEDApg5rlPGdoNAs4L22Um3jcB19BQBp+L9MTUWJibMwToPSvMdfmnBsUmTMav5bGvS/D1yl6lzqSuWCr932xXK6pbxato+22GJGlL/rQBc8Ezm217yWGAV6+xrUstd834iT2ToVVYtoNanh3R4ofKmkG6byxk1n+LtM+xaimt2qDzQNjj1FAHZ71/vCoLa9t7p5UgkV2jOGA7V5va64yW0s1xOUDk7QT0rY8KtFEi6nDJlJciVc9/WgLEvj3TtRuZ9OubBv3MEgMiDqRWv4nSWfwpefZXKSiEspHqBWBc+LrmLUp7AwZcMCjEcFa3jrmmKyWrSL5kuAyH3oA/PXx295c+Ib1rwsZNxzmrPwq16Xw74qtL5c4RwDXv3x68AWEOsyX9mFXzgCUHTNeS6X4IuYZt08LKjHK8UAfUGj3I1XXZNShcbJ4NzjPtXmfia+udZuL2wGfIVyee1WfC4v11W0sbaR41ZNn4V2niPwonhbQJb+fE7u3zeozQBxWgy2+gx2iKxknc5AHWsf4najLqCQ+exR2bODWvoqR3mrW908J2xnPHYVynj+9OqeIJzsCwRHKY46UAcj4svmsYlAYeZ5eCBT/AIF6g0+qX9jwGmXcv1rivGOqSXOrsrEbQMcVJ8NNUGk+L7ObdhTIFJ9jQB9xy3gvpPhxISC66tIjY7EadeCvQ68vt4Vt9Q8CpHnZJrUkwP1068r1CgRyvjL/AJGPwJ/2GpP/AE3XldVXP+LdEvtXfRrjSr+2sb3TL03kb3Nq1xG+YJoSpVZIz0mJzu6joaq/YfHH/Qw+G/8AwQz/APyZQB1VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAb8NsEMqqfldsmrJUeWVA4xiuTi0zxtGWI8R+HDuOTnQp//kypPsPjj/oYfDf/AIIZ/wD5MoA6eFQkSqBgAdKrajbQajaz2NwoZJEwQawfsPjj/oYfDf8A4IZ//kyoF0jxqLkzf8JH4d3kYx/YU+P/AEsoA4jwjqUvhnV9X0jUgwgLbY2Pp2rqbHRylneXMD/u0G5B61DrXgrxLrDvJda74dWVl2mSPQpgf/Syp9M8L+MdP0w2MfijQpYiMbpdDlLfpdigdzH8OeNZ1vTbzpznZz2Paum1fUnuLR7eYrvxkD1rnE+HXiNJ/OHiTQ/MznP9hy//ACXT7jwB4rnvRct4u0oNjGwaJJt/9KqAOV8V6TNrNrFBYSGKZTgAfxGqGh2nibSl/wBIVxApwy131p4F8U2zh18T6I7K+8F9Dl4P/gXW3PpHjKeJo5Ne8MlG6/8AEgn/APkygLl+10+C/wBGt5miX7SI/vY5zXlN94U8Q6j4pWSAMlozff6bcV6Rb6V40t4ljj8QeGwqjA/4kM//AMmVILDxuOniHw0P+4DP/wDJlAXHXfgyw1Kwih1QvPIoGXz3qxbeE9Njt0gkgR0jGFJHOKrfYfHH/Qw+G/8AwQz/APyZSGw8cEEf8JF4bHuNBn/+TKBGN4g0GDQtTt9WtLYvDFgMB2qP4rara3XghCJArzuu1e+fStSTRPGklpJby+JfDzo4wS2hTZ/9LK5TXPhX4j1mKOK78W6YscbblWPRZAM/jdGgZ5/a3F1punSOyhC646V5R4tv2gt5Jmk5ckcda+lZPhR4hktDbyeK9KdSMbjokmQP/AmuN1b9mW71MYn8aRKPRNII/nOaAPkW8lM07OSTk9TRau8UySpnKMGr6j/4ZG/6nb/yk/8A26pF/ZLKqQPGox/2Cf8A7fQI9C8Fa9F4j0L4XXsRG9NUkikA/vDTryvZK8f+Gfwg1HwTNpMUniiHUNN0+8e+WD+zTFI0jW8sON/nMAMTE/dPQcivYKAPEP2utb1XQfhtpt1oep32m3L6tHG0tncPC7IYZiVLKQcZAOPYV5RaeBvivL4V03xDefFOHTdNv7eK5ie/8Q3cO1ZE3qrErjdjqAT0Nej/ALa3/JLNK/7DUX/oiepLjTNQk8KfBDXYLG71HStGtbeW+t7SMyyLutYxHKI1yzbCCcAE89KAOT0HQPGWi+HH1vW/GI8UaTJdQWy3WmeLL4mPzJkh+UIArkM4JBYdDXqPh3w1aXK263WqeJJWcZJHiC/H5/vqt+Nru01PwNcXOnaXdWSza5pu43Vk1q9y3262HmFGAf0XLgE7fTBPVaXLDCrm4QI0ahgcY4oA5/VfCemWqPJHf+I/3Y5VvEeoAH8fPry7xwsum6cbzT9Z8SRc5CHXb0gr9TKa7P4kaoJA/kyTCOXAAQdSehrkru0vbrRXtbmGZ4gdiuRyc+tAHnba/qzSMf8AhI/EscMgxGw1m7O1sf8AXSp7y91200P7e/irxM425AXWLrn/AMicVoXfh7+zdNuoNTyjRASwMp4PHTNS+HdFebSJbu+Z5o58KsUg+UAdsUAedxeL/Fjosr+IfE/lNz+71e5JHt9/rXocVxrd3pUP2LVvFgupCC0k2tXYCj2xJj8663SPCmnWbwC9hEMMzbxH/CuOnNdLY6XFFp90qSqYoWygbqB1xQB55f6T4lT7Itv4g8VFnOGK63csD/4/xVB/Dnjs6q1svi7xIof51H9q3J2L7/vK9YhuY4rd4bZA6oeCoyct71p6dMlncJDcLmeXoXPSgDx/UdD8VWU6GTxZ4n8tlIH/ABN7nbu9zvzWd/Z/i4QQzHxb4jDygnyv7WusAD0PmZr2+6eG9up422SJAcyRhenpUGkPpc11IjnCREqgxng9qAPCNUtPHVvFHNb+JfFDByNqnVrjDD/vvNUE1jX4bnyrrxd4nMi5BRNWueT6H5+K+jNSfTUlSaIiXygVEeOBgVhat4b0nVIhdvaxmZl6BfusaAPGrW+8Sz2kkw8R+KRGGyj/ANs3OXHpjzKittf1X+0bq0uPFXiZTtzG39sXXyn0P7zrXeN4F1OeW4GnYh8ldq5H3x14Fc5L4Xvri5QanpxhlyTIYzkt6ZHbigDB1DUvFFhKsjeK/Ec9rs3Ns1e5BH0PmUWc/ja7ka5i8S+JRZkZRG1a5JI98PxUt1YtJKkNxcSQwREgQyAc+xHcirTz6oJo7e2ZreHHlq6DCYx94nvQBiy3fji3bfceL/ECo7bVQ6rcg59fv1NZ+JPEUMLxzeIfEN3Mp5c6xeKfpgSVaeyF9afumubloJi/++w9KoanpFzHcmeO3nW1HMq+aAMkdM0AdRpOr6nO5e91rxFHCFywXW73cDj/AK610FnMrxwPN4l8SETHChddvM9f+utcP4buFgeFWYPA0mwnP3eOOT1xXTLpcS2kt9C48tGKwxnofegDofBS6xYfFLwyH8Qa5d2Fzd3ETQXGpzzxMotJ2AKu5B5UH6ivoyvlz4datPefFXwhayIqRw3lyRjqx+x3HNfUdAHgH7a3/JLNK/7DUX/oievnXSfjl8RdI0qz03T/ABD5NlZwpbwR/YrZtkaKFUZMZJwAOSc19Fftrf8AJLNK/wCw1F/6Inr4qoA+0vhJdeIviF8PbTXPF3ifUZVXUkkW2igtI4ZDBKkke7bDv++gzhhnFeh6xqkVwASSpAwQDjOK4L4VSNpfwR0e3hUB/L86RW4JLMTkfhir+qpMHs7yG4DRN91Av3yexoAl1DUUvmltU2rcQ/OzY6r2FTaNcNf6e9ujMUQnc+OTWVDDdHVVYwoYZIgSf4jjqK6e4W3g8Ou1i4TzjlW9G70AYGpQWFzbk3W6WGNtrBhkKcVHqZhi0eKHTgibFDIx6FvT8azbbXLexS5sndHLLmRyejHpXn11r8k19Ja6nciG3lLCOTOOh4+hoA7fxLcSTaJawS3BBJALJ2+v+NWZ9WtNKtopnumSHyx5xY5+YdAR6V5Vq2t3sE6WcMyTRybcSE7twB4x9a3Nd0yXxBYw3qOQpjIe3U4O73oA6m48aacyTPaMzy43oUPyj3/CqC/EfTtWaGa6kZLizbfIqg4IHQ151L4b1mxubWxDtbGYbRuX+vcUvjLw5q/hR1N5sP2lQPMVcKQP5GgD03Q/iJe6o13LpvluJW5G3DbRx1+lQW/jK40vWFt7dVdHYs4/iH19653wb4cu7zR5rmB1sBt3o2PvcU2x8T2unakvmWsN1dRRsJpDgAt2JNAHot/4v0+Nrdo0kxOpV9ycjjriux8OXtmYY1kieJJFEkKtwWIFfM174tl1zWpDKY7ZYs7NnKj6muh0vxlqczRRJNFJ9kAfzGbHyjsKAPpe6guYJracYfdxhR0B9aybuKK8u5Irj9zPF828cbz6V5ZYfG2d5RA9r86ADLMAPqDW5B40gvWijlKMpJllkB6+wNAHMeOrW5Grq95CgiHKMq5Eh9xWJ9oinEtu8saFuEURcKuO5r2ayW21+K0ukEUsGSFRgMqOlcD468LHTHmuEtj5O4FShHGKAOWif7JBClnFALA53TCT+LuDTr23S8iKma2ngPz7Vc8n0zU6W0SwybtPUxhy21DlXBqbS9NhgTUJzAgiHzLCv58UAcl9imibyblHjWMgDncpB7HHQ13PgmBNXiubRHcxw9CT0PpWLHcTy3b3NsUCsNzo67dvHTnrV/wVrq2Gp3EO6IKqbpMfeY+9AG/4c0ddM+OHhWRWU+dcz4XuALK4r6Tr5y8G3qaj8R/B1w5JuPt84JI7fYrmvo2gDwD9tb/klmlf9hqL/wBET18YWkXn3UMWcb3C/ma+z/21v+SWaV/2Gov/AERPXyj8N7RLvxlpwljEkUb+Y6noQKAPpvSLyKz0aG0M7Na+WI41x90qMfkas/2miWS/bJGd423Iq9MCsewjnh1L9zZmRGcrtzwq47Ukej3sF+jRA4EnlvETnGemKAOhtvFkEGp7o4ybeTDfMDkNjkCsDWfE800lxbxsYIJX3Jx09xWwnhu8ih2S7BIrb0BH3uc8e9Q6ro0BWCe5hLRyjhlOBG49RQB4zrsVxLrNwllIJUlwCNxG71NJaCFIoWuAJ5ZGEWJOdpBrsdb8MRjWpntZkhhZPNhf/a7isjT/AA1Pe3qzAEMGJdyuApoAytQ0maPXo7aN0im274+PlH0q9p9zf2F/cXD3CxXMZ+dHOVI9q6NvD17eawlsGhnMREnn7sELVXVPDNxp1w0nkNcWs8pDkHJYHt+FAHaaHr2janokttqlwz6gg3Rbx8yHsBXLeNPEl34osYtMdIiciMNjJz05rEjtP7Pv7prk/ZyRiKSTkkf1ra0eN1v7PyEVwZP3of7ufUHtmgDD1XWbzw3p0ulCckRoAAxxsb0zXGQySLa3CXcLK0qltwOTXbfEuwhXXrl55AMfPtxuBHpXLy2j3NsBCw+0uv8Aqc8bBQBkrEEkXbGyqqbpMn7w9K3bMyQ2ud0SQygMuAD07Vct9Bnmj3Rm0B2chRlycdKmh0C++zxsIkZhjO44ZP8A61AGdZ6Sms3vkOphwuScE8n0qMDUtNu3s4CRFG2ED5GfxrtbayvYL5GMojixhpgMFvbpzTPEDZaGKSVHEjAlQgDKPXNAFbwt45vdEv1hlDmOM8Rqfvete0aXrtj4nsYreYhmMBkJJ6E187a3p08rRTwsgdVO7GMuPw707R9V1OzvQ1k8rZChuMbR/d+tAHsGpeG/7ESe4beLKEF1RAWaTNcGnmW98ssCS4unBBdj8q55Br0Hw34ss71ki1S+Qbl/fRN2A/hFQ+LrL98b7T4YxYqu/A4P/wCqgDmtTgjEv2mGFVbBIYjHyHjis7S4YoLlltYmm8sDdITww78+1XzdvcabLdSIZzgiGJBhsnoTWbpmn3VtNBKscieYS8sbknJ9wOg9qAPTfBbxXXiXwTcwW/lKNVnQnHf7Bd8fpXv9eEeEZJP7d8BpKqxs2qTuUQYC/wCg3Yr3egDwD9tb/klmlf8AYai/9ET147+zz4Ta/wBO1TV5FAG4QQuRnBHzN/QV7H+2mpf4XaSqjLHWoQAO58ieuf8AhpLF4Z8LWGlyEJJEu+XsGZhlgfpQB2egQGWeSVjsEkXAI+4wrX8mKW3huLnbFOh+cr/F6GvPtb8QiG3kkshvVzhBuwCR1X8qbp2vPqdkkdyWjhJ+UKcmMg9DQB7RaRwajaqWEcijpIvDfjWJqWjWtxZ3KXCho0fJx2Hqaz/DuoxeZ5UEhL7gJEzjH+0PatbxNczaVZPLDteN1/eA9x6igDzC+8MeZLdI0oby4/lUNwfRhUFppV/HFLNLOzW+QAEGcNjHPtVqQLcXst3YzGYcKIlb1rrdEnWBXW9CxxmPLoPvL70Acd4Z0nOryXN1O8ZQY8peh+vtXUavYNDp8rbAVVty15x4m8dRaTrXm25jubGOUguh5P1rpNL8bweIlmhiOyMIAUb72T/SgDmPF8sFvNBe31u5CMCyEZC113hFNG1k2siRyKGXMgCEc9s1majpFnqUFysouTOseUVm6e1ReHvEk2k2tv8AuBgDBQdaAMz4oW2kya9cwq4RzEFGRwK4HQLcnAHzTh/kOQNo9a6z4k3323Uci1UJcIGJLcj1zWFZaHbTQ21xb3UyiNgsoxnPfp6UAdp4U0y2W78wzBrh8h93P4+1dVPb6dZpl54nMh5XbnPsPes3w/Z29tbmOdTI0y5R04yO1btj4Zsrt1uXf5wuBk/d9aAKU7LdwxB2jWBOUDj/AArLbR5JI7me2t9pcfKzLnI+ladz4cEsEkumTNJ5LkqCeAe9bFrf3djpUEkCrPIxK4cYyRQBylv4TnulBMCxHj94Rg++B6VFF4Ue2iEEtsS43NvP8foa61786jKEvrjy5wAyxRnCgj+dalzqNlPHIrhvlXDbuP8AIoA8XvvDE2mWwkKebIzly6L8wFb1prV5c2EVhLH5aykI8snRU/xNd3BNZXjGKFk8lBg56uf8K4PxdbyF5okLRIHAjCfxfSgDn/GENrpN/OmnSyuEUElXO1TRY6hqD2ERgiV8jdnd831Iqa7t4p7dILjekpbJBHLKOtZ9zE1rM72m5bckIwU5IHcUAeq+DZC/ibwEGLEi/l5I6n7Dd5/pXv1fPvgc7vEPgFtjIov5gu7qf9Buuf5V9BUAeLftVQG48G+HUChiNdifaeh229w2P0rwK61h7i9aWZ5ArsCGU8E9MGvff2qpZ4fBnh+S0YLOutptJ6f8e1x/SvluS4lN4kkh8vzMkovIyeCaANYXlxHbywHcIGkyGJztIrsPD8kj2UUyIVaU+VJjt6EVy/hy1N3cNagKJEP3ZOQff8a9H8M6WhdrZJAhCbs4zg57igDe0e7jW6jmeUJNHHhWxtLgetUvEHiW+kMumsA3mfNECeQDSa1pt1a3KS7kZ0HBAyD+FcnqOoPdX0d1FC6/wdMgHvg9qAN7wnbS3N3HHcxmDawJKthge1afxWEltoElzazPHcL8kgLbcr61zf21tSn+xoJ4riPa7SKOM+9dD8Vmk1XwdZgwCSWMjc6DkY9RQB823TPczBJ5cYG4E9WHvV7QNS+zXYeOWVJgw+bPVR296y5fJF9Nl2AB+Ut+oNQBJHUsibx22UAfSGn6naXlnC9reCSVlAlwcMh9/aroh04oslo0se6T9674ZfcivnXw/wCIrzRL1Ht5Sh/i3LuB+tem6P4j0y4BW9vI0Mp3MEGBk0Adh4o8P2l7pUrWd7HLeRfMEAwSPrXD288+muJ0aRLGMASxvjd9DW6uu6Pplz5j3iyxqCpBONw7V594s8U2+o3M9vp8X2e0duQDkN9aAOos/F80dyzQjEA6EngD0rT0LxjJa3Uhub0rDI3AHOwH1ryS4vxEFjtyvTJGccelWLXUn8pRMcI3zFFHJ/GgD6RsdVgusnTbgxQLzIXP3j61ZvfGOm24lS3jWTYp3SHn8q8T8NrcX1xLDHmDcAwZZMg/X/CtrxLGkUSwRzRbzhpcDk4HU+lAHXRsdbnjuLW4USPyuDjavvV8aerfuJ2nlZmzujPyv7ZrhtKMtpH9nkMYR4w4ZW5C/wCFdZoviExRiOOB51AwrqOAfQmgCbUl8qYQwO5e3G5wvOOeM1USGa8kaeZmPlISxkHyir9vc3FzfTRfZoYvtBAdj1IHpWitlb3fl20yiGFG5YP978O5oA5i7tza6Ut1IVlmkBwwGXI9h2rDskWG3F0W3ryQjdF5/U16ffvp2no0MkaRkJ+5R2ywHqR2rivEuoWckVuqFZmXgRxDhSfXHU0Ad94XlRta8BhUYO2pysWI6/6Bd8D2r3GvCNEuXm8d+AYuFjiu5VKj1+wXP/1693oA8W/arGfBfh9cgFtbjUEnHJtrgV8ktFNY6rIt4/MLHO7r7V9c/tSWxvPCPh2BfvPrcePr9muDXzZ47sZIpY5Gj+dFCvxyR7+v1oAueH3jnha4SRnnQhnC8Ns9RXZT+JLLSGhmiZriB+Gcffj47+orx+yubm2lUrJ5YiXcpz1HtXSaRBN4k867tFO5MsYgevHPHoaAPQNe8WJf20clpdRvGRtYZ+8PUehrGvoJ4oopoWKmVd4UHKtnqSPX3rzoGexvZVVGCqQWQrwufauy0C5a5lh2s00NsQrurYCr7igDqPAWovZ+Ids0cl20hXcwXIQe9ep+KLpIb2NYbWJlnTY6uPlYe3oa5XwxplhDdNeW7OAT+7kX5iAecEd669v+Jq/mi3R3t/lIGefqO1AHiGu+CNPvNZMN1F9hifLCTsxzwM1xfibwk2jSSfYbgTL6Ie1fUdxpGmanMtvKFDFQWRjlV9/aud8XeB/IjKR7JIn4Ekagso/rQB8r3VnIlvukXCk4U+h9M1UWNwdpVty9ia9S8U+AjYhysjzgfNnO0fXHrXnskUhkKOuxhlcgcsaAGXMhmiUSRAEgHNVYPmuCHwEHTcetWVWL7O2+N3fdtwOMVGkQeN2CNtQd+tAEexDPIrADjCspyB9av2CRzqFl8yQovy7V449an0PT3uriLy4S0fBLAEgfWutjD6SHSLY0rHO0R5yPSgDl7K5lgTCTyRy5yAPlBX1rqrCcCOdL+JlR1A83PUeo9arTRz/NqFxbBIlIBjkGM56YqBoby7u1NviKGMZYfeAB7UAdZaSWLrZiO4Dy4A6feAPeu2jv7aKOLT7cMoJ3ZxjJNch4W09jEJGtDMxO0yrgBfoK6q0vYLN3g8svOp483qB7UAa1z9gtrZ90vmTgZGw8j6ntXIHV5dPuoTHIWMrEoinJzn3qzfX4t3ElvCyxknzXk6D6VhJe6ZcXTLbITJ3mbJA/GgDD1vWLy41XUp57hSW+SSTP3QP4RVTStWnt7RLm3hZoY5fnyMk+mPeszX7uBdQaMbZIgxOUGAW9feuw0DwxLq2nq0lyiQRrkFflVfqe5oA6z4UajJffEzwizyTMHvbhyrfdU/YrjAz619W18l/CZfJ+LPhWGOVZIBdT7CBjdizuATj0r60oA8p/aFtHvtH8K28UgjkfW1KsfUWlyQPxxj8a+eviZbXsMW57dmQ/KGH8J7g19HfHNN9p4RXKjOuD73T/AI87qvIvivBK1jshVSXXDAnhl/xoA+e5Ummg4B2xEqV/u5rb8IaxdaLrVvcQMCVIWSLoGX3rKntZoFkW3Emerg9RUumLi93TJuXjLA85oA9d8e6TDLbw63YpmCVMTRBc5zWN4MgjinSSwjdFlGHR+cD6dxXYeCZH1Dw3LZXULvbkYSQdV/8ArVzo0nULXUfMtTiOI8n/AD3oA73TrD/TLafTsxxGQecsTfKPfHavSLSLy7lijRrckZJ3YLj1rz7w7cCVJI2wk20ESKOSfcVv6H5vnlby4InxmOUDcMehoA2LjTrVzLdCV7bUcFST91xXPJa6/b3L723Wjcq45wfTHpVi/wBbtrqSWzkYG4QbgyjAbHoapefqN00ccepokZ4MZf5lHvQBjalp8l+kpZAZMlWU8q349jXnep+AptVhaWxxbKGJaQ8gH0PpXrsr3WmlrSeZnjb5shQCT9e9SWstvFaS2yxuTcAsPLU5XjuKAPDtN+Hl6kjA3sEbDk+YcA1paZ8OpL3T7hfL865WT5niHGPQV3N+181sttPbCTcSFLJ94dh9a2NIebStDfJ8qQfM0bLgYoA4mPww+jaFhwyx/wB0D5l+prmL2RRBIsu0Swf8tG6sPYV03iHU5tckNtb7448hwTwrj6VxepRmK633eyWIA5WIbifY0AZer6jcXNnFZCZpYU+YnHLH0rR0m5t7OdLldxiWPa0Tcbm7/WsOezeWWNxKLZJDuAbgCn3949tAEDrP/SgDrtI8Y31lPc3gtgmnjOE6fkPWrs3iYPGZYN8TyDdtOGbB7+1ecy6kt0Y1cKo/vc8ewFa5sYjpkrvcSiUjCITgt7UAbep62r+TAgkmkY5xn5SfesXV9SvmeWKAIFcBdkXAGOtUrzKJCiTbJCuwjvVaGaT7CYot2UfDNjBb6mgDQ0aKzW8hn1Rd6p/yzXofatjXPE0aHfBIIoMFYrWM8Zx1auJuZZGYbyY0znAPGPerRjhihSSYRyMTgjuBQB6R8B5vtPxh8JTtKS3mXA2en+iT19pV8U/AKSN/jF4T8qERr5lxznr/AKJPX2tQB5V+0GZF0jwq0BYSLrasu0ZPFpcmvNfiBfQ6r4Y3BXSdOCwGGRvQ+xr0v9oK4e10jwvPGjOya1nC9f8Ajzus1xutwxa94aF5bRoLvbtcA4Eo9/egD5wtZ2/tOWK72mLoW6HNTCxUyYtt28NlWA+Uir+p6SzTzhCAyNl0ZfmX/PrXUeGZI4bPybqNS+Mk9SB6+4oA6n4eaiNJEcV38rTD5RjKP9PSoPEOqyjVbhLVMq5yYyeVP+yaoTa3pTWUtoswgvYzuj3cqT6qe1Z+jvcIZJZXMsc7ZEp/hPpQB0/gaWTVLtrbebe4A++eMH2r0CRl0eKSa4x5kY+d0OVb6jtXK+FrS1imE7XaSNKRlTgFT7V1GqRtBGkaSB/ObbvK5BHvQBz8so1B/tcluIoM7lKDgD1qa3dYnE6yRSgHAO0gke9W9StTY2Dtb3agKPmjK5U+2O1YketSPaR2tmUWWfkMfuxmgDop9VhuYS3mBzHy3mDaF+nrWHHrUkd4l5bYiUHyxIW4+hBqDW9ZSERDWPKBjXBKpxJ9axbptPvWSRJo44urJux/9agDd8a+LXfS0O238+N8oyONxP0rkFvb7VdP+0y6rOcNgoPmH0rD+If2WW0huLCKeAwPhiM8+49abot5ZtojQG4kAJ3NtO3J/HvQBLc3S/Z/LjlVZmJQSkkBR6ViJNPaWc0sDu6AmNyBkH/PrTDPbodpAeGJ84Y8jPrT7y6tYrUw/aQ6SZIQNjHtQBhzalH5bb42Z9oEbMcnHeodPjjE74iMiyrgA8kZ70t3aTrao7Wzxoc98nFVbZSEZw8yoPuhf8aALr6b5E7OSoTOFkY9fwqJ52muQHiLoqkAngE+tNvWinCkblWMAgb+9VzJ5+wTOSy8IMYFAGyZLKxgjeZWmuB9wA+tUJfNnmlVyY2kG7bu7VXurjzAIJHRY0GSV7mq37liCzM2ByScZHtQArFHlO9v3a8ZH8RqayKTTlSoUY4yen096rTKJDsQkqOdo6U6N3iQSRnDK31oA9Q/Z8Yf8Lq8LqchjLckLnOB9kmr7fr4V/ZyYyfHLw07nMhe5yf+3WavuqgDyX9o29h0/QfDFzdbvJTWlDbeuDaXI/rXH2ljFJ4Xe+065AVhuTB4/EVt/tbKH8BaGp6HWk/9JrivK/CNyYNIMayuYWX7rNgr/jQBUZ4bzUBcvsN9nBA43fQ+tZmvwTtKIpjHHE4/duBtYH61uW+lrNqL3qhltnPDoMqG9/SqGuMzX01mwEsIGdxHKH/CgDHhtZ2nhijRGXAUGQfMp+tdjpkd6GXT5IFVn43t90/jWFHY3lr5cqSbk/5ZvnIB9DXYaTcXckPmyWhMgG1h1A9xQB1fh/w2dPDHUIogkg4P3wfxrWluLUW7WEj7JcHY8ZyCPeuSsfEEggnhnjldVbKhOCpHfHcVX0++uGvGvGjV7RWyHQ5K+uRQBY0sQSXU6XAkkRjhXibOB+NHiTRrW201pbOxeeZjw33SPeuhuLiC8tFuLKOBGfqyDofWkHiVbIx29zZySSDgSYBVqAPHL29QqLPUfMZ1xuDqWC/jUW2B4PssYFwG/wBX8uP1r1/UrDTdVlaV4Y4pZhygwMiqs2j2mlRC3TTizMAUZeQPxoA84vIM2MUMiGF0IA3Pxis650a5LloVinQchMAD616pPo1rZss9y3mW5X5sMGx7EVQ8mxjuBJbWzCDHPnNtXHegDyb+zL68nk8mzlik6FwMq1WYvA19Isd1LB5dupzJIx+97169ceItItY4ohIYY1HARQUPsTXG+JPF8WorJaWrl4AcBETAx9aAOE8QahBpym2jt0JIx5hOSa5NpZ5IGVWDKc7UTr+NbWtSR3l8AESELkMW6GsdrmSyuw0JR2PGVXJIoAziJ0kZCjbu4I5FOaFQsbs5aQ8lO4q7cTzreB5ozvZeRnBqC4tHIWSQ8HnbnoKAIyySgIsQjGMeuTT44xCU3qGGCSpNRNK8UoZFUAjCjOaFZt7KTlyck9z7UAQJIULqBt56+lPkYqEAYY65705maIFhGAPU1BDGJWVWOWY5xigD1H9nGOOP43+F9jl2Zrkk/wDbrNX3VXwl+zgf+L5+GBtxhrkf+Ss1fdtAHiv7Vkfm+CtATOM60nIP/TtcV47oTBtIEcoLOpwrY7V7P+1EsT+EfDy3DbYzrSAse3+i3OP1ryvw0s1nN5caLJbOMsV+bb7igDT8I3zWspWKWMoTh4pRjf68VmfEO1tzfx3FmPL3cbFOCD6fStry/wDTXGqWMMkX3o5Y/lYj6etUNQ0+1vvMis5jcYGQkhw6+wNAHFWYvvtTxJdJCCN2N24Ee4rf0rVLzTxFFOfP807QYjnn1rm7yO702a4lSGJ4Yh1fqAas6dcPKscqfuGxuwoyuf6UAdTPcr5yxNIImkb77qRitQXH9lWj287QywSdJkOQfrWJpDXmqXSSXEKiKPrkAlq1bmwt8geTJIkjZG0lSn0oA0tJlhKZin4H9zjP1FNvdJvHlZ0kMkLjIKsOPwqpZ6Db2chvILp1bbgxzN0rIkubiy1VyksjiThVU5XNAEsV9cQSst19ofyzhdnXH1ro9J1m3A3SSXRh6MrnlTWDLeFbqBZrTMrtjB4rZv8ATYJAHa3kSd8AfNlfyoAtiPSLu4P2S6GTzt5rC1u4HntF5El2FGNu7GB64rasdFltIiLfUYIZGGORzisaWOfSryW5laSd/u7lIYGgDmppTdwCIWRs7dSQTI3J/Cs6C1gga4h86Fcfddwck+grfuom1HU45kmljYfPiYjbx2rQ1HUPttp5T6ZHOyfxxjaB75oA8s1CzkkEi3M8QUAnKrg1gykIkDmAxqhwmD9/3Ndvf6GhvTNOJ2ifosfIH41Cktnpc7MLWOYgYXzlyQf5UAcVexXMsnmeX854UjtVKVnSOVJSd54I712k95LKZLgWxaRhgHGAPoK5W6hmMzSPDuc5OPb3oAzlibaTJlGUZ570wAqS2WBbnI7VdnhuXiZ+nAznv7Ck8lvL3FwvHzZ6fSgCtCHnZI1TcTwAT1qWS3NtM5l+SRB933qa0gKn7RBKqhehPaqcjtK8jztudzye9AHpP7NPPxt8MNknL3JP/gLNX3hXwn+zaiJ8bPCwUnO+5yM/9Os1fdlAHj37TdvJdeFvDkMUZkdtaU7R7WtyT+grzLwlp8lpceakhWXsvTj0Ir134+3S2WmeFZ3+6utc8etndD+teYyTw3V6Li22ALgDD4P4CgD0zw7aaV4is20/VIV+0LyroOR9DXDeNfBU3hvVEu7WOWePO7MYzuH+NdL4OnkF/FcNJ8ydWHB+leq6lZpqVh8pG/GVb3oA+dp9CttRtpHiceTKvzQyLhlNYTeGo7WAqIp4XJ+8pDIfwr3u20tGkkiuo445++V+Vqz9Z8FwX0avG7JIpyFXoTQB574U0WJOLmcEv93d8uPpWzPoU0UsitIXtjymw7iDVvU9IXS9p1K4ljB4VgvH5CsV74W9uJoNREoDbvkzyPSgC7H4Ml1UPC9z5LP8ys68Aemasr8JDGRJHIskh5DB/lzVqy8TLcRwxztiI984NdJpmrRRylIJ3Yf3XHQUActP8PtThhHlJHLcKOMHNZ2o+H/GX2cItrH5Y6g4zj2NetLfTGRRblXLDOScAVI97frExeEdOuM0AeMXbXdppyxXNufPAwxxnH1rB86yVFN5JhQfuRjk16Z4ku5bkzYtomkHRsY596821CxJbztVIBXlRGuB9KAK92uj3twEs9NuJnUgM+7OPwFb1j4UudRkwLeeFDgbd+Biq3h+ewsJTdSRsS4+Xnk/UV6TouszwWkks2l+6sScYoAy4PhlayQgXl15cfoWzisfVfhz4fs4HEoWYgfKxOcVreIPGMIsJ1G8THoqcAV55feIZ7i381JzJKoPyjotAHIa42k6ZcSrbo87xkrtdSAD7DvXB63cm/uFNvGIVzluMZ9hW14gu5b5jcXt4dingdyawyE1ZFhtl2MG++zEigDHv2aaLYku8g4VAeB+NVow7Q+ScFc9PStifRUtX2y3Ss3U7VwKzJpYlh8tTng4IHNAD45IhZmCLHmHqW4x9KzZEZNvzAsTjgdqdOwi2MhZ2IzkiklLOEII3Hqvp+NAHp37OAA+NvhbEZU7rnLE5z/os1fddfCP7Npb/hePhccYzcn/AMlZq+7qAPIv2lIhN4c8NRkE7taUcev2W5xXgl2s9vctA8UiynoD3+le8/tL3K2fhnw3cSKWRNaXIH/XrcivIjdrqMEZMhEQGVbGStAFfQ9UuYbxI1uMOBkZz8vtX0R8OfEovdKjgustOvBIr5kdJbLU1dbhbqJudvH5V2vgvxJHBqixbnti3IDevpQB9ISWyzMZDgkdARzTWUwushVio/u81jaBryXMISYNvUYznr9K1JZrgyxmzKFP41frQBPc2tjq0IS4iWVD6iufvPAmkBW+zRvCx7oePyqzcajqMLu0diZoc4/dkAqawbzxM9u7w3LTLKfuo4xxQBkal4ESCeNxcGRFOdu3BNbGkaRJZgguzLjhcDp6ZrDn1uYysHDGP7y4kwan07xoZoyk8QZV68jOKAOtjs5W+XmKP/aq9BbWyQtGryEnuWNcc3ju0K7I4/mXj1qpJ4zkm/1UYLD+EtigDpovDha6eR5uCchQxOaq6j4TivJf31qZo19WxVODxUSFigX98eqkk1q22vzhAs6eQDwGPOfrQBiX/gvRJIwILd7WRPm3FiKz77Ufs1i8L6g4jXj5eSav+M9RP2Rj9rhQ928wZxXmd94m0sQm3jEjydDJ2z60AVrnWPOuLpVhLxA4BkGCf8a5XX/sdzbOI4pImHLETfpgUzWr+8RmktJG8nONzAj8qz7fTJ9ViX7Na3bqxy8gUnn8qAM7QdMtr64EN7LHbwM3K53Ma6y/Gh6PAIrJo1K/eyvP59q5240i70kkixaEA8SSryTTLjNxEovnjFup3MI8ZJ+tAGD4huzcyO9qowPQdK5sqybleFg/qeMV0N7cwm5U6ejQwoSG3ng1k6m8lwXn80ADjapoAy7jJIjRfm7Z70AEkhkBkHAI6Um37z8jA+83NJblkQse/TPWgD079msf8Xs8MFuG33IPv/os1fd1fB37Nmf+F6+GMnjNzgf9us1feNAHK/ETwRYeO9ItNP1S6vbWO2uhdxyWbIH3hHTB3owIxI3b0rjI/gTo8cPlJ4k8SBPQNaf/ACPRRQBXH7PugLIZB4h8SBz38y1/+MVYj+BOjx42+JPEnHQlrQ/zt6KKANW1+FSWoAt/GHidMehs/wD5HrRTwJeR/d8beJgfXy7DP/pNRRQBPF4O1KLds8c+JgG65isDn87Wqt18P7i6AE/jLxE4HrDp/wD8i0UUAV3+GQkTa/i3xAykY5hsP/kWqKfByyRtyeJ/ESH/AGVsh/K2oooAig+C1hbySPD4p8TI0nLFWtBn/wAl6kb4N2TAhvFXiU56nNnn8/s9FFACx/B2zjnWaPxX4lWVRgMPsfT/AMB6lPwlhJyfF/ig9+Wsz/7b0UUAUb34IaZfAi68T+JpM+r2g/lb1AvwE0NQuPEPiL5eRzacf+S9FFAF63+DNhbsDH4m8QkjpvSyf+dsa24/Al1HD5UXjPxCiYxhYNPH8rWiigDndZ+CGm6zJv1PxT4onbOeZLUD8hABWZL+zl4ZlUK2u+JNo7LLbL/KCiigCu37M3hJhhta8SEf9drf/wCM0w/sw+DznOseJOf+m1v/APGaKKAEP7MHg4/8xfxJ/wB/rf8A+M0f8Mv+Ds5/tfxJ/wB/7f8A+M0UUAbvgf4DeGfB3iyw8QabqOtT3tn5hjS5lhMZ3xtGchYlPRz364r1uiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Alobar holoprosencephaly consisting of a single ventricle, fused thalami, and absence of the midline structures (falx cerebri, corpus callosum, cavum septum pellucidum).",
"    <br>",
"     (B) Semilobar holoprosencephaly consisting of a single ventricle, incomplete fusion of the thalami, and partially separated lateral ventricles. The arrow points to a small falx cerebri.",
"     <br>",
"      (C) Lobar holoprosencephaly consisting of fusion of the anterior horns of the lateral ventricle and absent cavum septum pellucidum.",
"      <div class=\"footnotes\">",
"       T: thalami.",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Ana Monteagudo, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9619=[""].join("\n");
var outline_f9_25_9619=null;
var title_f9_25_9620="Hamate fractures";
var content_f9_25_9620=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hamate fractures",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9620/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9620/contributors\">",
"     Patrice Eiff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9620/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9620/contributors\">",
"     Karl B Fields, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9620/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9620/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/25/9620/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper extremity fractures are among the most common of the extremity injuries with carpal fractures accounting for 18 percent of hand fractures and 6 percent of all fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Of these, fractures to bones of the distal row are less frequent than fractures of the bones of the proximal row (ie, scaphoid, lunate, triquetrum, and pisiform). Hamate fractures account for 2 to 4 percent of the carpal fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews fractures of the hamate in adults. An overview of carpal fractures in adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=see_link\">",
"     \"Overview of carpal fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PERTINENT ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The body of the hamate articulates distally with the bases of the 4th and 5th metacarpals, radially with the capitate and proximally with the triquetrum and lunate (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70211 \" href=\"UTD.htm?37/16/38146\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef69097 \" href=\"UTD.htm?1/31/1527\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef78359 \" href=\"UTD.htm?26/34/27172\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53465 \" href=\"UTD.htm?28/11/28853\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63301 \" href=\"UTD.htm?38/7/39030\">",
"     figure 4",
"    </a>",
"    ). The hook of the hamate (hamulus) is the distal border of Guyon's canal (",
"    <a class=\"graphic graphic_figure graphicRef57601 \" href=\"UTD.htm?15/0/15364\">",
"     figure 5",
"    </a>",
"    ), which contains the ulnar artery and nerve. The anatomy of the wrist is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14039?source=see_link\">",
"     \"Anatomy and basic biomechanics of the wrist\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fractures involving the hamate, particularly the hook, can injure branches of the ulnar artery and nerve, and thus it is important to ensure that blood flow and sensation is intact in the little and ring fingers. The ulnar nerve also supplies the intrinsic hand muscles, with the distal most innervation involving the dorsal interosseous muscle of the index finger (index finger abduction).",
"   </p>",
"   <p>",
"    The hook of the hamate develops from an ossification center separate from the body of the hamate. In some adults it persists as the os hamulus proprium. This normal variant can present a potential diagnostic pitfall if misinterpreted as a hamate fracture (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Radiographic findings'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the hook of the hamate are more common than fractures elsewhere in the bone. These often result from a fall on the outstretched hand that puts the transverse carpal ligament in tension and causes avulsion of the hook from the body. In sports, fracture of the hook of the hamate can occur when the end of a golf club, racquet, or bat is forced into the palm, exerting direct pressure on the hypothenar eminence, and thus the hamulus. The fracture typically occurs in the nondominant hand in golfers and batsmen [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS AND EXAMINATION FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is usually localized over the hypothenar eminence; swelling may be minimal or absent (",
"    <a class=\"graphic graphic_picture graphicRef86753 \" href=\"UTD.htm?39/38/40548\">",
"     picture 1",
"    </a>",
"    ). Hamate fractures are sometimes misdiagnosed as a wrist sprain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the fracture has compromised Guyon's canal the patient may have paresthesias in the 4th and 5th digits. Concomitant arterial injury may cause pallor along the ulnar border of the hand, although this is unlikely as collateral circulation from the palmar arch can provide flow to this area.",
"   </p>",
"   <p>",
"    Arterial to arterial embolization or vessel spasm resulting from ulnar artery injury may cause ischemic changes, a phenomenon known as the \"hypothenar hammer syndrome.\" However, this phenomenon is more often the result of repetitive injury to the hypothenar region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\", section on 'Secondary RP'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOGRAPHIC FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures or dislocations of the hamate body can be seen on antero posterior (AP) radiographs of the wrist or hand (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66660 \" href=\"UTD.htm?3/53/3935\">",
"     image 2",
"    </a>",
"    ). An AP view and obliques may show small avulsion fractures from the distal articular surface just proximal to the base of the 5th metacarpal.",
"   </p>",
"   <p>",
"    The hook or hamulus can be visualized with either a 20 degree supinated lateral view, or with a carpal tunnel view (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59836 \" href=\"UTD.htm?18/28/18894\">",
"     image 3",
"    </a>",
"    ) where the wrist is maximally extended and the X-ray tube angled 25 degrees inferiorly from the plane of the palm [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/1,4-7\">",
"     1,4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If suspicion is high and plain film radiographs are not conclusive, a CT scan of the wrist can be used for definitive diagnosis. CT can be especially helpful in visualizing the base of the hook when the patient cannot adequately extend the wrist because of pain (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60282 graphicRef75387 \" href=\"UTD.htm?10/60/11205\">",
"     image 4A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As noted above, the hook of the hamate ossifies independently from the body of the hamate. A separate bone known as the os hamulus proprium may be present in some adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/4\">",
"     4",
"    </a>",
"    ]. When the hamate is bipartite the radiolucent region separating the hamulus from the body is typically smooth and the margins are uniformly calcified. In the case of a hamate fracture, in contrast, the edges of the fragments are typically linear or jagged and the cortical or subchondral bone is disrupted. If there is any doubt, views of the uninjured wrist may be valuable or thin-cut CT can be used to assess further.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR SURGICAL REFERRAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with displaced fractures of the body of the hamate, or those with hook fractures who cannot tolerate prolonged immobilization should be referred for hand surgery evaluation and possible operative intervention. The literature suggests that following excision of the hook of hamate, patients can return to full activities within four to six weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal management of an acute hamate hook fracture is uncertain. Some authors recommend excision in all cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/8\">",
"     8",
"    </a>",
"    ] while others recommend at least a trial of immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. Those who have been managed appropriately with immobilization but fail to heal should be referred for excision. Additionally, at the onset, if there is any evidence of flexor tendon injury with acute fracture, patient should be referred.",
"   </p>",
"   <p>",
"    Competitive athletes and those in occupations requiring gripping often proceed with surgical excision at the outset because of the pressure to get the individual back to full activity as soon as possible, ie, not waiting for four to six weeks to see if they will heal with immobilization. In other patients, without this time pressure or demands on the use of their hand, initial non-operative treatment is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INITIAL TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hook fractures or displaced hamate body fractures that are being referred for operative consideration can be protected in a volar splint (",
"    <a class=\"graphic graphic_figure graphicRef65696 \" href=\"UTD.htm?42/15/43263\">",
"     figure 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=see_link\">",
"     \"Splinting of musculoskeletal injuries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=see_link\">",
"     \"Patient information: Cast and splint care (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-displaced hamate body, avulsion fractures and fractures of the hook undergoing cast therapy can typically be placed into a definitive short arm cast unless swelling is prohibitive. The cast should include the metacarpophalangeal (MCP) joints of the 4th and 5th digits [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/4\">",
"     4",
"    </a>",
"    ]. The MCP joints should be in flexion to prevent shortening of the collateral ligaments (",
"    <a class=\"graphic graphic_figure graphicRef80299 \" href=\"UTD.htm?4/10/4261\">",
"     figure 7",
"    </a>",
"    ) and thus minimize the loss of motion that can result from prolonged immobilization of the MCP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonoperatively managed patients should be immobilized with the short arm cast (with 4th and 5th digits) for a total of four to six weeks. Some hook fractures take up to 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/3,10\">",
"     3,10",
"    </a>",
"    ]. radiographs can be repeated at two to three week intervals to assess the progress of healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Those managed nonoperatively can be returned to work or sports activity immediately with casting, if able to perform their appropriate functions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. Workers and athletes who have undergone operative intervention should be restricted from active participation until after four to six weeks of immobilization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9620/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An aggressive attempt to increase range of motion is begun after casting and when pain has subsided. In both situations, protective splinting should be continued for three months and thereafter until full pain-free range of motion and strength have returned.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fractures of the hook of the hamate are more common than fractures of the body.",
"     </li>",
"     <li>",
"      Guyon's Canal is adjacent to the hook of the hamate, and thus the examination must include an assessment for damage to the ulnar artery or nerve when a hook of the hamate fracture occurs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pertinent anatomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms and examination findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Body fractures can be visualized with standard hand films, but the hook is best visualized with a carpal tunnel view or a lateral view with the wrist in 20 degrees of supination. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Radiographic findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All displaced fractures of the body and hook fractures where the patient cannot tolerate prolonged immobilization should be referred for operative intervention. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications for surgical referral'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nondisplaced and avulsion fractures of the body and certain cases of hook fracture are treated with a short arm cast (with 4th and 5th digits) for four to six weeks or possibly more with hook fractures. Protection during sports is continued for three months afterward. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Follow-up care'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Recommendations for return to sport or work'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15938079\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to acknowledge Kevin E Burroughs, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dobyns JH, Beckenbaugh RD, Bryan RS, et al. Fractures of the hand and wrist. In: Hand Surgery, 3rd, Flynn JE (Ed), Williams &amp; Wilkins, Philadelphia 1982.",
"    </li>",
"    <li>",
"     Eiff MP, Hatch RL. Chapter 5: Carpal fractures. In: Fracture Management for Primary Care, 3rd, Saunders, Philadelphia 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9620/abstract/3\">",
"      Geissler WB. Carpal fractures in athletes. Clin Sports Med 2001; 20:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9620/abstract/4\">",
"      Binzer, TC, Carter PR. Hook of the hamate fracture in athletes. Oper Tech Sports Med 1996; 4:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9620/abstract/5\">",
"      Lacey JD, Hodge JC. Pisiform and hamulus fractures: easily missed wrist fractures diagnosed on a reverse oblique radiograph. J Emerg Med 1998; 16:445.",
"     </a>",
"    </li>",
"    <li>",
"     Seitz WH, Papandrea RF. Fractures and dislocations of the wrist. In: Rockwood and Green's Fractures in Adults, 5th, Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002.",
"    </li>",
"    <li>",
"     Geissler W, Slade JF. Fractures of the carpal bones. In: Operative Hand Surgery, 6th, Green DP (Ed), Churchill Livingstone, Edinburgh 2011. p.639.",
"    </li>",
"    <li>",
"     McCue FC, Bruce JF, Koman JD. Wrist and hand. In: DeLee and Drez's Orthopedic Sports Medicine Principles and Practice, 2nd, Saunders, Philadelphia 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9620/abstract/9\">",
"      Steinberg B. Acute wrist injuries in the athlete. Orthop Clin North Am 2002; 33:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9620/abstract/10\">",
"      Whalen JL, Bishop AT, Linscheid RL. Nonoperative treatment of acute hamate hook fractures. J Hand Surg Am 1992; 17:507.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 203 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-293D88DB16-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9620=[""].join("\n");
var outline_f9_25_9620=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PERTINENT ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS AND EXAMINATION FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOGRAPHIC FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INDICATIONS FOR SURGICAL REFERRAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INITIAL TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RECOMMENDATIONS FOR RETURN TO SPORT OR WORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15938079\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/203\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/203|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?37/16/38146\" title=\"diagnostic image 1\">",
"      Normal adult wrist AP xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/53/3935\" title=\"diagnostic image 2\">",
"      Hamate body fracture xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/28/18894\" title=\"diagnostic image 3\">",
"      Hook of hamate fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/23/16753\" title=\"diagnostic image 4A\">",
"      Coronal CT of hamate fracture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/27/27071\" title=\"diagnostic image 4B\">",
"      3D reconstruction CT hamate fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/203|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/31/1527\" title=\"figure 1\">",
"      Anatomy of the volar aspect of the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/34/27172\" title=\"figure 2\">",
"      Anatomy wrist dorsal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/11/28853\" title=\"figure 3\">",
"      Wrist joints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/7/39030\" title=\"figure 4\">",
"      Wrist ligaments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/0/15364\" title=\"figure 5\">",
"      Major branches of the ulnar nerve at the wrist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/15/43263\" title=\"figure 6\">",
"      Volar forearm splint",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/10/4261\" title=\"figure 7\">",
"      MCP lig volar plate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/203|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/38/40548\" title=\"picture 1\">",
"      Hamate palpation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/45/14039?source=related_link\">",
"      Anatomy and basic biomechanics of the wrist",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/49/4886?source=related_link\">",
"      Overview of carpal fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15208?source=related_link\">",
"      Splinting of musculoskeletal injuries",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_25_9621="Group B streptococcus: Virulence factors and pathogenic mechanisms";
var content_f9_25_9621=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Group B streptococcus: Virulence factors and pathogenic mechanisms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9621/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9621/contributors\">",
"     Lawrence C Madoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9621/contributors\">",
"     Carol J Baker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9621/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9621/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9621/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9621/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/25/9621/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group B streptococcus (GBS; Streptococcus agalactiae) is a gram-positive coccus that frequently colonizes the human genital and gastrointestinal tracts [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is an important cause of infection in three populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates &mdash; GBS infection is acquired in utero or during passage through the vagina. Neonatal disease is categorized by the age at onset into early- and late-onset infection. Early-onset is the most common form of neonatal GBS infection; it generally presents at or within 12 hours of birth but, by definition, can occur through day six of life. The most common manifestations are bacteremia without a focus, sepsis, pneumonia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      meningitis. Late-onset infection occurs after day six and up to 90 days of life. It most often presents as bacteremia without a focus (60 percent of cases) but meningitis (35 percent) and focal infections also occur. Late-onset infections most frequently are caused by serotype III GBS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link\">",
"       \"Group B streptococcal infection in neonates and young infants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pregnant women &mdash; GBS is a frequent cause of urinary tract infection (usually asymptomatic bacteriuria), chorioamnionitis, postpartum endometritis, and peripartum bacteremia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=see_link\">",
"       \"Group B streptococcal infection in pregnant women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonpregnant adults &mdash; GBS is increasingly recognized as a cause of sepsis, soft tissue infections, and other focal infections in nonpregnant adults. These infections occur predominantly in those with chronic underlying medical conditions, such as diabetes mellitus, malignancy especially breast cancer, and liver disease. However, GBS also can cause infection in healthy elderly patients over the age of 65 years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36936?source=see_link\">",
"       \"Group B streptococcal infections in nonpregnant adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The microbiology of GBS will be reviewed here. GBS infection and treatment in neonates and young infants, pregnant women, and nonpregnant adults and prevention strategies through chemoprophylaxis and vaccination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36936?source=see_link\">",
"     \"Group B streptococcal infections in nonpregnant adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=see_link\">",
"     \"Group B streptococcal infection in neonates and young infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=see_link\">",
"     \"Group B streptococcal infection in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40984?source=see_link\">",
"     \"Vaccines for the prevention of group B streptococcal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcus agalactiae, the sole member of Lancefield group B, forms small 3 to 4 mm, grey-white colonies that have a narrow zone of beta hemolysis on blood agar [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. Lancefield identified the group B antigen, a cell wall-associated carbohydrate that distinguishes GBS from other streptococcal species [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical microbiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS is identified in the clinical laboratory by its characteristic narrow zone of beta hemolysis; by its elaboration of CAMP factor, which enhances the hemolysis caused by beta lysins of many Staphylococcus aureus strains; and by biochemical characteristics, including lack of hydrolysis of bile esculin agar and hydrolysis of hippurate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Commercial kits with antisera that recognize the group B antigen are used to confirm the identity of isolates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Virulence factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBS produces many extracellular substances, some of which have a role either in virulence or as protective antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/1\">",
"     1",
"    </a>",
"    ]. The best characterized are the capsular polysaccharides, which confer serotype specificity to GBS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. These complex carbohydrates are composed of approximately 150 repeating oligosaccharide subunits [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The nine capsular serotypes currently recognized differ in their arrangements of monosaccharides within the oligosaccharide repeating units. However, each subunit contains a mono-, di-, or trisaccharide side chain terminating in an N-acetylneuraminic acid (sialic acid) residue.",
"   </p>",
"   <p>",
"    The capsule confers virulence to the organism, at least in part, by inhibiting the deposition of complement components on the surface of the organism in the absence of serotype-specific antibody. The sialic acid moiety is critical to this function. Antibodies to capsular polysaccharide confer protection against invasive disease, at least in neonates and young infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/11\">",
"     11",
"    </a>",
"    ]. Subsequent data suggest a role for GBS capsular sialic acid moieties in molecular mimicry of host structures. Capsular residues bind neutrophil Siglec-9 resulting in impaired neutrophil response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The invasion associated gene (iagA), which encodes a glycosyltransferase and produces a cell membrane anchor for lipoteichoic acid, plays a role in bacterial invasion of the blood-brain barrier. In a mouse model of hematogenous meningitis, animals challenged with a GBS iagA mutant developed bacteremia comparable to mice challenged with wild-type GBS organisms, but had significantly lower mortality (20 versus 90 percent) and a decreased incidence of meningitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For a particular strain of serotype III GBS that has been strongly associated with neonatal meningitis after the first week of life, a surface-anchored protein called hypervirulent GBS adhesin (HvgA) is thought to mediate its hypervirulence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/14\">",
"     14",
"    </a>",
"    ]. Expression of HvgA promotes adherence to the intestinal epithelium and cells that form the blood-brain barrier. When GBS expressing HvgA are inoculated into mice, the bacteria can be detected in their meninges, brain parenchyma, and cerebral vasculature. In contrast, lower numbers of GBS are found at these sites in mice infected with HvgA deletion mutants.",
"   </p>",
"   <p>",
"    C proteins and other related surface proteins also are known to be involved in protective immunity and may have a role in virulence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. As an example, some neonatal isolates contain fewer tandem repeats in the alpha C surface protein than do their corresponding maternal isolate; these organisms, which may be selected for under specific antibody pressure, are less sensitive to killing by specific antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/17\">",
"     17",
"    </a>",
"    ]. On the other hand, in vitro studies show that organisms with larger numbers of repeats generate less antibody response [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/18\">",
"     18",
"    </a>",
"    ]. The following hypothesis can reconcile these seemingly contradictory findings. In nature, GBS has a relatively high number of repeats, which tends to diminish the antibody response; if an antibody response occurs, the organism loses repeats, thereby removing the inciting antigen. In addition, the alpha C protein has been shown to have a role in invasion by GBS into cultured cervical epithelial cells that is related to binding of host glycosaminoglycans [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pilins, long known for their role in virulence of gram-negative pathogens, have also been demonstrated to occur in group B streptococci and function as adhesins, promote CNS entry, and enhance biofilm formation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/20\">",
"     20",
"    </a>",
"    ]. Antibodies directed against pilus-islands 1, 2a, and 2b are protective in a murine model of lethal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/21\">",
"     21",
"    </a>",
"    ]. Other substances produced by GBS, which are less completely characterized, include hemolysins, protease CspA, Pbp1a, Serine-rich protein (Srr-1), CAMP factor, pigment, hyaluronate lyase, complement factor 5a (C5a) peptidase, nucleases, and lipoteichoic acid. Among these, the best evidence for virulence in human infection is for beta hemolysin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/22\">",
"     22",
"    </a>",
"    ] and C5a peptidase [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple complete genomic sequences for GBS have been published and are available through online databases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9621/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Analysis of these genomic data should enable the identification of new vaccine antigens and improve the understanding of pathogenic mechanisms and epidemiology of GBS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11248?source=see_link\">",
"       \"Patient information: Group B streptococcus and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20251296\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group B streptococcus is an important cause of invasive infection in neonates and pregnant women. It is also an increasingly recognized pathogen in other adults, particularly the elderly and those with underlying medical conditions. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is the only streptococcus in the Lancefield group B and is distinguished by its narrow zone of beta hemolysis, elaboration of CAMP factor, hydrolysis of hippurate, and lack of bile esculin agar hydrolysis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virulence factors include the polysaccharide capsule, C-proteins, and pilins, which are also targets of protective antibody responses. The invasion associated gene and, for certain strains, the hypervirulent GBS adhesion protein may be instrumental in the tropism of Group B streptococcus for the central nervous system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Virulence factors'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Edwards MS, Nizet V, Baker CJ. Group B Streptococcal Infections. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington JS, Klein JO, Wilson CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.419.",
"    </li>",
"    <li>",
"     Wessels MR, Kasper DL. Group B streptococcus. In: Infectious Diseases, Gorbach SL, Bartlett JG, Blacklow NR (Eds), WB Saunders, Philadelphia 1997.",
"    </li>",
"    <li>",
"     Madoff, LC, Kasper, DL. Group B streptococcal infection. In: Obstetric and Perinatal Infections, Charles, D (Ed), Mosby Year Book, Boston, 1993, p. 210.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/4\">",
"      Lancefield RC. A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B). J Exp Med 1934; 59:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/5\">",
"      Jennings HJ, Katzenellenbogen E, Lugowski C, Kasper DL. Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus. Biochemistry 1983; 22:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/6\">",
"      Jennings HJ, Rosell KG, Katzenellenbogen E, Kasper DL. Structural determination of the capsular polysaccharide antigen of type II group B Streptococcus. J Biol Chem 1983; 258:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/7\">",
"      Wessels MR, Bened&iacute; WJ, Jennings HJ, et al. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun 1989; 57:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/8\">",
"      Rubens CE, Wessels MR, Heggen LM, Kasper DL. Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad Sci U S A 1987; 84:7208.",
"     </a>",
"    </li>",
"    <li>",
"     Wessels MR, Benedi VJ, Kasper DL, et al. Type III capsule and virulence of group B streptococci. In: Genetics and Molecular Biology of Streptococci, Lactococci, and Enterococci, Dunny GM, Cleary PP, McKay LL (Eds), American Society for Microbiology, Washington, DC 1991. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/10\">",
"      Kasper DL. Bacterial capsule--old dogmas and new tricks. J Infect Dis 1986; 153:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/11\">",
"      Baker CJ, Kasper DL. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. N Engl J Med 1976; 294:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/12\">",
"      Carlin AF, Uchiyama S, Chang YC, et al. Molecular mimicry of host sialylated glycans allows a bacterial pathogen to engage neutrophil Siglec-9 and dampen the innate immune response. Blood 2009; 113:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/13\">",
"      Doran KS, Engelson EJ, Khosravi A, et al. Blood-brain barrier invasion by group B Streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid. J Clin Invest 2005; 115:2499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/14\">",
"      Tazi A, Disson O, Bellais S, et al. The surface protein HvgA mediates group B streptococcus hypervirulence and meningeal tropism in neonates. J Exp Med 2010; 207:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/15\">",
"      Johnson DR, Ferrieri P. Group B streptococcal Ibc protein antigen: distribution of two determinants in wild-type strains of common serotypes. J Clin Microbiol 1984; 19:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/16\">",
"      Madoff LC, Michel JL, Gong EW, et al. Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein. Infect Immun 1992; 60:4989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/17\">",
"      Madoff LC, Michel JL, Gong EW, et al. Group B streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. Proc Natl Acad Sci U S A 1996; 93:4131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/18\">",
"      Gravekamp C, Kasper DL, Michel JL, et al. Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are inversely related to the number of repeats. Infect Immun 1997; 65:5216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/19\">",
"      Baron MJ, Filman DJ, Prophete GA, et al. Identification of a glycosaminoglycan binding region of the alpha C protein that mediates entry of group B Streptococci into host cells. J Biol Chem 2007; 282:10526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/20\">",
"      Konto-Ghiorghi Y, Mairey E, Mallet A, et al. Dual role for pilus in adherence to epithelial cells and biofilm formation in Streptococcus agalactiae. PLoS Pathog 2009; 5:e1000422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/21\">",
"      Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009; 199:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/22\">",
"      Nizet V, Gibson RL, Chi EY, et al. Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells. Infect Immun 1996; 64:3818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/23\">",
"      Glaser P, Rusniok C, Buchrieser C, et al. Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol 2002; 45:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9621/abstract/24\">",
"      Tettelin H, Masignani V, Cieslewicz MJ, et al. Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A 2002; 99:12391.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3174 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-D2AB0E8FD6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9621=[""].join("\n");
var outline_f9_25_9621=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20251296\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical microbiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Virulence factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20251296\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/16/18698?source=related_link\">",
"      Group B streptococcal infection in neonates and young infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/3/43062?source=related_link\">",
"      Group B streptococcal infection in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36936?source=related_link\">",
"      Group B streptococcal infections in nonpregnant adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?10/63/11248?source=related_link\">",
"      Patient information: Group B streptococcus and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40984?source=related_link\">",
"      Vaccines for the prevention of group B streptococcal disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_25_9622="Renal atheroembolus histology";
var content_f9_25_9622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56672&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Renal atheroembolus histology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph of an atheroembolus in a muscular renal artery showing cleft-like spaces (arrow) due to washout of the cholesterol crystals during histologic processing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9622=[""].join("\n");
var outline_f9_25_9622=null;
var title_f9_25_9623="Coronary artery stent thrombosis: Clinical presentation and management";
var content_f9_25_9623=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Coronary artery stent thrombosis: Clinical presentation and management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9623/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9623/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9623/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9623/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9623/contributors\">",
"     Stephan Windecker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9623/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9623/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/25/9623/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1043308818\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary artery stents, particularly drug-eluting stents (DES), are used in the majority of patients who undergo percutaneous coronary intervention (PCI) to improve symptoms in patients with obstructive coronary artery disease. They function both to prevent abrupt closure of the stented artery soon after the procedure as well as to lower the need for repeat revascularization compared to balloon angioplasty alone (formerly referred to as percutaneous transluminal coronary angioplasty).",
"   </p>",
"   <p>",
"    Stent thrombosis is an uncommon but serious complication of PCI with stenting. Most patients present with an acute coronary syndrome, usually with ST-segment elevation on the electrocardiogram. Its cause is total or subtotal thrombotic occlusion of a coronary artery by thrombus that originates in or close to an intracoronary stent. This finding is seen at the time of coronary angiography and it is necessary in most cases to secure the diagnosis. Death and myocardial infarction are not infrequent complications of stent thrombosis.",
"   </p>",
"   <p>",
"    This topic will discuss the presentation and management of and outcomes after acute coronary artery stent thrombosis. Issues related to its incidence, timing, risk factors, and prevention are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043309813\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with stent thrombosis usually present with an acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction, or ST-elevation myocardial infarction). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=see_link\">",
"     \"Initial evaluation and management of suspected acute coronary syndrome in the emergency department\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, patients present with criteria for the diagnosis of acute ST-elevation myocardial infarction (STEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=see_link\">",
"     \"Criteria for the diagnosis of acute myocardial infarction\"",
"    </a>",
"    .) In a report from the United States CathPCI Registry, among almost 7100 cases of stent thrombosis identified during a 16-month period, approximately 60 percent presented with STEMI, 23 percent with non-ST elevation MI, and 17 percent with unstable angina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with early (&lt;1 month after stent placement) are somewhat more likely to develop cardiogenic shock than those with late (1 to 12 months) or very late (&gt;12 months) stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At the time of coronary angiography, most patients have complete thrombotic occlusion (TIMI flow grade 0) of the involved vessel (",
"    <a class=\"graphic graphic_table graphicRef51941 \" href=\"UTD.htm?1/49/1819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"     2",
"    </a>",
"    ]. The culprit lesion is more common in the left anterior descending artery (48 percent) in patients with early and late stent thrombosis, whereas the right coronary artery (38 percent) is more commonly involved in cases of very late stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stent thrombosis should be considered in any patient who presents with an acute coronary syndrome (ACS) after PCI with stenting, particularly within the past year. In the CathPCI Registry, 1.8 percent of all PCI for ACS were attributable to stent thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"     2",
"    </a>",
"    ]. In a 2012 report from two hospitals in Minneapolis, Minnesota, USA, nearly 11 percent of all STEMI were attributable to definite stent thrombosis according to the Academic Research Consortium (ARC) criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the possibility of stent thrombosis should be considered in any patient who presents with ACS after stent placement, there is no information from the history, physical examination, or electrocardiogram that can be used to clearly discriminate between stent thrombosis and ACS due to ischemia from a lesion(s) not related to prior stent placement. In the presence of ST-elevation or other changes suggestive of target (stented) vessel ischemia, the suspicion for stent thrombosis should be higher. Such an event would be classified as probable stent thrombosis by the Academic Research Consortium (ARC) criteria unless angiography confirms another culprit. We accept the ARC criteria for the diagnosis of stent thrombosis; these criteria include categories of definite, probable, and possible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who have unexplained death after stent placement for which stent thrombosis is a reasonable cause are categorized as having either probable or possible stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H2#H2\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition of definite stent thrombosis is as follows: angiographic or tissue (from thrombectomy at the time of angiography) confirmation of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent, with or without vessel occlusion, which is associated with acute onset of ischemic symptoms at rest or ECG signs of acute ischemia or typical rise and fall of cardiac biomarkers within 48 hours of angiography. Definite stent thrombosis may also be determined by pathologic confirmation of stent thrombosis at the time of an autopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H2#H2\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Definitions of stent thrombosis and restenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the (incidental) finding of thrombus within a stent in a patient without clinical findings is possible, this is a rare event. Most of these individuals have an elevated troponin value.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1128708641\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since stents are often placed in proximal segments of major coronary arteries, acute thrombotic occlusion presents as severe ischemia or myocardial infarction, often ST-elevation myocardial infarction (STEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. The approach to the management of patients with unstable angina or acute MI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=see_link\">",
"     \"Overview of the acute management of ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=see_link\">",
"     \"Overview of the acute management of unstable angina and non-ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of patients with stent thrombosis is similar to that for other patients with an acute coronary syndrome (ACS). However, as outcomes in these patients appear to be worse than in individuals with ACS due to plaque rupture in a native coronary artery, it is critically important that the time to reperfusion be as short as possible. (See",
"    <a class=\"local\" href=\"#H1043309842\">",
"     'Compared to de novo coronary thrombosis'",
"    </a>",
"    below.) Thus, in patients with unstable angina or non-ST elevation MI who are being considered for either a non-urgent invasive or a conservative strategy as might be reasonable in some patients with ACS and no prior stent placement, urgent coronary angiography should be considered. Patients with STEMI should be managed with primary percutaneous coronary intervention, although restoration of blood flow with intracoronary fibrinolysis has been used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=see_link\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1128708648\">",
"    <span class=\"h2\">",
"     Periprocedural considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recanalization of the occluded artery is possible in over 95 percent of cases. Manual thrombus aspiration can be used in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"     2",
"    </a>",
"    ] and in one study was associated with greater epicardial and microvascular myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/8\">",
"     8",
"    </a>",
"    ]. Similar to patients with STEMI due to de novo thrombosis, we perform thrombectomy in most cases of stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=see_link&amp;anchor=H9#H9\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\", section on 'Thrombectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, contributing factors such as suboptimal stent apposition or prior placement of an undersized stent are present. We perform intravascular ultrasound in most cases of stent thrombosis and use this information for subsequent stent sizing and to confirm complete stent apposition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts feel that new stent implantation should be avoided unless there is a clear indication such as a flow-limiting dissection. In many cases, we repeat stent placement unless thrombus aspiration and balloon angioplasty yield an optimal result. We generally guide the decision making about the type of stent placement (bare metal versus drug-eluting) in a manner similar to patients with de novo stenting, with drug-eluting stents preferred if the patient is able to comply with the recommended duration of dual antiplatelet therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H18#H18\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The periprocedural antithrombotic approach, including the use of parenteral antiplatelet and anticoagulant therapies does not differ from that recommended for patients with acute ST-elevation myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1128708655\">",
"    <span class=\"h2\">",
"     Long-term antiplatelet therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poor compliance with the recommendation for dual antiplatelet therapy (DAPT) may be the primary cause of development of stent thrombosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=see_link&amp;anchor=H10#H10\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Risk factors'",
"    </a>",
"    .) In addition, resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    may be an important contributing factor in many cases. The optimal approach to antiplatelet therapy after stent thrombosis in patients who demonstrate clopidogrel nonresponse on platelet testing, or a genetic predisposition to it, is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=see_link&amp;anchor=H2#H2\">",
"     \"Nonresponse and resistance to clopidogrel\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients who present with stent thrombosis while on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , it is likely the risk of recurrent stent thrombosis is increased. While no trials of alternate antiplatelet regimens, such as switching to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    or higher dose clopidogrel, have been performed in these patients, we believe that the benefit from the use of more potent antiplatelet therapy outweighs the increase in risk of bleeding in most patients. Therefore, we suggest discharging the patient on prasugrel 10 mg daily or ticagrelor 90 mg twice daily, in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . The minimum duration of DAPT should be one year, with longer courses for patients who are tolerating such therapy.",
"   </p>",
"   <p>",
"    Similarly, for patients who present with stent thrombosis after completing the recommended duration of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , the optimal preventative antiplatelet strategy is unknown. We suggest initiating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    10 mg daily or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    90 mg twice daily rather than restarting clopidogrel and continuing DAPT for a minimum of one year or longer in patients tolerating this regimen. However, in patients who will not receive either prasugrel or ticagrelor, clopidogrel 75 mg daily (in addition to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) should be restarted.",
"   </p>",
"   <p>",
"    In patients who have sustained stent thrombosis, the optimal duration of DAPT is unknown. While we suggest continuing DAPT for more than one year in all patients with stent thrombosis, continual monitoring of the relative benefits and risks (primarily the risk of bleeding) is necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043309820\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043309828\">",
"    <span class=\"h2\">",
"     MI and death",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following studies highlight high rates of myocardial infarction (MI) and death after acute stent thrombosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with an acute coronary syndrome and angiographically confirmed (definite) stent thrombosis in a pooled analysis, the 30-day rate of MI was 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 30-day mortality rates after stent thrombosis are 7 percent for angiographically confirmed and 19 percent for clinically identified stent thrombosis for bare metal stents (BMS) based upon pooled clinical trial data [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/5\">",
"       5",
"      </a>",
"      ] and 15 percent with drug-eluting stents (DES) based upon a large real-world registry [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/9\">",
"       9",
"      </a>",
"      ]. One study of 7315 stent thrombotic events found that in-hospital mortality was higher in patients with early stent thrombosis (up to 30 days after stent placement) compared with late (30 days to one year) and very late stent (after one year) thrombosis (7.9 versus 3.8 and 3.6 percent; p &lt;0.01) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Six-month mortality is between 20 and 25 percent among survivors of stent thrombosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/10\">",
"       10",
"      </a>",
"      ]. Some studies have reported higher six-month mortality rates after stent thrombosis with DES compared to BMS (17 to 45 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/11-14\">",
"       11-14",
"      </a>",
"      ] and 9 to 21 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/5,6\">",
"       5,6",
"      </a>",
"      ], respectively). However, other studies have shown equivalent mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/14\">",
"       14",
"      </a>",
"      ]. Predictors of six-month mortality include very late stent thrombosis, implantation of a stent during PCI for ST, and failure to achieve optimal angiographic reperfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mortality at one year after definite DES thrombosis is between 10 and 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/10,15-17\">",
"       10,15-17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Longer-term mortality (450 days) after definite stent thrombosis was 22 percent in the TRITON-TIMI 38 trial of acute coronary syndrome patients who were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      and then underwent PCI with stenting [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The overall rates of death and MI at four years were 31 and 83 percent, respectively, after definite or possible stent thrombosis (ARC definition) in a pooled analysis of eight randomized trials comparing DES to BMS [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/19\">",
"       19",
"      </a>",
"      ]. The outcomes with DES and BMS stent thrombosis were combined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043309835\">",
"    <span class=\"h2\">",
"     Recurrent stent thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not well studied, the incidence of recurrent stent thrombosis is relatively high. In a review of 95 patients with BMS thrombosis, 11 patients (12 percent) had recurrent stent thrombosis at six months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/6\">",
"     6",
"    </a>",
"    ]. In a registry of DES, recurrence was 4.6 percent at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/15\">",
"     15",
"    </a>",
"    ]. In a report of 431 patients in the Dutch stent thrombosis registry, the cumulative incidence of definite or probable recurrent stent thrombosis was 20.1 percent at three years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiographic predictors of recurrent stent thrombosis include a larger post-procedural vessel diameter and a larger residual thrombus burden [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043309842\">",
"    <span class=\"h2\">",
"     Compared to de novo coronary thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;ST-elevation MI (STEMI) is characterized by intraluminal thrombus irrespective of whether the initial event is de novo (in association with plaque rupture) or stent related. However, clinical outcomes appear worse with the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=see_link\">",
"     \"Epidemiology of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=see_link&amp;anchor=H3#H3\">",
"     \"Antiplatelet therapy after coronary artery stenting\", section on 'Long-term antiplatelet therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an attempt to understand this difference, clinical and angiographic outcomes in patients with STEMI due to stent thrombosis (n = 92) and de novo coronary thrombosis (n = 98) were compared in a retrospective study of patients who underwent primary PCI for STEMI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/10\">",
"     10",
"    </a>",
"    ]. The following findings were noted in patients with stent thrombosis compared to those with de novo coronary thrombosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In-hospital major adverse cardiovascular and cerebrovascular events were significantly higher (22.6 versus 9.2 percent), including a significantly higher in-hospital death rate (17.4 versus 7.1 percent). However, there were no differences at six-month follow-up.",
"     </li>",
"     <li>",
"      Successful reperfusion using angiographic criteria was significantly lower (80.4 versus 96.9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another study of approximately 3300 patients with STEMI between 2002 and 2010, mortality was similar between those with STEMI due to stent thrombosis compared to those with de novo coronary thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/3\">",
"     3",
"    </a>",
"    ]. However, the rate of reinfarction was higher in those with stent thrombosis.",
"   </p>",
"   <p>",
"    In a cohort of 2464 individuals with STEMI treated with primary percutaneous coronary intervention, the mid-term outcomes of those with angiographically proven stent thrombosis (3 percent) were compared to those with a primary coronary artery event (97 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9623/abstract/21\">",
"     21",
"    </a>",
"    ]. At six months, those with stent thrombosis were shown to have significantly higher rates of non-fatal MI and",
"    <span class=\"nowrap\">",
"     restenosis/reocclusion",
"    </span>",
"    (54 versus 17 and 10 versus 1 percent), while the rate of death was not significantly different (12 versus 8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1043308826\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stent thrombosis is an uncommon but serious complication of percutaneous coronary intervention with stenting. Most patients present with an acute coronary syndrome, usually with ST-segment elevation on the electrocardiogram. Its cause is total or subtotal thrombotic occlusion of a coronary artery by thrombus that originates in or close to an intracoronary stent. This finding is seen at the time of coronary angiography and it is necessary, in most cases, to secure the diagnosis. Death and myocardial infarction are not infrequent complications of stent thrombosis. (See",
"      <a class=\"local\" href=\"#H1043309813\">",
"       'Clinical presentation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, the acute management of patients with stent thrombosis is similar to that for other patients with an acute coronary syndrome (ACS). Important points include considering the diagnosis in any patient ACS with prior stent placement and a rapid attempt to restore vessel patency. (See",
"      <a class=\"local\" href=\"#H1128708641\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with stent thrombosis while on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , we suggest switching the patient to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      10 mg daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      90 mg twice daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1128708655\">",
"       'Long-term antiplatelet therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients diagnosed with stent thrombosis who have completed the minimum recommended course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      , we suggest starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      10 mg daily or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/0/38919?source=see_link\">",
"       ticagrelor",
"      </a>",
"      90 mg twice daily, rather than restarting clopidogrel 75 mg daily (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1128708655\">",
"       'Long-term antiplatelet therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with stent thrombosis, irrespective of whether they were or were not on DAPT at the time of the event, we suggest dual antiplatelet therapy for a minimum of one year after the event, rather than shorter periods of time (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The ultimate duration of DAPT will require continual assessment of the benefits and risks (in particular, bleeding risk).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/1\">",
"      Holmes DR Jr, Kereiakes DJ, Garg S, et al. Stent thrombosis. J Am Coll Cardiol 2010; 56:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/2\">",
"      Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv 2012; 5:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/3\">",
"      Brodie BR, Hansen C, Garberich RF, et al. ST-segment elevation myocardial infarction resulting from stent thrombosis: an enlarging subgroup of high-risk patients. J Am Coll Cardiol 2012; 60:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/4\">",
"      Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/5\">",
"      Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001; 103:1967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/6\">",
"      Wenaweser P, Rey C, Eberli FR, et al. Stent thrombosis following bare-metal stent implantation: success of emergency percutaneous coronary intervention and predictors of adverse outcome. Eur Heart J 2005; 26:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/7\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/8\">",
"      Mahmoud KD, Vlaar PJ, van den Heuvel AF, et al. Usefulness of thrombus aspiration for the treatment of coronary stent thrombosis. Am J Cardiol 2011; 108:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/9\">",
"      Ong AT, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005; 45:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/10\">",
"      Chechi T, Vecchio S, Vittori G, et al. ST-segment elevation myocardial infarction due to early and late stent thrombosis a new group of high-risk patients. J Am Coll Cardiol 2008; 51:2396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/11\">",
"      Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/12\">",
"      Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/13\">",
"      Mishkel GJ, Moore AL, Markwell S, et al. Long-term outcomes after management of restenosis or thrombosis of drug-eluting stents. J Am Coll Cardiol 2007; 49:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/14\">",
"      Burzotta F, Parma A, Pristipino C, et al. Angiographic and clinical outcome of invasively managed patients with thrombosed coronary bare metal or drug-eluting stents: the OPTIMIST study. Eur Heart J 2008; 29:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/15\">",
"      de la Torre-Hern&aacute;ndez JM, Alfonso F, Hern&aacute;ndez F, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpa&ntilde;ol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008; 51:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/16\">",
"      van Werkum JW, Heestermans AA, de Korte FI, et al. Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases. Circulation 2009; 119:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/17\">",
"      Kimura T, Morimoto T, Kozuma K, et al. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: Observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation 2010; 122:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/18\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008; 371:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/19\">",
"      Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/20\">",
"      Porto I, Burzotta F, Parma A, et al. Angiographic predictors of recurrent stent thrombosis (from the Outcome of PCI for stent-ThrombosIs MultIcentre STudy [OPTIMIST]). Am J Cardiol 2010; 105:1710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9623/abstract/21\">",
"      Parodi G, Memisha G, Bellandi B, et al. Effectiveness of primary percutaneous coronary interventions for stent thrombosis. Am J Cardiol 2009; 103:913.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87310 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-E4F9E9D48D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9623=[""].join("\n");
var outline_f9_25_9623=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1043308826\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1043308818\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1043309813\">",
"      CLINICAL PRESENTATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1128708641\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1128708648\">",
"      Periprocedural considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1128708655\">",
"      Long-term antiplatelet therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1043309820\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043309828\">",
"      MI and death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043309835\">",
"      Recurrent stent thrombosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1043309842\">",
"      Compared to de novo coronary thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1043308826\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/87310\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/87310|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/49/1819\" title=\"table 1\">",
"      TIMI flow grades",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/60/16329?source=related_link\">",
"      Clinical manifestations and diagnosis of cardiogenic shock in acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25209?source=related_link\">",
"      Criteria for the diagnosis of acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/20/44361?source=related_link\">",
"      Epidemiology of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/43/15034?source=related_link\">",
"      Initial evaluation and management of suspected acute coronary syndrome in the emergency department",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/41/44697?source=related_link\">",
"      Overview of the acute management of ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/20/37193?source=related_link\">",
"      Overview of the acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31721?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Periprocedural management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_25_9624="Cervical cytology: Evaluation of atypical and malignant glandular cells";
var content_f9_25_9624=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical cytology: Evaluation of atypical and malignant glandular cells",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9624/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9624/contributors\">",
"     Anne Kathryn Goodman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9624/contributors\">",
"     Christine H Holschneider, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9624/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9624/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9624/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9624/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/25/9624/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cytology became the standard screening test for cervical cancer and premalignant cervical lesions with the introduction of the Papanicolaou (Pap) smear in 1941 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/1\">",
"     1",
"    </a>",
"    ]. Liquid-based, thin layer preparation (eg, ThinPrep, SurePath) of cervical cytology specimens was a subsequent modification in technique.",
"   </p>",
"   <p>",
"    Atypical glandular cells on cervical cytology usually originate from the glandular epithelium of the endocervix or endometrium. Atypical glandular cells are found less commonly than of abnormal squamous cells. Women with atypical glandular cells require further evaluation for premalignant conditions of the cervix, uterus, and rarely, ovary.",
"   </p>",
"   <p>",
"    Evaluation of women with cervical cytology with atypical or malignant glandular cells is reviewed here. Cervical cancer screening strategies and techniques, interpretation of cervical cytology results, follow-up of other abnormal cytology results, and management of cervical neoplasia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link\">",
"     \"Screening for cervical cancer: Rationale and recommendations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=see_link\">",
"     \"Cervical cytology: Interpretation of results\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=see_link\">",
"     \"Cervical cytology: Evaluation of low grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=see_link\">",
"     \"Cervical cytology: Evaluation of high grade squamous intraepithelial lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29161205\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terminology for reporting cervical cytology was standardized by the Bethesda System in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/2\">",
"     2",
"    </a>",
"    ]. This system has been revised several times and the current system was developed in 2001 (",
"    <a class=\"graphic graphic_table graphicRef71416 \" href=\"UTD.htm?18/51/19261\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The terminology used to classify atypical glandular cells is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Atypical glandular cells (AGC)",
"      </strong>",
"      &ndash; Endocervical, endometrial, or not otherwise specified (NOS) is noted as a",
"      <strong>",
"       subcategory",
"      </strong>",
"      . This replaces the previous term \"atypical glandular cells of undetermined significance (AGUS)\". &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Atypical glandular cells, favor neoplastic",
"      </strong>",
"      &ndash; Endocervical, endometrial, or NOS is noted as a subcategory. This designation is for specimens that show features suggestive of, but not sufficient for, an interpretation of adenocarcinoma.",
"     </li>",
"     <li>",
"      <strong>",
"       Endocervical adenocarcinoma in situ (AIS)",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Adenocarcinoma",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When glandular cell abnormalities are present, it should be noted whether there are changes favoring neoplasia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19068430\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glandular abnormalities are found in approximately 0.1 to 2.1 percent of cervical cytology samples [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/5\">",
"     5",
"    </a>",
"    ]. Atypical glandular cells (AGC) are found most commonly in women age 40 or older. As an example, AGC occurred more frequently in women ages 40 to 69 than in other age groups (1.1 to 2.4 versus 0 to 0.8 per 1000 women) in a study of over 75,000 cervical cytology specimens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/6\">",
"     6",
"    </a>",
"    ]. This was in contrast with abnormal squamous cytologic findings (atypical squamous cells or a squamous intraepithelial lesion), which were most common in women ages 15 to 29.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16564920\">",
"    <span class=\"h1\">",
"     RISK OF PREMALIGNANT OR MALIGNANT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atypical glandular cells (AGC) on cervical cytology are associated with premalignant or malignant disease in approximately 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/7-16\">",
"     7-16",
"    </a>",
"    ]. Interestingly, most of the lesions found upon histologic evaluation are squamous rather than glandular [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. The abnormalities may found in the cervix or uterus, or rarely, at other sites (eg, ovary).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H483192\">",
"    <span class=\"h2\">",
"     Histology and site of lesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glandular cells on cervical cytology originate from the endocervix or endometrium, or rarely, from other sites (eg, ovaries). Histologic evaluation may identify normal findings or squamous or glandular lesions.",
"   </p>",
"   <p>",
"    The distribution of histology and anatomic site was illustrated in two literature reviews that included approximately 4300 women with AGC (or atypical glandular cells of undetermined significance [AGUS] for specimens evaluated using the pre-2001 Bethesda classification) (see",
"    <a class=\"local\" href=\"#H29161205\">",
"     'Terminology'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Findings were benign in 64 to 71 to percent of women; abnormalities included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cervical intraepithelial neoplasia &ndash; 20 to 28 percent, comprised of:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Low grade cervical intraepithelial neoplasia (CIN 1) &ndash; 9 percent",
"     </li>",
"     <li>",
"      High grade cervical intraepithelial neoplasia (CIN 2,3) &ndash; 11 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cervical carcinoma &ndash; 1 percent",
"     </li>",
"     <li>",
"      Cervical adenocarcinoma in situ &ndash; 3 to 4 percent",
"     </li>",
"     <li>",
"      Cervical adenocarcinoma &ndash; 2 percent",
"     </li>",
"     <li>",
"      Endometrial hyperplasia &ndash; 1 percent",
"     </li>",
"     <li>",
"      Endometrial adenocarcinoma &ndash; 2 to 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The lower rate of glandular compared with squamous cervical abnormalities diagnosed in women with AGC may due in part to a lower sensitivity of cervical cytology for detecting endocervical glandular dysplasia and malignancy than for detecting squamous malignancy. This lower sensitivity has been attributed to several factors: it can be difficult for the cytopathologist to distinguish between high-grade squamous cells and glandular cells; endometrial cells, reactive endocervical cells, tubal metaplasia, and cervical endometriosis may mimic adenocarcinoma in situ; and lesions may not be seen or sampled because they are small or high in the endocervical canal. Another reason for underdiagnosis is the presence of minimal, poorly preserved endocervical cells, which are difficult to assess [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'Effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AGC has also been associated with less frequent histologies, including adenosquamous cervical cancer and uterine carcinosarcoma (formerly referred to as malignant mixed M&uuml;llerian tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, further evaluation results in a diagnosis of disease at sites other than the cervix or uterus. AGC has been associated with ovarian, fallopian tube, or vaginal cancer, and some cases of colon or breast cancer have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/17,22\">",
"     17,22",
"    </a>",
"    ]. Ovarian cancer has been reported in 0.1 to 0.6 percent of women with AGC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/14,17,23\">",
"     14,17,23",
"    </a>",
"    ]. In addition, some women with AGC have benign cervical or endometrial findings (eg, endometrial polyps, tubal metaplasia) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/14,24\">",
"     14,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H483200\">",
"    <span class=\"h2\">",
"     Modifying factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patient characteristics and cytologic are predictive of the likely type and severity of abnormality associated with AGC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H483365\">",
"    <span class=\"h3\">",
"     AGC subcategory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several subcategories are used to further characterize a result of AGC on cervical cytology (eg, AGC-not otherwise specified [NOS]; AGC-endometrial), as noted above (see",
"    <a class=\"local\" href=\"#H29161205\">",
"     'Terminology'",
"    </a>",
"    above). The cytologic subcategory is somewhat predictive of the histologic diagnosis. As an example, in a study of 460 AGC women with AGC, the most common lesions for each subcategory were: AGC-NOS (endometrial adenocarcinoma: 10.2 percent); AGC-endocervical (invasive cervical adenocarcinoma: 5.9 percent; adenocarcinoma in situ: 2.4 percent; and CIN 2,3: 5.3 percent); AGC-endometrial (endometrial adenocarcinoma: 27.8 percent; and atypical complex endometrial hyperplasia: 22.2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/25\">",
"     25",
"    </a>",
"    ]. A limitation of this study was that it combined AGC, favor neoplasia subcategories with other AGC categories (eg, AGC, favor neoplasia-endometrial was combined with AGC-endometrial), thus increasing the likelihood of malignancy in each subcategory.",
"   </p>",
"   <p>",
"    There are few data about the histologic correlation of AGC classified as favor neoplasia. In one study (n = 138), high-grade CIN, AIS, or invasive cervical or endometrial cancer was found more often in women with AGC, favor neoplasia compared with other women with AGC (56 versus 8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6833383\">",
"    <span class=\"h3\">",
"     Coexisting squamous cytologic abnormality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately half of women with AGC have a coexisting squamous cytologic abnormality (atypical squamous cells or a squamous intraepithelial lesion), and these women appear to be more likely to have a squamous rather than a glandular lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/9,25,26\">",
"     9,25,26",
"    </a>",
"    ]. As an example, in a study that included 353 women with AGC who underwent histologic evaluation, the proportion of squamous lesions was higher in those with AGC plus a squamous cytologic finding (squamous: 90 percent; glandular: 10 percent) compared with AGC alone (squamous: 72 percent; glandular: 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8318502\">",
"    <span class=\"h3\">",
"     Human papillomavirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive test for human papillomavirus (HPV) strains that are high risk for cervical cancer in women with AGC is associated with a histologic diagnosis of CIN, particularly those with AGC-not otherwise specified [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Testing for HPV is not a reliable method of triaging follow-up of AGC cytology, as it is for atypical squamous cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/26\">",
"     26",
"    </a>",
"    ]. How, it is useful in the further evaluation of women with AGC. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Negative or low-grade findings on initial evaluation'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=see_link&amp;anchor=H16#H16\">",
"     \"Screening for cervical cancer: Rationale and recommendations\", section on 'HPV testing as triage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8318382\">",
"    <span class=\"h3\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of malignancy in women with AGC increases with age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/7,12,14,25,31\">",
"     7,12,14,25,31",
"    </a>",
"    ]. As an example, in one retrospective study of 662 women with AGC, the rate of malignancy was highest in women 50 years or older (15 percent including: endometrial 12.7 percent; ovarian cancer 1.4 percent; cervical adenocarcinoma 0.9 percent) compared with those ages 40 to 49 years (2.8 percent) or less than 40 years (2.0 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/14\">",
"     14",
"    </a>",
"    ]. In contrast, the most common lesion in women younger than 40 years was squamous and premalignant, ie, CIN 2,3 (approximately 15.4 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H483388\">",
"    <span class=\"h3\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some data suggest that women with persistent AGC-NOS (two or more cytology results) are at especially high risk of significant glandular disease (three of five women had endometrial adenocarcinoma in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/11\">",
"     11",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few data regarding AGC during pregnancy or the postpartum period. Based upon available data, the incidence of AGC and of significant neoplasia appears to be similar or higher than in other women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of atypical glandular cells (AGC) on cervical cytology is a significant marker for premalignant disease of the cervix or endometrium, as discussed above (see",
"    <a class=\"local\" href=\"#H483192\">",
"     'Histology and site of lesion'",
"    </a>",
"    above). Thus, evaluation of women with AGC includes testing of both these sites. The approach to evaluation differs somewhat for each AGC subcategory: not otherwise specified (NOS), endocervical, or endometrial (see",
"    <a class=\"local\" href=\"#H29161205\">",
"     'Terminology'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    For pregnant women with AGC, endocervical sampling with a curette and endometrial sampling should",
"    <strong>",
"     NOT",
"    </strong>",
"    be performed, as there is a risk of disturbing the pregnancy; however, the endocervical canal may be sampled gently with a cytobrush.",
"   </p>",
"   <p>",
"    Positive findings are treated as appropriate for the histologic diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=see_link\">",
"     \"Cervical adenocarcinoma in situ\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"     \"Invasive cervical adenocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link\">",
"     \"Small cell neuroendocrine carcinoma of the cervix\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     All AGC categories (except endometrial)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cervical cytology with a finding of AGC-NOS or AGC-endocervical (including those classified as &ldquo;favor neoplasia&rdquo;); adenocarcinoma in-situ (AIS); or adenocarcinoma are evaluated initially with [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/27,34-36\">",
"     27,34-36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical colposcopy with directed cervical biopsies and sampling of the endocervical canal",
"     </li>",
"     <li>",
"      Endometrial sampling is performed for all women &ge;35 years-old and for younger women at risk for endometrial neoplasia (risk factors or symptoms are present) (",
"      <a class=\"graphic graphic_table graphicRef62089 \" href=\"UTD.htm?38/30/39403\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58600 \" href=\"UTD.htm?18/38/19052\">",
"       table 3",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing for high-risk human papillomavirus (HPV) is not necessary if it has not been done previously because colposcopy and endometrial sampling are required regardless of HPV results.",
"   </p>",
"   <p>",
"    These procedures are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=see_link\">",
"     \"Colposcopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link&amp;anchor=H7#H7\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\", section on 'HPV testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=see_link\">",
"     \"Endometrial sampling procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     AGC endometrial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have AGC-endometrial or AGC-endometrial, favor neoplastic, do not require colposcopy as part of the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. They should be evaluated with endometrial sampling and endocervical sampling.",
"   </p>",
"   <p>",
"    If the cytology report also has abnormal squamous findings (atypical squamous cells or squamous intraepithelial lesion) in combination with AGC-endometrial, colposcopy should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=see_link\">",
"     \"Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NEGATIVE OR LOW-GRADE FINDINGS ON INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of women with atypical glandular cells (AGC) and negative or low-grade results on initial evaluation for cervical or endometrial neoplasia depends upon the AGC subcategory.",
"   </p>",
"   <p>",
"    Glandular neoplasia of the cervix, in contrast with squamous disease, is often characterized by noncontiguous lesions (&ldquo;skip lesions&rdquo;). In addition, some glandular disease may be located high in the cervical canal. Thus, some women will require cervical conization to detect disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     AGC NOS or endocervical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with AGC-NOS or AGC-endocervical are managed based on the findings of the initial evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No cervical intraepithelial lesion [CIN] 2 or higher (CIN 2+), no adenocarcinoma in-situ (AIS), and no cancer &ndash; Cotest with cervical cytology and HPV testing at 12 and 24 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If cytology and HPV testing are negative &ndash; Cotest three years later. If these results are normal, return to routine screening.",
"     </li>",
"     <li>",
"      If cytology or HPV are abnormal &ndash; Perform colposcopy. If the colposcopic findings are nondiagnostic, endometrial sampling should be performed. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CIN 1 or CIN2+ or glandular abnormalities should be managed as appropriate for the specific abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=see_link\">",
"     \"Invasive cervical cancer: Staging and evaluation of lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=see_link\">",
"     \"Cervical adenocarcinoma in situ\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=see_link\">",
"     \"Invasive cervical adenocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=see_link\">",
"     \"Small cell neuroendocrine carcinoma of the cervix\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=see_link\">",
"     \"Classification and diagnosis of endometrial hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481362\">",
"    <span class=\"h3\">",
"     Persistent abnormal cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with persistent findings of AGC-NOS or AGC-endocervical who have nondiagnostic findings with repeat colposcopy and endometrial biopsy, we suggest conization (cold knife, electrocautery, or laser techniques are acceptable). In addition, vaginal colposcopy should be performed in women with a history of exposure to diethyl stilbestrol. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=see_link&amp;anchor=H565948378#H565948378\">",
"     \"Outcome and follow-up of diethylstilbestrol (DES) exposed individuals\", section on 'Health care of DES-exposed individuals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481210\">",
"    <span class=\"h2\">",
"     AGC favor neoplasia, AIS, adenocarcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical cytology classified as AGC, favor neoplasia, adenocarcinoma in situ, or adenocarcinoma is associated with a very high risk of underlying invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If initial evaluation is negative in women with these results, a diagnostic excisional procedure followed by an endocervical curettage of the remaining endocervix is required [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. We suggest a cold knife conization rather than a loop electrosurgical excision procedure in order to avoid thermal artifact at the margins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Procedures for cervical conization\"",
"    </a>",
"    .). If the results of the diagnostic excisional procedure are negative, endometrial sampling is required. In our practice, we perform a dilation and curettage at the same time as the cone biopsy. If the results of the diagnostic excisional procedure and endometrial sampling are negative, a pelvic ultrasound is performed to look for a fallopian tube or ovarian lesion. (See",
"    <a class=\"local\" href=\"#H481607\">",
"     'Evaluation for ovarian cancer or other malignancies'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481535\">",
"    <span class=\"h2\">",
"     AGC endometrial",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the results of the initial evaluation are negative for premalignant or malignant lesions, colposcopy should be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. If a cervical abnormality is found, it should be managed as appropriate for the specific abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=see_link\">",
"     \"Cervical intraepithelial neoplasia: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If evaluation with endometrial biopsy and colposcopy are negative, the patient may resume routine screening for cervical cancer. Some experts advise that if the patient has a persistent finding of AGC endometrial or has symptoms of other malignancies associated with AGC, the patient be evaluated for disease at sites other than the cervix or uterus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    that endometrial sampling be repeated in 12 months. (See",
"    <a class=\"local\" href=\"#H481607\">",
"     'Evaluation for ovarian cancer or other malignancies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H481607\">",
"    <span class=\"h1\">",
"     EVALUATION FOR OVARIAN CANCER OR OTHER MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, atypical glandular cells (AGC) on cervical cytology is associated with a primary tumor at sites other than the cervix or uterus (see",
"    <a class=\"local\" href=\"#H483192\">",
"     'Histology and site of lesion'",
"    </a>",
"    above). Evaluation for disease at other sites is required for selected women who have negative findings despite comprehensive evaluation (ie, colposcopy, endometrial biopsy, conization). This includes women with cytologic findings associated with a high risk of malignancy (persistent AGC-NOS or AGC-endocervical; AGC, favor neoplasia; adenocarcinoma in situ; adenocarcinoma).",
"   </p>",
"   <p>",
"    These patients should be evaluated for primary or metastatic disease involving the fallopian tube, ovary, and other pelvic and abdominal organs. A systematic review that included almost 7000 women with a Pap smear with atypical glandular cells found that 6.4 percent had ovarian or fallopian tube carcinoma and 6.9 percent had cancers of sites other than the cervix, endometrium, ovarian, or fallopian tube [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9624/abstract/17\">",
"     17",
"    </a>",
"    ]. The first line study is a transvaginal ultrasound. Women with an adnexal mass are further evaluated for ovarian or tubal cancer.",
"   </p>",
"   <p>",
"    Women with no adnexal mass should be evaluated for colon or other intraabdominal malignancy with colonoscopy and abdominal computed tomography or magnetic resonance imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"       \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atypical glandular cells (AGC) are found in approximately 0.1 to 2.1 percent of cervical cytology samples. The presence of AGC is associated with premalignant or malignant lesion of the endocervix or endometrium occurs in approximately 30 percent of cases. (See",
"      <a class=\"local\" href=\"#H19068430\">",
"       'Incidence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16564920\">",
"       'Risk of premalignant or malignant disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term atypical glandular cells-not otherwise specified (NOS) in the Bethesda 2001 classification replaced the previous term atypical glandular cells of undetermined significance. (See",
"      <a class=\"local\" href=\"#H29161205\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of malignancy in women with AGC increases with age. Malignancy is diagnosed in approximately 15 percent of women with AGC who are 50 years or older. (See",
"      <a class=\"local\" href=\"#H8318382\">",
"       'Age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all women with AGC (except AGC-endometrial), the initial evaluation includes colposcopy. Endometrial sampling is performed for women &ge;35 years-old and for younger women with risk factors or symptoms of endometrial neoplasia (",
"      <a class=\"graphic graphic_table graphicRef62089 \" href=\"UTD.htm?38/30/39403\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58600 \" href=\"UTD.htm?18/38/19052\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'All AGC categories (except endometrial)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have AGC-endometrial or AGC-endometrial, favor neoplasia, are evaluated with endometrial sampling and endocervical sampling. If results from these tests are negative, colposcopy and HPV testing is performed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'AGC endometrial'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with negative or low-grade findings on initial evaluation require further assessment, including cotesting with cervical cytology and high-risk human papillomavirus testing or, in some cases, repeat endometrial sampling and cervical conization. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Negative or low-grade findings on initial evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H481362\">",
"       'Persistent abnormal cytology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rarely, AGC is associated with a primary tumor at sites other than the cervix or uterus. Evaluation for disease at other sites is required for selected women who have negative findings despite comprehensive evaluation. This includes women with cytologic findings associated with a high risk of malignancy (persistent AGC-NOS or AGC-endocervical; AGC, favor neoplasia; adenocarcinoma in situ; adenocarcinoma). (See",
"      <a class=\"local\" href=\"#H481607\">",
"       'Evaluation for ovarian cancer or other malignancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/1\">",
"      Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol 1941; 42:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/2\">",
"      The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989; 262:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/3\">",
"      Broder S. From the National Institutes of Health. JAMA 1992; 267:1892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/4\">",
"      Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/5\">",
"      Marques JP, Costa LB, Pinto AP, et al. Atypical glandular cells and cervical cancer: systematic review. Rev Assoc Med Bras 2011; 57:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/6\">",
"      Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol 2004; 191:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/7\">",
"      Sharpless KE, Schnatz PF, Mandavilli S, et al. Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol 2005; 105:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/8\">",
"      Veljovich DS, Stoler MH, Andersen WA, et al. Atypical glandular cells of undetermined significance: a five-year retrospective histopathologic study. Am J Obstet Gynecol 1998; 179:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/9\">",
"      Geier CS, Wilson M, Creasman W. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol 2001; 184:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/10\">",
"      Eddy GL, Strumpf KB, Wojtowycz MA, et al. Biopsy findings in five hundred thirty-one patients with atypical glandular cells of uncertain significance as defined by the Bethesda system. Am J Obstet Gynecol 1997; 177:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/11\">",
"      Chhieng DC, Elgert P, Cohen JM, Cangiarella JF. Clinical significance of atypical glandular cells of undetermined significance in postmenopausal women. Cancer 2001; 93:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/12\">",
"      DeSimone CP, Day ME, Tovar MM, et al. Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol 2006; 107:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/13\">",
"      Tam KF, Cheung AN, Liu KL, et al. A retrospective review on atypical glandular cells of undetermined significance (AGUS) using the Bethesda 2001 classification. Gynecol Oncol 2003; 91:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/14\">",
"      Zhao C, Florea A, Onisko A, Austin RM. Histologic follow-up results in 662 patients with Pap test findings of atypical glandular cells: results from a large academic womens hospital laboratory employing sensitive screening methods. Gynecol Oncol 2009; 114:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/15\">",
"      Scheiden R, Wagener C, Knolle U, et al. Atypical glandular cells in conventional cervical smears: incidence and follow-up. BMC Cancer 2004; 4:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/16\">",
"      Hammoud MM, Haefner HK, Michael CW, Ansbacher R. Atypical glandular cells of undetermined significance. Histologic findings and proposed management. J Reprod Med 2002; 47:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/17\">",
"      Schnatz PF, Guile M, O'Sullivan DM, Sorosky JI. Clinical significance of atypical glandular cells on cervical cytology. Obstet Gynecol 2006; 107:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/18\">",
"      Ruba S, Schoolland M, Allpress S, Sterrett G. Adenocarcinoma in situ of the uterine cervix: screening and diagnostic errors in Papanicolaou smears. Cancer 2004; 102:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/19\">",
"      Kim TJ, Kim HS, Park CT, et al. Clinical evaluation of follow-up methods and results of atypical glandular cells of undetermined significance (AGUS) detected on cervicovaginal Pap smears. Gynecol Oncol 1999; 73:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/20\">",
"      Zhao C, Florea A, Austin RM. Clinical utility of adjunctive high-risk human papillomavirus DNA testing in women with Papanicolaou test findings of atypical glandular cells. Arch Pathol Lab Med 2010; 134:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/21\">",
"      Cheng RF, Hernandez E, Anderson LL, et al. Clinical significance of a cytologic diagnosis of atypical glandular cells of undetermined significance. J Reprod Med 1999; 44:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/22\">",
"      Schnatz PF, Pattison K, O'Sullivan DM. The association of breast disease and atypical glandular cells on cervical cytology. Menopause 2011; 18:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/23\">",
"      Cheng WF, Chen YL, You SL, et al. Risk of gynaecological malignancies in cytologically atypical glandular cells: follow-up study of a nationwide screening population. BJOG 2011; 118:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/24\">",
"      Saad RS, Takei H, Liu YL, et al. Clinical significance of a cytologic diagnosis of atypical glandular cells, favor endometrial origin, in Pap smears. Acta Cytol 2006; 50:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/25\">",
"      Zhao C, Austin RM, Pan J, et al. Clinical significance of atypical glandular cells in conventional pap smears in a large, high-risk U.S. west coast minority population. Acta Cytol 2009; 53:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/26\">",
"      Wright TC Jr, Cox JT, Massad LS, et al. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002; 287:2120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/27\">",
"      Derchain SF, Rabelo-Santos SH, Sarian LO, et al. Human papillomavirus DNA detection and histological findings in women referred for atypical glandular cells or adenocarcinoma in situ in their Pap smears. Gynecol Oncol 2004; 95:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/28\">",
"      Castle PE, Fetterman B, Poitras N, et al. Relationship of atypical glandular cell cytology, age, and human papillomavirus detection to cervical and endometrial cancer risks. Obstet Gynecol 2010; 115:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/29\">",
"      Irvin W, Evans SR, Andersen W, et al. The utility of HPV DNA triage in the management of cytological AGC. Am J Obstet Gynecol 2005; 193:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/30\">",
"      Zeferino LC, Rabelo-Santos SH, Villa LL, et al. Value of HPV-DNA test in women with cytological diagnosis of atypical glandular cells (AGC). Eur J Obstet Gynecol Reprod Biol 2011; 159:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/31\">",
"      Koonings PP, Price JH. Evaluation of atypical glandular cells of undetermined significance: is age important? Am J Obstet Gynecol 2001; 184:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/32\">",
"      Tam KF, Cheung AN, Szeto E, Ngan HY. Atypical glandular cells diagnosed during pregnancy and the postpartum period: a retrospective analysis. Eur J Obstet Gynecol Reprod Biol 2011; 155:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/33\">",
"      Chhieng DC, Elgert P, Cangiarella JF, Cohen JM. Significance of AGUS Pap smears in pregnant and postpartum women. Acta Cytol 2001; 45:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/34\">",
"      Massad LS, Einstein MH, Huh WK, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis 2013; 17:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9624/abstract/35\">",
"      Krane JF, Lee KR, Sun D, et al. Atypical glandular cells of undetermined significance. Outcome predictions based on human papillomavirus testing. Am J Clin Pathol 2004; 121:87.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.asccp.org/ (Accessed on March 22, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3229 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.236-1521AB7FD8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9624=[""].join("\n");
var outline_f9_25_9624=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29161205\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19068430\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16564920\">",
"      RISK OF PREMALIGNANT OR MALIGNANT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H483192\">",
"      Histology and site of lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H483200\">",
"      Modifying factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H483365\">",
"      - AGC subcategory",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6833383\">",
"      - Coexisting squamous cytologic abnormality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8318502\">",
"      - Human papillomavirus infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8318382\">",
"      - Age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H483388\">",
"      - Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      All AGC categories (except endometrial)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AGC endometrial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NEGATIVE OR LOW-GRADE FINDINGS ON INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      AGC NOS or endocervical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H481362\">",
"      - Persistent abnormal cytology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H481210\">",
"      AGC favor neoplasia, AIS, adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H481535\">",
"      AGC endometrial",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H481607\">",
"      EVALUATION FOR OVARIAN CANCER OR OTHER MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3229\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3229|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/51/19261\" title=\"table 1\">",
"      Bethesda class cervix cytol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39403\" title=\"table 2\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/38/19052\" title=\"table 3\">",
"      Indications endometrial evaluat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37736?source=related_link\">",
"      Cervical adenocarcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33895?source=related_link\">",
"      Cervical cytology: Evaluation of atypical squamous cells (ASC-US and ASC-H)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28517?source=related_link\">",
"      Cervical cytology: Evaluation of high grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6086?source=related_link\">",
"      Cervical cytology: Evaluation of low grade squamous intraepithelial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/15/40185?source=related_link\">",
"      Cervical cytology: Interpretation of results",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/2/30762?source=related_link\">",
"      Cervical intraepithelial neoplasia: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/17/33048?source=related_link\">",
"      Cervical intraepithelial neoplasia: Procedures for cervical conization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26535?source=related_link\">",
"      Classification and diagnosis of endometrial hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/14/24808?source=related_link\">",
"      Colposcopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/131?source=related_link\">",
"      Endometrial sampling procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/49/6938?source=related_link\">",
"      Invasive cervical adenocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21849?source=related_link\">",
"      Invasive cervical cancer: Staging and evaluation of lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3322?source=related_link\">",
"      Outcome and follow-up of diethylstilbestrol (DES) exposed individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=related_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/16/38154?source=related_link\">",
"      Screening for cervical cancer: Rationale and recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5498?source=related_link\">",
"      Small cell neuroendocrine carcinoma of the cervix",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_25_9625="Piroxicam: Drug information";
var content_f9_25_9625=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Piroxicam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?18/0/18437?source=see_link\">",
"    see \"Piroxicam: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37399?source=see_link\">",
"    see \"Piroxicam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F210653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Feldene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F210654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Piroxicam&reg;;",
"     </li>",
"     <li>",
"      Dom-Piroxicam;",
"     </li>",
"     <li>",
"      Novo-Pirocam;",
"     </li>",
"     <li>",
"      Nu-Pirox;",
"     </li>",
"     <li>",
"      PMS-Piroxicam",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F210703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Nonsteroidal Anti-inflammatory Drug (NSAID), Oral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F210658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Osteoarthritis, rheumatoid arthritis:",
"     </b>",
"     Oral: 10-20 mg daily in 1-2 divided doses (maximum dose: 20 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Ankylosing spondylitis (Canadian labeling; not an approved use in U.S. labeling):",
"     </b>",
"     Oral: 10-20 mg daily in 1-2 divided doses (maximum dose: 20 mg daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F210659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Initiate therapy cautiously at low end of dosing range.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2532884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     No specific dosage adjustment provided in manufacturer&rsquo;s labeling; however, a dosage reduction is recommended. Caution and close monitoring is advised for patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute. Use is contraindicated in patients with deteriorating renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     Use is not recommended (has not been studied); if therapy must be initiated, close monitoring is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     Use is contraindicated in severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or in patients with deteriorating renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F210660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustment provided in manufacturer&rsquo;s labeling; however, a dosage reduction is recommended.",
"     <b>",
"      Note:",
"     </b>",
"     Canadian labeling contraindicates use in severe impairment or in patients with active liver disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F210633\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 10 mg, 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Feldene&reg;: 10 mg, 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F210618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088596.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088596.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13333827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May administer with food or milk to decrease GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F210636\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic treatment of acute and chronic rheumatoid arthritis and osteoarthritis",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Symptomatic treatment of ankylosing spondylitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3198225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Feldene&reg; may be confused with FLUoxetine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Piroxicam may be confused with PARoxetine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flogene [Brazil] may be confused with Flogen brand name for naproxen [Mexico]; Florone brand name for diflorasone [Germany, Greece]; Flovent brand name for fluticasone [U.S., Canada]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F210701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Reported with piroxicam or other NSAIDS:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, bleeding, constipation, diarrhea, dyspepsia, flatulence, heartburn, nausea, perforation, ulcer, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia, bleeding time increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Renal function abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Agranulocytosis, anaphylactic reaction, angina exacerbated, angioedema, aplastic anemia, arrhythmia, aseptic meningitis, blurred vision, bone marrow suppression, CHF, cystitis, decreased hearing, dyspnea, epistaxis, erythema multiforme, gastritis, hallucinations, hemolytic anemia, hepatitis, hyperkalemia, hypertension, interstitial nephritis, jaundice, leukopenia, liver failure, MI, nephrotic syndrome, pancreatitis, pancytopenia, peripheral neuropathy, photosensitivity, polydipsia, polyuria, renal failure, Stevens-Johnson syndrome, tachycardia, thrombocytopenia, toxic amblyopia, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F210639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or asthma-type reactions to piroxicam, aspirin, other NSAIDs or any component of the formulation; perioperative pain in the setting of coronary artery bypass graft (CABG) surgery; active gastrointestinal bleeding",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Recent or recurrent history of GI bleeding; active GI inflammatory disease; inflammatory bowel disease; cerebrovascular bleeding or other bleeding disorders; severe liver impairment or active liver disease; severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute) or deteriorating renal disease; known hyperkalemia; children and adolescents &lt;16 years of age; use in the third trimester of pregnancy; breast-feeding, severe uncontrolled heart failure",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F210622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid reactions: Even in patients without prior exposure anaphylactoid reactions may occur; patients with \"aspirin triad\" (bronchial asthma, aspirin intolerance, rhinitis) may be at increased risk. Do not use in patients who experience bronchospasm, asthma, rhinitis, or urticaria with NSAID or aspirin therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs are associated with an increased risk of adverse cardiovascular thrombotic events, including MI and stroke.",
"     </b>",
"     Risk may be increased with duration of use or pre-existing cardiovascular risk factors or disease. Carefully evaluate individual cardiovascular risk profiles prior to prescribing. Use caution with fluid retention or heart failure. Use is contraindicated in severe heart failure. Concurrent administration of ibuprofen, and potentially other nonselective NSAIDs, may interfere with aspirin&rsquo;s cardioprotective effect. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of cardiovascular events; alternate therapies should be considered for patients at high risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: May cause drowsiness, dizziness, blurred vision, and other neurologic effects which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Discontinue use with blurred or diminished vision and perform ophthalmologic exam. Periodically evaluate vision in all patients receiving long term therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal events:",
"     <b>",
"      [U.S. Boxed Warning]: NSAIDs may increase risk of gastrointestinal irritation, inflammation, ulceration, bleeding, and perforation.",
"     </b>",
"     These events may occur at any time during therapy and without warning. Use caution with a history of GI disease (bleeding or ulcers), concurrent therapy with aspirin, anticoagulants and/or corticosteroids, smoking, use of alcohol, the elderly or debilitated patients. Use the lowest effective dose for the shortest duration of time, consistent with individual patient goals, to reduce risk of GI adverse events; alternate therapies should be considered for patients at high risk. Use is contraindicated with active peptic ulcers. When used concomitantly with &le;325 mg of aspirin, a substantial increase in the risk of gastrointestinal complications (eg, ulcer) occurs; concomitant gastroprotective therapy (eg, proton pump inhibitors) is recommended (Bhatt, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Platelet adhesion and aggregation may be decreased; may prolong bleeding time; patients with coagulation disorders or who are receiving anticoagulants should be monitored closely. Anemia may occur; patients on long-term NSAID therapy should be monitored for anemia. Rarely, NSAID use has been associated with potentially severe blood dyscrasias (eg, agranulocytosis, thrombocytopenia, aplastic anemia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: NSAID use may increase the risk of hyperkalemia, particularly in the elderly, diabetics, renal disease, and with concomitant use of other agents capable of inducing hyperkalemia (eg, ACE-inhibitors). Monitor potassium closely. Canadian labeling contraindicates use in patients with known hyperkalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Serum sickness: A serum sickness-like reaction can rarely occur; watch for arthralgias, pruritus, fever, fatigue, and rash.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin reactions: NSAIDs may cause serious skin adverse events including exfoliative dermatitis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN); discontinue use at first sign of skin rash or hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Do not administer to patients with aspirin-sensitive asthma; severe bronchospasm may occur. Use caution in patients with other forms of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Coronary artery bypass graft surgery:",
"     <b>",
"      [U.S. Boxed Warning]: Use is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.",
"     </b>",
"     Risk of MI and stroke may be increased with use following CABG surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with decreased hepatic function (contraindicated in severe hepatic impairment). Closely monitor patients with any abnormal LFT. Severe hepatic reactions (eg, fulminant hepatitis, liver failure) have occurred with NSAID use, rarely; discontinue if signs or symptoms of liver disease develop, or if systemic manifestations occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution; may cause new-onset hypertension or worsening of existing hypertension. Monitor blood pressure closely with initiation and during piroxicam therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: NSAID use may compromise existing renal function; dose-dependent decreases in prostaglandin synthesis may result from NSAID use, reducing renal blood flow which may cause renal decompensation. Patients with impaired renal function, dehydration, heart failure, liver dysfunction, those taking diuretics, and ACE inhibitors, and the elderly are at greater risk of renal toxicity. Rehydrate patient before starting therapy; monitor renal function closely. Use is contraindicated in severe renal failure (Canadian labeling also contraindicates use in patients with deteriorating renal disease). Long-term NSAID use may result in renal papillary necrosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid chronic use (unless alternative agents ineffective and patient can receive concomitant gastroprotective agent); nonselective oral NSAID use is associated with an increased risk of GI bleeding and peptic ulcer disease in older adults in high risk category (eg, &gt;75 years or age or receiving concomitant oral/parenteral corticosteroids, anticoagulants, or antiplatelet agents) (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Poor CYP2C9 metabolizers: Use with caution; hepatic metabolism may be reduced resulting in elevated serum concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical/dental procedures: Withhold for at least 4-6 half-lives prior to surgical or dental procedures.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F210697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F210627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of other Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Aliskiren. Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of Aliskiren.  Management: Monitor renal function periodically in patients receiving aliskiren and any nonsteroidal anti-inflammatory agent.  Patients at elevated risk of renal dysfunction include those who are elderly, are volume depleted, or have pre-existing renal dysfunction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Nonsteroidal Anti-Inflammatory Agents may decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: Nonsteroidal Anti-Inflammatory Agents may enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Tricyclic, Tertiary Amine): May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Nonsteroidal Anti-Inflammatory Agents may enhance the nephrotoxic effect of CycloSPORINE (Systemic). Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents. Specifically, elevated diclofenac concentrations have been reported.  Management: Consider alternatives to nonsteroidal anti-inflammatory agents (NSAIDs).  Monitor for evidence of nephrotoxicity, as well as increased serum cyclosporine concentrations and systemic effects (e.g., hypertension) during concomitant therapy with NSAIDs.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Increase monitoring for signs/symptoms of bleeding. The Canadian product monograph for dabigatran specifically recommends avoiding concomitant use with GIIb/IIIa inhibitors or ticlopidine, or with aspirin used for stroke prevention in atrial fibrillation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Digoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: When possible, avoid use of drotrecogin within 7 days of use of any IIb/IIIa antagonists, higher dose aspirin (more than 650 mg/day), or use of other antiplatelet agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Eplerenone. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glucosamine: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Haloperidol: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Haloperidol. Specifically including drowsiness and confusion.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur. Management: Concomitant treatment with these agents should generally be avoided. If used concomitantly, increased diligence in monitoring for adverse effects (eg, bleeding, bruising, altered mental status due to CNS bleeds) must be employed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrALAZINE: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of HydrALAZINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to impaired platelet function and an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Nasal): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketorolac (Systemic): May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the diuretic effect of Loop Diuretics.  Management: Monitor for decreased therapeutic effects of loop diuretics with concurrent use of an NSAID. Consider avoiding concomitant use of these agents in CHF or cirrhosis with ascites. Concomitant use of bumetanide with indomethacin is  not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. An increased risk of bleeding may occur. Nonsteroidal Anti-Inflammatory Agents may diminish the cardioprotective effect of Agents with Antiplatelet Properties. This interaction is likely specific to aspirin, and not to other antiplatelet agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of other Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PEMEtrexed: NSAID (Nonselective) may increase the serum concentration of PEMEtrexed.  Management: Patients with mild-to-moderate renal insufficiency (estimated creatinine clearance 45-79 mL/min) should avoid NSAIDs for 2-5 days prior to, the day of, and 2 days after pemetrexed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PRALAtrexate: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of PRALAtrexate. More specifically, NSAIDS may decrease the renal excretion of pralatrexate.  Management: Closely monitor for increased pralatrexate serum levels and/or toxicity if used concomitantly with an NSAID. Monitor for decreased pralatrexate serum levels with NSAID discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Nonsteroidal Anti-Inflammatory Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Nonsteroidal Anti-Inflammatory Agents may enhance the neuroexcitatory and/or seizure-potentiating effect of Quinolone Antibiotics. Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Avoid concurrent use of clopidogrel with rivaroxaban unless the anticipated benefits outweigh the risks of bleeding.  Avoid concurrent use of rivaroxaban with other antiplatelet agents whenever possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: NSAID (Nonselective) may enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. NSAID (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of NSAID (Nonselective).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Choline Magnesium Trisalicylate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective). NSAID (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Consider using alternative analgesics, when appropriate, and/or addition of an gastroprotective agent.  Monitor patients closely for signs/symptoms of bleeding, and for evidence of diminished SSRI effectiveness with concurrent use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the antiplatelet effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: May enhance the nephrotoxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the risk of acute phosphate nephropathy may be enhanced. Management: Consider avoiding this combination by temporarily suspending treatment with NSAIDs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: Nonsteroidal Anti-Inflammatory Agents may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse events may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treprostinil: May enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Bleeding may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: Nonsteroidal Anti-Inflammatory Agents may increase the serum concentration of Vancomycin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): NSAID (Nonselective) may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F210649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may enhance gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Onset of effect may be delayed if piroxicam is taken with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid alfalfa, anise, bilberry, bladderwrack, bromelain, cat's claw, celery, chamomile, coleus, cordyceps, dong quai, evening primrose, fenugreek, feverfew, garlic, ginger, ginkgo biloba, ginseng (American, Panax, Siberian), grapeseed, green tea, guggul, horse chestnut seed, horseradish, licorice, prickly ash, red clover, reishi, SAMe (S-adenosylmethionine), sweet clover, turmeric, white willow (all have additional antiplatelet activity).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F210629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9513525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in the initial animal reproduction studies; therefore, the manufacturer classifies piroxicam as pregnancy category C. NSAID exposure during the first trimester is not strongly associated with congenital malformations; however, cardiovascular anomalies and cleft palate have been observed following NSAID exposure in some studies. The use of a NSAID close to conception may be associated with an increased risk of miscarriage. Nonteratogenic effects have been observed following NSAID administration during the third trimester including: Myocardial degenerative changes, prenatal constriction of the ductus arteriosus, fetal tricuspid regurgitation, failure of the ductus arteriosus to close postnatally; renal dysfunction or failure, oligohydramnios; gastrointestinal bleeding or perforation, increased risk of necrotizing enterocolitis; intracranial bleeding (including intraventricular hemorrhage), platelet dysfunction with resultant bleeding; pulmonary hypertension. Because they may cause premature closure of the ductus arteriosus, use of NSAIDs late in pregnancy should be avoided (use after 31 or 32 weeks gestation is not recommended by some clinicians). The chronic use of NSAIDs in women of reproductive age may be associated with infertility that is reversible upon discontinuation of the medication.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F210663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9513528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Piroxicam is excreted into breast milk. Breast-feeding is not recommended by the manufacturer.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F210642\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food to decrease GI adverse effect.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F210641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Feldene Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $421.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $720.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Piroxicam Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $260.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (100): $448.63",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F210631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Occult blood loss, hemoglobin, hematocrit, electrolytes, and periodic renal and hepatic function tests; periodic ophthalmologic exams with chronic use",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F210643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antiflog (IT);",
"     </li>",
"     <li>",
"      Atidem (PE);",
"     </li>",
"     <li>",
"      Baxo (JP);",
"     </li>",
"     <li>",
"      Brexic (IN);",
"     </li>",
"     <li>",
"      Brexin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SG, SY, YE);",
"     </li>",
"     <li>",
"      Brucam (MX);",
"     </li>",
"     <li>",
"      Candyl-D (NZ);",
"     </li>",
"     <li>",
"      Dacam (FI);",
"     </li>",
"     <li>",
"      Dolonex (IN);",
"     </li>",
"     <li>",
"      Edecam (MX);",
"     </li>",
"     <li>",
"      Erazon (RU);",
"     </li>",
"     <li>",
"      Exipan (IL);",
"     </li>",
"     <li>",
"      Facicam (MX);",
"     </li>",
"     <li>",
"      Felden (AT, CH, DK, FI, NO);",
"     </li>",
"     <li>",
"      Feldene (AE, AR, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CI, CN, CO, CY, EC, EE, EG, ET, FR, GB, GH, GM, GN, GR, GY, HK, ID, IE, IL, IQ, IR, IT, JM, JO, JP, KE, KP, KW, LB, LR, LY, MA, ML, MR, MU, MW, MX, MY, NE, NG, NL, OM, PE, PH, PK, PL, PT, QA, SA, SC, SD, SG, SL, SN, SR, SY, TH, TN, TR, TT, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Feldene Gel (AU, BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TH, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Flamic Gel (TH);",
"     </li>",
"     <li>",
"      Flexirox (FR);",
"     </li>",
"     <li>",
"      Focus (TW);",
"     </li>",
"     <li>",
"      Genoldene (MX);",
"     </li>",
"     <li>",
"      Hawksone (TH);",
"     </li>",
"     <li>",
"      Hotemin (CZ, MY);",
"     </li>",
"     <li>",
"      Improntal (ES);",
"     </li>",
"     <li>",
"      Infeld (ID);",
"     </li>",
"     <li>",
"      Inflamene (BR, ID);",
"     </li>",
"     <li>",
"      Ketazon (AR);",
"     </li>",
"     <li>",
"      Konshien (TW);",
"     </li>",
"     <li>",
"      Leal (UY);",
"     </li>",
"     <li>",
"      Macroxam (PH);",
"     </li>",
"     <li>",
"      Mobilis (AU);",
"     </li>",
"     <li>",
"      Mobilus D (AU);",
"     </li>",
"     <li>",
"      Movon Gel (IN);",
"     </li>",
"     <li>",
"      Movon-20 (IN);",
"     </li>",
"     <li>",
"      Murupe Patch 48 (KP);",
"     </li>",
"     <li>",
"      Nysa (PH);",
"     </li>",
"     <li>",
"      Palpasin (PH);",
"     </li>",
"     <li>",
"      PC-20 (TH);",
"     </li>",
"     <li>",
"      Pemar (CN);",
"     </li>",
"     <li>",
"      Pillozen (KP);",
"     </li>",
"     <li>",
"      Piram (TH);",
"     </li>",
"     <li>",
"      Piram-D (NZ);",
"     </li>",
"     <li>",
"      Pirax (TH);",
"     </li>",
"     <li>",
"      Pirkam (DK);",
"     </li>",
"     <li>",
"      Pirocam (TW);",
"     </li>",
"     <li>",
"      Pirocutan (DE);",
"     </li>",
"     <li>",
"      Pirocutan Gel (DE);",
"     </li>",
"     <li>",
"      Pirom (DK);",
"     </li>",
"     <li>",
"      Pirox (IN, MX);",
"     </li>",
"     <li>",
"      Piroxedol (CO);",
"     </li>",
"     <li>",
"      Piroxene (PY);",
"     </li>",
"     <li>",
"      Piroxicam (CO);",
"     </li>",
"     <li>",
"      Piroxim (AE, BF, BH, BJ, CI, CO, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Pixicam (ZA);",
"     </li>",
"     <li>",
"      Priorheum (DE);",
"     </li>",
"     <li>",
"      Proxalyoc (FR);",
"     </li>",
"     <li>",
"      Proximax (PH);",
"     </li>",
"     <li>",
"      Pyridam (ID);",
"     </li>",
"     <li>",
"      Pyroxy (TH);",
"     </li>",
"     <li>",
"      Rheo-Ma Inj (KP);",
"     </li>",
"     <li>",
"      Rheugesic (ZA);",
"     </li>",
"     <li>",
"      Rhumagel (SG);",
"     </li>",
"     <li>",
"      Rosiden (KP, MY, SG);",
"     </li>",
"     <li>",
"      Roxicam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Roxifen (SG);",
"     </li>",
"     <li>",
"      Roxium (TH);",
"     </li>",
"     <li>",
"      Ruvamed (GR);",
"     </li>",
"     <li>",
"      Salvacam (CR, DO, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Sefdene (HK, SG);",
"     </li>",
"     <li>",
"      Sinalgico (AR);",
"     </li>",
"     <li>",
"      Sotilen (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Stopen (CO);",
"     </li>",
"     <li>",
"      Toricam Gel (TW);",
"     </li>",
"     <li>",
"      Tropidene (ID);",
"     </li>",
"     <li>",
"      Unicam (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Xicalom (ID);",
"     </li>",
"     <li>",
"      Xicam (TH);",
"     </li>",
"     <li>",
"      Xycam (ZA);",
"     </li>",
"     <li>",
"      Zitumex (GR);",
"     </li>",
"     <li>",
"      Zunden (IT);",
"     </li>",
"     <li>",
"      Zuparex (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F210621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reversibly inhibits cyclooxygenase-1 and 2 (COX-1 and 2) enzymes, which results in decreased formation of prostaglandin precursors; has antipyretic, analgesic, and anti-inflammatory properties",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Other proposed mechanisms not fully elucidated (and possibly contributing to the anti-inflammatory effect to varying degrees), include inhibiting chemotaxis, altering lymphocyte activity,  inhibiting neutrophil aggregation/activation, and decreasing proinflammatory cytokine levels.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F210638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.14 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic predominantly via CYP2C9; metabolites are inactive",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine and feces (small amounts) as unchanged drug (5%) and metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/11533352 /pubmed\" id=\"11533352 \" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhatt DL, Scheiman J, Abraham NS, et al, &ldquo;ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risk of Antiplatelet Therapy and NSAID Use. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 52(18):1502-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/19017521/pubmed\" id=\"19017521\" target=\"_blank\">",
"        19017521",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brooks PM and Day RO, &ldquo;Nonsteroidal Anti-inflammatory Drugs - Differences and Similarities,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(24):1716-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/2034249/pubmed\" id=\"2034249\" target=\"_blank\">",
"        2034249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Capone ML, Sciulli MG, Tacconelli S, et al, &ldquo;Pharmacodynamic Interaction of Naproxen With Low-Dose Aspirin in Healthy Subjects,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2005, 45(8):1295-1301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/15837265/pubmed\" id=\"15837265\" target=\"_blank\">",
"        15837265",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Catella-Lawson F, Reilly MP, Kapoor SC, et al, &ldquo;Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(25):1809-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/11752357/pubmed\" id=\"11752357\" target=\"_blank\">",
"        11752357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chan TY, &ldquo;Severe Asthma Attacks Precipitated by NSAIDs,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1995, 29(2):199.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clinch D, Banerjee AK, and Ostick G, &ldquo;Absence of Abdominal Pain in Elderly Patients With Peptic Ulcer,&rdquo;",
"      <i>",
"       Age Ageing",
"      </i>",
"      , 1984, 13(2):120-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/6731166/pubmed\" id=\"6731166\" target=\"_blank\">",
"        6731166",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clive DM and Stoff JS, &ldquo;Renal Syndromes Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1984, 310(9):563-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/6363936/pubmed\" id=\"6363936\" target=\"_blank\">",
"        6363936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drouet A, Jean-Pastor MJ, and Valance J, &ldquo;Visual Hallucinations Induced by Piroxicam,&rdquo;",
"      <i>",
"       Presse Med",
"      </i>",
"      , 1995, 24(10):504.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferraris VA, Saha SP, Oestreich JH, et al, &ldquo;2012 Update to the Society of Thoracic Surgeons Guideline on Use of Antiplatelet Drugs in Patients Having Cardiac and Noncardiac Operations,&rdquo;",
"      <i>",
"       Ann Thorac Surg",
"      </i>",
"      , 2012, 94(5):1761-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/23098967/pubmed\" id=\"23098967\" target=\"_blank\">",
"        23098967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerber D, &ldquo;Adverse Reactions of Piroxicam,&rdquo;",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(9):707-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/2958264/pubmed\" id=\"2958264\" target=\"_blank\">",
"        2958264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, &ldquo;Prevention of Gastroduodenal Injury Induced by Chronic Nonsteroidal Anti-inflammatory Drug Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):675-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/2642452/pubmed\" id=\"2642452\" target=\"_blank\">",
"        2642452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gurwitz JH, Avorn J, Ross-Degnan D, et al, &ldquo;Nonsteroidal Anti-inflammatory Drug-Associated Azotemia in the Very Old,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1990, 264(4):471-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/2366280/pubmed\" id=\"2366280\" target=\"_blank\">",
"        2366280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hawkey CJ, Karrasch JA, Szczepa&ntilde;ski L, et al, &ldquo;Omeprazole Compared With Misoprostol for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/9494149/pubmed\" id=\"9494149\" target=\"_blank\">",
"        9494149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heerdink ER, Leufkens HG, Herings RM, et al, &ldquo;NSAIDs Associated With Increased Risk of Congestive Heart Failure in Elderly Patients Taking Diuretics,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(10):1108-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/9605782/pubmed\" id=\"9605782\" target=\"_blank\">",
"        9605782",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(4):465-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/22563589/pubmed\" id=\"22563589\" target=\"_blank\">",
"        22563589",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoppmann RA, Peden JG, and Ober SK, &ldquo;Central Nervous System Side Effects of Nonsteroidal Anti-inflammatory Drugs. Aseptic Meningitis, Psychosis, and Cognitive Dysfunction,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(7):1309-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/2064481/pubmed\" id=\"2064481\" target=\"_blank\">",
"        2064481",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2009, 53(15):e1-e90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/19358937/pubmed\" id=\"19358937\" target=\"_blank\">",
"        19358937",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobi J, Fraser GL, Coursin DB, et al, &ldquo;Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2002, 30(1):119-41. Available at file://www.sccm.org/pdf/sedatives.pdf",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/11902253/pubmed\" id=\"11902253\" target=\"_blank\">",
"        11902253",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Knodel LC, &ldquo;Preventing NSAID-Induced Ulcers: The Role of Misoprostol,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1989, 4:37-41.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan TO, Anderson A, and Bertram D, &ldquo;Effect of Indomethacin on Blood Pressure in Elderly People With Essential Hypertension Well Controlled on Amlodipine or Enalapril,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 2000, 13(11):1161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/11078175/pubmed\" id=\"11078175\" target=\"_blank\">",
"        11078175",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Page J and Henry D, &ldquo;Consumption of NSAIDs and the Development of Congestive Heart Failure in Elderly Patients: An Underrecognized Public Health Problem,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2000, 160(6):777-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/10737277/pubmed\" id=\"10737277\" target=\"_blank\">",
"        10737277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pope JE, Anderson JJ, and Felson DT, &ldquo;A Meta-analysis of the Effects of Nonsteroidal Anti-inflammatory Drugs on Blood Pressure,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1993, 153(4):477-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/8435027/pubmed\" id=\"8435027\" target=\"_blank\">",
"        8435027",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pounder R, &ldquo;Silent Peptic Ulceration: Deadly Silence or Golden Silence?&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 1989, 96(2 Pt 2 Suppl):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/2642448/pubmed\" id=\"2642448\" target=\"_blank\">",
"        2642448",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Verbeeck RK, &ldquo;Pharmacokinetic Drug Interactions With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(1):44-66.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/2199127/pubmed\" id=\"2199127\" target=\"_blank\">",
"        2199127",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yeomans ND, Tulassay Z, Juhasz L, et al, &ldquo;A Comparison of Omeprazole With Ranitidine for Ulcers Associated With Nonsteroidal Anti-inflammatory Drugs,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(11):719-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/25/9625/abstract-text/9494148/pubmed\" id=\"9494148\" target=\"_blank\">",
"        9494148",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9781 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-199.231.185.123-B6CE745EC8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9625=[""].join("\n");
var outline_f9_25_9625=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709215\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210653\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210654\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210703\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210658\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210659\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2532884\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210660\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210633\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210618\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874786\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333827\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210636\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3198225\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210701\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210639\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210622\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210697\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210627\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210649\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210629\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9513525\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210663\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9513528\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210642\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210641\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210631\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210643\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210621\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F210638\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9781\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9781|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?18/0/18437?source=related_link\">",
"      Piroxicam: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/33/37399?source=related_link\">",
"      Piroxicam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_25_9626="Ovulation induction with clomiphene citrate";
var content_f9_25_9626=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ovulation induction with clomiphene citrate",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9626/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9626/contributors\">",
"     Emre Seli, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9626/contributors\">",
"     Aydin Arici, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9626/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9626/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/25/9626/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/25/9626/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/25/9626/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate has been the most widely used treatment for fertility enhancement for the past 40 years. Clomiphene was a revolutionary advance in reproductive medicine and quickly became popular for induction of ovulation because of its ease of administration and minimal side effects. Ironically, it was initially synthesized as a synthetic estrogen for possible use as a contraceptive.",
"   </p>",
"   <p>",
"    The pharmacology, indications, and administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate will be reviewed here. Other drugs for induction of ovulation are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"     \"Strategies for improving the efficacy of clomiphene induction of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    is a triphenylethylene derivative distantly related to diethylstilbestrol. It acts as a selective estrogen receptor modulator, similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    . All three drugs are competitive inhibitors of estrogen binding to estrogen receptors and have mixed agonist and antagonist activity, depending upon the target tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The commercially available form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    is the dihydrogen citrate salt (clomiphene citrate). It contains two stereoisomers: zu-clomiphene (38 percent) and en-clomiphene (62 percent), which were originally called the cis-isomer and trans-isomer, respectively. En-clomiphene is cleared rapidly, while zu-clomiphene has a long half-life. The two clomiphene isomers have mixed estrogenic and antiestrogenic effects that vary among species. Zu-clomiphene appears to have greater estrogenic activity than en-clomiphene [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    14C-labeled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate is absorbed by the gastrointestinal tract. Fifty percent of the oral dose is excreted after five days, but radioactivity from labeled clomiphene appears in the feces up to six weeks after administration. However, the pharmacologic effect of clomiphene citrate is brief [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    exerts its major effects on the hypothalamus, pituitary, ovary, and uterus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Hypothalamus and pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most evidence suggests that the primary site of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    action is the hypothalamus, where it appears to bind to hypothalamic estrogen receptors, thereby blocking the negative feedback effect of circulating endogenous estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    treatment stimulates secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH), resulting in increased serum concentrations. When clomiphene is administered to normally cycling women, LH pulse frequency (but not amplitude) increases, suggesting an increase in hypothalamic gonadotropin-releasing hormone (GnRH) pulse frequency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/5\">",
"     5",
"    </a>",
"    ]. In women with polycystic ovary syndrome, who have a high frequency pattern of LH pulses at baseline, the administration of clomiphene citrate increases in LH pulse amplitude and baseline serum concentrations of LH and FSH [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"     \"Physiology of gonadotropin-releasing hormone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In vitro data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate also has a pituitary site of action where it causes an increase in the gonadotropin response to GnRH [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ovary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ovarian actions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    are for the most part secondary to the effects of elevated FSH and LH on ovarian follicular development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=see_link\">",
"     \"Physiology of the normal menstrual cycle\"",
"    </a>",
"    .) Clomiphene is an estrogen agonist in the absence of estrogen, thereby enhancing FSH stimulation of LH receptors in granulosa cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Uterus and cervix",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    acts primarily as an antiestrogen in the uterus, cervix, and vagina. The following findings may explain the low pregnancy rates in clomiphene-induced ovulatory cycles:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The normal increase in uterine volume and endometrial thickening that occurs during spontaneous menstrual cycles is largely absent during",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      -induced cycles, despite higher estradiol levels [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal luteal phase endometrial morphology has been found in some [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/10,11\">",
"       10,11",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/12\">",
"       12",
"      </a>",
"      ], studies.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       Clomiphene",
"      </a>",
"      citrate directly impairs implantation efficiency in mice [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data on the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    on cervical mucus are conflicting. While one study found no detrimental effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/14\">",
"     14",
"    </a>",
"    ], another noted a decrease in the quality and quantity of cervical mucus at all clomiphene doses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/15\">",
"     15",
"    </a>",
"    ]. In a meta-analysis, a detrimental effect was seen only with doses &ge;100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate has no apparent progestational, corticotropic, androgenic, or antiandrogenic effects, nor does it interfere with adrenal or thyroid function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate is used to induce ovulation in selected populations of anovulatory women, and in women with ovulatory infertility to increase follicular number and fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    in men is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=see_link\">",
"     \"Management of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=see_link\">",
"     \"Treatment of male infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Oligoovulation or anovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical approach to ovulation induction requires a uniform understanding of the causes and nomenclature of anovulation. The classification adopted by the World Health Organization (WHO) provides a practical guide to appropriate therapeutic intervention (",
"    <a class=\"graphic graphic_table graphicRef69734 \" href=\"UTD.htm?29/15/29947\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of ovulation induction\", section on 'Classification of anovulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary indication for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate is infertility secondary to oligoovulation or anovulation in normogonadotropic, normoprolactinemic, euthyroid women (WHO class 2). These women produce gonadotropin and estradiol (as evidenced by spontaneous menses or withdrawal bleeding in response to a progesterone challenge) and are therefore able to respond to clomiphene, which is the best initial treatment in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"     17",
"    </a>",
"    ]. This group includes women with polycystic ovary syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, women who have primary hypogonadism (WHO class 3), as demonstrated by serum FSH concentrations at or above 40",
"    <span class=\"nowrap\">",
"     mIU/mL,",
"    </span>",
"    have little or no response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Hypogonadotropic women (WHO class 1) with low FSH and low estradiol production (eg, exhibiting failure to respond to progesterone challenge) are also unlikely to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate, because of their low estradiol.",
"   </p>",
"   <p>",
"    In women with anovulatory infertility (in general, those with polycystic ovary syndrome [PCOS]) an ovulatory rate of 80 percent and a pregnancy rate of 30 to 40 percent can be expected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/2,18,19\">",
"     2,18,19",
"    </a>",
"    ]. Of those who ovulate, approximately 50 percent do so at a dose of 50 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Cycle fecundity is illustrated in the table (",
"    <a class=\"graphic graphic_table graphicRef71247 \" href=\"UTD.htm?6/43/6843\">",
"     table 2",
"    </a>",
"    ). The ovulatory rate is lower with increasing age, body mass index, insulin resistance, and free androgen index [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/22\">",
"     22",
"    </a>",
"    ]. Another antiestrogen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , is also effective for ovulation induction in women with PCOS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/23\">",
"     23",
"    </a>",
"    ]. However, tamoxifen is rarely used for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Unexplained infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;This term describes couples who have no identifiable etiology of infertility after a comprehensive evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=see_link\">",
"     \"Unexplained infertility\"",
"    </a>",
"    .) The estimated per cycle fecundity rate in couples with unexplained infertility followed expectantly is 1.3 to 4.1 percent compared with 20 to 25 percent in couples without infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatment in these couples is empiric. Intrauterine insemination (IUI) either alone or in combination with superovulation is a viable option, keeping in mind the high spontaneous pregnancy rates in these patients. Most recently, the FASTT trial (fast track and standard treatment trial) showed per cycle fecundity rate of 7.6 percent in women with unexplained infertility treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    and IUI for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy and limitations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    therapy in couples with unexplained infertility are illustrated by the following data from randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized placebo-controlled crossover trial administered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      or placebo for up to three months to 118 women with unexplained infertility [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/26\">",
"       26",
"      </a>",
"      ]. The greatest increase in three-month conception rates occurred when clomiphene was given to women with infertility lasting more than three years (14 versus 3 percent for placebo).",
"     </li>",
"     <li>",
"      Two additional trials reported similar improvements in conception rates with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      in couples with unexplained infertility. One study compared clomiphene citrate and intrauterine insemination (IUI) with periovulatory intercourse [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/27\">",
"       27",
"      </a>",
"      ], while the other compared urinary LH-timed IUI with clomiphene-stimulated,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"       human chorionic gonadotropin",
"      </a>",
"      -timed IUI [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A Cochrane analysis of six clinical trials concluded that",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"        clomiphene",
"       </a>",
"       /IUI",
"      </span>",
"      treatment was superior to no treatment or placebo for unexplained subfertility (odds ratio 2.5 for clinical pregnancy per treatment cycle) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate in couples with unexplained infertility has been attributed to correction of subtle ovulatory dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ovulation of more than one oocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Controlled superovulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to being used as an empiric therapy for unexplained infertility,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    has been used with assisted reproductive technologies. It promotes the development of multiple follicles when given to ovulatory women, leading to multiple ovulation and supraphysiologic luteal phase progesterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/30\">",
"     30",
"    </a>",
"    ]. It can be given alone, or it may be used to reduce the amount of more expensive gonadotropins administered for controlled superovulation in preparation for in vitro fertilization-embryo transfer, gamete intrafallopian transfer, or other assisted reproductive technologies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     HOW TO USE CLOMIPHENE CITRATE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pretreatment evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Absent or infrequent ovulation is the main indication for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate treatment. The menstrual history alone may be diagnostic of anovulation; however, if the diagnosis is uncertain, ovulatory dysfunction should be established by testing (",
"    <a class=\"graphic graphic_table graphicRef62767 \" href=\"UTD.htm?2/47/2811\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders of pituitary, adrenal, and thyroid origin that can cause anovulation should be excluded prior to the initiation of therapy as targeted treatment of these endocrinopathies can result in normal ovulation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=see_link\">",
"     \"Overview of infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pretreatment evaluation should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete history and physical examination.",
"     </li>",
"     <li>",
"      Semen analysis to identify seminal abnormalities that also might require treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hysterosalpingogram, if the clinical history suggests uterine or tubal pathology may also be present, and in women over 35 years of age to avoid ineffective treatment when fertility is in decline [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Early follicular phase serum FSH concentration for women older than 35 years of age and women at any age with unexplained infertility, a single ovary, or a history of ovarian surgery, endometriosis, or poor response to gonadotropins. Successful induction of ovulation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      is unlikely in women with elevated FSH concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An endometrial biopsy may be indicated to assess hyperplastic changes in women with chronic anovulation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"       \"Chronic menorrhagia or anovulatory uterine bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A pelvic examination or a pelvic ultrasound to rule out ovarian cysts, especially in patients with known tendency to form functional cysts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Initiation of therapy and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate therapy for ovulation induction is typically started on the fifth day of a cycle, following either spontaneous or induced bleeding. However, the results of therapy, in terms of ovulatory rates, pregnancy, or spontaneous miscarriage, are comparable when clomiphene is begun as early as day two [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/31\">",
"     31",
"    </a>",
"    ]. For in vitro fertilization, clomiphene is begun on the third day of the cycle because earlier administration is thought to stimulate the development of multiple follicles, which is desirable in this setting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no laboratory or clinical parameters that predict the dose necessary to achieve ovulation. The initial dose, empirically, is 50 mg daily for five days; starting with a higher dose does not result in higher pregnancy rates. If ovulation does not occur in the first cycle of treatment, the dose is increased to 100 mg. Thereafter, the dose is increased by increments of 50 mg to a maximum daily dose of 150 mg (100 mg is the maximum dose approved by the FDA and the American College of Obstetricians and Gynecologists does not encourage the use of more than 150 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/32\">",
"     32",
"    </a>",
"    ]) until ovulation is achieved, at which point the woman should attempt to conceive for four to six cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"     17",
"    </a>",
"    ]. Longer courses (eight days) can be considered in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -resistant women if exogenous gonadotropin therapy, the preferred therapy in this situation, is not an option (patient preference or cost) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17,33\">",
"     17,33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Modified regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most conceptions initiated by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate occur within the first six ovulatory cycles. Approximately 50 percent occur at the 50 mg dose, another 20 to 25 percent at 100 mg, and 10 percent at 150 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/18,19,34\">",
"     18,19,34",
"    </a>",
"    ]. There is no benefit to increasing the clomiphene dose in subsequent cycles once ovulation occurs.",
"   </p>",
"   <p>",
"    The LH surge occurs from 5 to 12 days after the last day of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    administration. The day of ovulation is generally consistent in each cycle once ovulation has been established. The couple is advised to have intercourse every other day for one week beginning",
"    <strong>",
"     five days",
"    </strong>",
"    after the last day of medication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to treatment should be monitored. A basal body temperature (BBT) chart is effective and does not increase the cost of treatment. Conversion of a uniphasic to a biphasic basal temperature curve suggests retrospectively that ovulation has occurred. However, a BBT charting can be tedious for some patients and is not useful for timing of intercourse, as the temperature rise occurs one to five days after the midcycle LH surge and up to four days after ovulation.",
"   </p>",
"   <p>",
"    A midluteal (one week after ovulation or one week before the expected menses) serum progesterone concentration greater than 3",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (ideally greater than 10",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    provides reliable evidence that ovulation has occurred. An endometrial biopsy to confirm the adequacy of the luteal phase is not recommended.",
"   </p>",
"   <p>",
"    Determination of the ovulatory LH surge by urinary LH kits is useful in women with inconclusive BBT charts. Urinary LH monitoring also provides information on appropriate timing of intercourse during a given cycle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/35\">",
"     35",
"    </a>",
"    ]. The LH surge typically occurs 5 to 12 days after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    administration is completed. Ovulation generally occurs 14 to 26 hours after the detection of the urinary LH surge and almost always within 48 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/36\">",
"     36",
"    </a>",
"    ]. Therefore, the interval of highest fertility is the day of the LH surge and the following two days.",
"   </p>",
"   <p>",
"    Serial transvaginal ultrasound can be used to monitor the number and size of developing follicles and to time",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/60/26564?source=see_link\">",
"     human chorionic gonadotropin",
"    </a>",
"    administration if necessary. Serial transvaginal ultrasound may also provide evidence of ovulation (follicle enlargement followed by collapse suggests ovulation). Some advocate ultrasound monitoring of just the first",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    cycle in order to exclude hyperresponse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/20\">",
"     20",
"    </a>",
"    ]. However, adding ultrasonographic monitoring and urinary LH testing is costly and does not appear to improve pregnancy rates significantly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=see_link\">",
"     \"Evaluation of the menstrual cycle and timing of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1121988288\">",
"    <span class=\"h3\">",
"     Ovarian enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine physical and ultrasound examinations to detect ovarian enlargement are not always necessary before every new treatment cycle, but should be considered in symptomatic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of ovarian",
"    <span class=\"nowrap\">",
"     enlargement/theca",
"    </span>",
"    lutein cysts from ovarian stimulation is controversial. We recommend withholding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    in these cases until the cyst(s) disappear either spontaneously or after suppression with oral contraceptive pills or GnRH agonists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1121988228\">",
"    <span class=\"h2\">",
"     Number of cycles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the observations that pregnancy rates are low after six cycles of treatment, and that 12 or more cycles may increase the risk of ovarian neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/38\">",
"     38",
"    </a>",
"    ], the American College of Obstetricians and Gynecologists has suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    treatment be limited to fewer than 12 cycles, and that the number of gonadotropin cycles be minimized, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Ovarian cancer'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RESULTS OF THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    therapy by specific indication are discussed above: anovulation (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Oligoovulation or anovulation'",
"    </a>",
"    above), and unexplained infertility (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Unexplained infertility'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    A literature review including data from over 5000 patients with a variety of indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    therapy reported an ovulation rate of 73 percent and a pregnancy rate of 36 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/39\">",
"     39",
"    </a>",
"    ]. Of patients who became pregnant, the miscarriage rate was approximately 20 percent and the multiple pregnancy rate was 8 to 13 percent. Almost all of the pregnancies that did not miscarry resulted in a live birth. A theoretical projection of the results of clomiphene induction of ovulation in 100 women concluded that 25 of the 100 would succeed in delivering a singleton healthy baby.",
"   </p>",
"   <p>",
"    The discrepancy between the ovulation and pregnancy rates may be partly explained by the peripheral antiestrogenic effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    on cervical mucus (impairing fertilization) and the endometrium (impairing implantation) or by hypersecretion of LH [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/39\">",
"     39",
"    </a>",
"    ]. High LH levels can compromise pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After six months of treatment, the pregnancy rate per cycle falls substantially despite regular ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/41\">",
"     41",
"    </a>",
"    ]. In addition, pregnancy rates are lower among women who ovulate only after receiving higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    . Failure to conceive despite ovulatory cycles, particularly at higher doses, may be due to clomiphene's antiestrogenic effects on the quantity and quality of cervical mucus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/3\">",
"     3",
"    </a>",
"    ] and on the endometrium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A hysterosalpingogram should be performed, if not already done, in any woman who fails to conceive within three to six treatment cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"     17",
"    </a>",
"    ]. Failure to conceive after a maximum of six ovulatory treatment cycles indicates a need to further evaluate for factors potentially causing infertility or to change to another treatment strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Pregnancy and perinatal outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The probability of multifetal pregnancy is increased: twins have been reported in 6.9 to 9 percent of pregnancies, triplets in 0.3 to 0.5 percent, quadruplets in 0.3 percent, and quintuplets in 0.13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/2,42\">",
"     2,42",
"    </a>",
"    ]. The risk may be reduced by ultrasound monitoring and withholding hCG, IUI, or intercourse if more than two follicles &gt;15 mm diameter are seen. Additional information on outcomes of multiple gestations is discussed elsewhere (see individual topic reviews on twins, triplets, and high order multiples).",
"   </p>",
"   <p>",
"    Most [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17,19,43-46\">",
"     17,19,43-46",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/47\">",
"     47",
"    </a>",
"    ] studies suggest that the frequencies of congenital malformations and spontaneous abortion are",
"    <strong>",
"     not",
"    </strong>",
"    increased in pregnancies after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report of 1034 pregnancies and 935 newborns after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      -induced ovulation [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/43\">",
"       43",
"      </a>",
"      ], spontaneous abortion and visible congenital malformations occurred in 14.2 and 2.3 percent, respectively, rates comparable to those in mothers who spontaneously ovulated.",
"     </li>",
"     <li>",
"      In contrast, a newer report by the National Birth Defects Prevention Study of the Centers for Disease Control examined 30 different birth defects in a multicenter case control study of deliveries between 1997 and 2005 [",
"      <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/47\">",
"       47",
"      </a>",
"      ]. The exposure of interest was",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate use for two months before conception through the first month of pregnancy. Several significant associations between clomiphene use and birth defects were observed, but because of the small number of cases in several categories and the inability to assess the effects of clomiphene separately from subfertility, these results should be interpreted with caution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rates of ectopic pregnancy are not increased with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/48\">",
"     48",
"    </a>",
"    ]. A specific association between clomiphene and hypospadias was suggested and refuted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence of developmental delays or learning disabilities in children whose mothers took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/49\">",
"     49",
"    </a>",
"    ]. Several studies have found a mildly increased risk of preterm birth in pregnancies (singleton and multiple) after assisted reproduction compared with natural pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/50-53\">",
"     50-53",
"    </a>",
"    ]. This effect has not been shown to be specific to clomiphene and is likely to be due, at least in part, to comorbidities in subfertile women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/54\">",
"     54",
"    </a>",
"    ], rather than the ovulation stimulation.",
"   </p>",
"   <p>",
"    There does not appear to be an increase in cancer risk in children conceived using ovulation induction drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link\">",
"     \"Overview of ovulation induction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=see_link\">",
"     \"Pregnancy outcome after assisted reproductive technology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     General",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    are not dose-related, as they can occur at the 50 mg dose. Uncomplicated ovarian enlargement develops in approximately 14 percent of women, but true ovarian hyperstimulation syndrome is rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of ovulation induction\", section on 'Multiple gestation and ovarian hyperstimulation syndrome (OHSS)'",
"    </a>",
"    .) We withhold clomiphene in women with ovarian enlargement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyst(s) until the ovaries return to pretreatment size. Ovarian enlargement can be assessed by symptoms and pelvic examination; routine ultrasound monitoring is unnecessary.",
"   </p>",
"   <p>",
"    Hot flashes are common, occurring in 10 to 20 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/32,55\">",
"     32,55",
"    </a>",
"    ]. They may result from hypoestrogenism at the hypothalamic level due to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    blockade of estrogen receptors. Additional problems related to the hyperestrogenic environment induced by clomiphene citrate include abdominal distention and pain (5.5 percent), nausea and vomiting (2.2 percent), and breast discomfort (2 percent). These symptoms abate soon after cessation of therapy.",
"   </p>",
"   <p>",
"    Visual symptoms, such as blurring, double vision,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scotomata, develop in 1 to 2 percent of women and are usually reversible. However, because they may persist, their onset warrants discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/56\">",
"     56",
"    </a>",
"    ]. They have been thought to represent retinal toxicity, but in one study of eight women with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -associated visual blurring or persistent afterimages, rechallenge appeared to affect the visual cortex rather than the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mood swings, depression, and headaches can also occur, but are rarely serious enough to consider terminating treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Luteal phase defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     Clomiphene",
"    </a>",
"    citrate, while used to improve luteal function, may also cause an iatrogenic luteal phase defect when used to induce ovulation in anovulatory women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/58\">",
"     58",
"    </a>",
"    ]. The mechanism may be related to antiestrogenic effects of clomiphene citrate on the endometrium or inhibition of steroidogenesis in granulosa and lutein cells. Increasing the dose of clomiphene does not correct the luteal phase defect. However, preovulatory hCG",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supplemental progesterone may prevent the problem. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Supplementary and alternative treatments'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ovarian cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of fertility drugs has been associated with neoplasia, particularly borderline ovarian tumors, in some, but not all, studies. In one series, the risk appeared to be only in women who had undergone more than 12 cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/38\">",
"     38",
"    </a>",
"    ]. The apparent association between fertility drug use and epithelial ovarian cancer appears to be related to the fact that these drugs are more likely to be used in infertile women, who are known to be at higher risk of developing ovarian cancer. This issue is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of ovulation induction\", section on 'Ovarian cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the observations that pregnancy rates are low after six cycles of treatment, and that 12 or more cycles may increase the risk of ovarian neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/38\">",
"     38",
"    </a>",
"    ], the American College of Obstetricians and Gynecologists has suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    treatment be limited to fewer than 12 cycles, and that the number of gonadotropin cycles be minimized, as well [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There does",
"    <strong>",
"     not",
"    </strong>",
"    appear to be an increased risk of breast cancer in women treated with fertility drugs. However, interpretation of the available data is limited by several factors, such as survey information, small subgroup numbers, lack of evaluation by drug",
"    <span class=\"nowrap\">",
"     type/dose",
"    </span>",
"    or cause of infertility, and confounding by the presence of other risk factors for breast cancer. Women taking infertility drugs can be reassured that these drugs probably do not increase their risk of breast cancer, although it is not clear whether some subgroups may be at increased risk. Further investigation is required. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H26#H26\">",
"     \"Overview of ovulation induction\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Uterine cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A retrospective cohort study including over 8000 women evaluated for infertility between 1965 and 1988 suggested there may be an association between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    use and development of uterine cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/59\">",
"     59",
"    </a>",
"    ]. Data from questionnaires and registries were used. The major findings from this study were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infertile study participants had a significantly higher risk of developing uterine cancer than women in the general population, standardized incidence ratio (SIR): 1.56 (95% CI 1.1-2.1).",
"     </li>",
"     <li>",
"      Infertile women who used",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      had a significantly higher risk of developing uterine cancer than women in the general population, SIR 2.14 (95% CI 1.3-3.3); however, infertile women who did not use clomiphene were not at significantly increased risk: SIR 1.24 (95% CI 0.8-1.9).",
"     </li>",
"     <li>",
"      The relative risk of uterine cancer was not significantly increased for infertile users compared with infertile nonusers: RR 1.79 (95% CI 0.9-3.4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relatively small number of uterine cancers and incomplete ascertainment of cases preclude a definite conclusion regarding uterine cancer risk. This study does not provide sufficient evidence to change current recommendations for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=see_link\">",
"     \"Endometrial carcinoma: Epidemiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUPPLEMENTARY AND ALTERNATIVE TREATMENTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461342\">",
"    <span class=\"h2\">",
"     Hypocaloric diet and exercise training",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one trial, women with PCOS who were resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    were randomized to a hypocaloric diet plus exercise for six weeks, or a clomiphene cycle without diet or exercise, or a combination of a hypocaloric diet plus exercise for six weeks followed by a clomiphene cycle. The women who received a diet and exercise followed by clomiphene had a higher ovulation rate than the other two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Modified regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate (200 to 250 mg daily) may be given for 8 to 10 days in women who are refractory to standard doses. This extended regimen of clomiphene is particularly well suited for women who cannot receive exogenous gonadotropins, but the overall experience is limited and the dose exceeds current FDA recommendations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"     \"Strategies for improving the efficacy of clomiphene induction of ovulation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Human chorionic gonadotropin",
"    </span>",
"    &nbsp;&mdash;&nbsp;An absent or inadequate midcycle LH surge may result in a failure to ovulate or a short luteal phase, despite",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -induced follicular development. In this situation, exogenous hCG (single dose 10,000 IU IM) may be added to the regimen. It is given when transvaginal ultrasonography (TVS) shows that the leading follicle has reached 18 to 20 mm in diameter [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/61\">",
"     61",
"    </a>",
"    ]. It should be noted that premature administration of hCG acts like a premature LH surge and may result in follicular atresia.",
"   </p>",
"   <p>",
"    In many institutions, hCG is routinely used to induce ovulation and to time intrauterine insemination. However, routine administration of exogenous hCG is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for women in whom an endogenous LH surge can be detected, as it does not enhance the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -IUI treatment in these women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17,23,62-64\">",
"     17,23,62-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A progressive rise in the serum estradiol concentration is also evidence for advancing follicular development and maturation, but serial TVS to monitor follicle size is superior and should be used to time hCG administration. Ovulation occurs approximately 36 to 44 hours after the injection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dopamine agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a dopamine agonist is needed to lower the serum prolactin concentration to permit ovulation, either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/2/7206?source=see_link\">",
"     cabergoline",
"    </a>",
"    is effective. Bromocriptine has the advantage of the greater certainty that it does not cause birth defects, but cabergoline has the advantage that it is more likely to be tolerated and more likely to be effective in lowering the prolactin. Of note, cabergoline also appears to be safe when used for infertility in women with hyperprolactinemic anovulation, but there are still fewer observed pregnancies with the drug when compared with bromocriptine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41510?source=see_link&amp;anchor=H103131441#H103131441\">",
"     \"Management of lactotroph adenoma (prolactinoma) during pregnancy\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dopamine agonists (specifically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    ) have also been tried in women with normal serum prolactin and no galactorrhea who have failed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    therapy. However, there is only anecdotal evidence to support its use in this setting. The addition of bromocriptine to clomiphene is no more effective than clomiphene alone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H33#H33\">",
"     \"Overview of ovulation induction\", section on 'Dopamine agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Infertility in PCOS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese anovulatory women with polycystic ovary syndrome (PCOS) and hyperinsulinemia are sometimes unresponsive to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    treatment. Weight loss (5 to 10 percent) alone or in combination with exercise is associated with reduced hyperinsulinemia and hyperandrogenism and a high rate of resumption of ovulation. Other options include laparoscopic ovarian drilling, gonadotropins, and combination therapy (addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , etc) (",
"    <a class=\"graphic graphic_table graphicRef56718 \" href=\"UTD.htm?4/36/4684\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/65\">",
"     65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of polycystic ovary syndrome in adults\", section on 'Ovulation induction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Metformin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with PCOS and ovulatory infertility are insulin resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=see_link\">",
"     \"Clinical manifestations of polycystic ovary syndrome in adults\"",
"    </a>",
"    .) In these women, elevated insulin secretion may directly stimulate ovarian androgen secretion and result in anovulation. Reducing insulin secretion with an insulin sensitizing agent such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    may lower ovarian androgen secretion and increase the rate of spontaneous ovulation. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    is currently recommended as the first-line drug for ovulation induction in women with PCOS. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Dexamethasone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anovulatory women in WHO group 2 appear to have reduced ovulation and pregnancy rates when they are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    . Some studies suggested that treatment with clomiphene plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or pretreatment with oral contraceptives improved pregnancy rates in these women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=see_link\">",
"     \"Strategies for improving the efficacy of clomiphene induction of ovulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a consensus statement from the American Society for Reproductive Medicine and the European Society for Human Reproduction and Embryology suggests that combination therapies such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    plus clomiphene not be used. They recommend that if clomiphene therapy is unsuccessful, the next step should be exogenous gonadotropin therapy or laparoscopic ovarian surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/65\">",
"     65",
"    </a>",
"    ]. In contrast, a Cochrane review supports the use of dexamethasone plus clomiphene in clomiphene-resistant women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, a patient's values and preferences should play an important role in determining treatment options. Therefore, for patients who place a high value on avoiding multiple gestations, ovarian hyperstimulation, or potential surgical complications, it is reasonable to offer additional attempts at ovulation induction with combination medical therapy (",
"    <a class=\"graphic graphic_table graphicRef56718 \" href=\"UTD.htm?4/36/4684\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Ovarian drilling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic ovarian drilling may be considered in women with PCOS who fail to ovulate despite an adequate trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17,65\">",
"     17,65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=see_link\">",
"     \"Laparoscopic surgery for ovulation induction in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Aromatase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential role of aromatase inhibitors in ovulation induction is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=see_link\">",
"     \"Ovulation induction with aromatase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H461387\">",
"    <span class=\"h3\">",
"     Tamoxifen and raloxifene",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    , like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    , is a selective estrogen receptor modulator. Tamoxifen has been used as an ovulation induction agent, but clomiphene therapy resulted in a higher ovulation rate in one randomized trial (64 versus 52 percent for clomiphene and tamoxifen, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/66\">",
"     66",
"    </a>",
"    ]. Clomiphene treatment was also associated with more pregnancies than tamoxifen treatment (19 versus 11 percent). In a second trial, clomiphene and raloxifene were similarly effective in inducing ovulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Alpha-glucosidase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/10/44197?source=see_link\">",
"     acarbose",
"    </a>",
"    (an alpha-glucosidase inhibitor) to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    therapy in clomiphene-resistant women may result in an improvement in ovulatory rates. However, in one trial, acarbose was not as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/68\">",
"     68",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=see_link\">",
"     \"Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Gonadotropins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    -resistant women, another option is sequential therapy with a standard clomiphene citrate regimen (50 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    cycle days 5 to 9) followed by low dose gonadotropins (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12565?source=see_link\">",
"     menotropins",
"    </a>",
"    [hMG] or recombinant FSH) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"     17",
"    </a>",
"    ]. Combination treatment may be safer and is less costly, but not more effective than gonadotropins given alone. This therapy should be administered by clinicians with relevant expertise because of the high costs and risk of complications. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of ovulation induction\", section on 'Gonadotropin therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate as the first line ovulation induction therapy for women with oligoovulation or anovulation who are normogonadotropic, normoprolactinemic, and euthyroid (eg, PCOS) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). It is also recommended as initial therapy for those with unexplained infertility or luteal phase defect. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       Clomiphene",
"      </a>",
"      is initially begun on cycle day 3 to 5 at a dose of 50 mg daily for five days. If ovulation does not occur in the first cycle of treatment, the dose is increased to 100 mg. Thereafter, the dose is increased by increments of 50 mg to a maximum daily dose of 150 mg until ovulation is achieved. The couple is advised to have intercourse every other day for one week beginning five days after the last day of medication. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'How to use clomiphene citrate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The response to treatment may be monitored using a basal body temperature chart",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      midluteal serum progesterone concentration (greater than 3",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      is suggestive of ovulation). Serial transvaginal ultrasound may also be used, although it increases the cost without having a significant effect on pregnancy rates. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Further evaluation or change in therapy is indicated for women who do not conceive after having six ovulatory cycles. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Initiation of therapy and dose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risks and complications should be discussed. The most common of these are hot flashes (10 to 20 percent), uncomplicated ovarian enlargement (14 percent), and multiple gestation (primarily twins, &lt;10 percent). True ovarian hyperstimulation is rare. Less frequent side effects include abdominal distention and pain,",
"      <span class=\"nowrap\">",
"       nausea/vomiting,",
"      </span>",
"      breast discomfort, visual symptoms, mood swings, and headaches. Visual symptoms warrant discontinuation of therapy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exogenous hCG (single dose 10,000 IU IM) is indicated in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      -resistant women who have an absent or inadequate midcycle LH surge. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Human chorionic gonadotropin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In couples with unexplained infertility, intrauterine insemination should be added to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      therapy to optimize chances of conception. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Unexplained infertility'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/1\">",
"      Glasier AF, Irvine DS, Wickings EJ, et al. A comparison of the effects on follicular development between clomiphene citrate, its two separate isomers and spontaneous cycles. Hum Reprod 1989; 4:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/2\">",
"      Dickey RP, Holtkamp DE. Development, pharmacology and clinical experience with clomiphene citrate. Hum Reprod Update 1996; 2:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/3\">",
"      Kettel LM, Roseff SJ, Berga SL, et al. Hypothalamic-pituitary-ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertil Steril 1993; 59:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/4\">",
"      Jorgensen SE, Starup J, Roos J, Micic S. Studies on the mode of action of clomiphene citrate. Acta Obstet Gynecol Scand 1976; 55:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/5\">",
"      Kerin JF, Liu JH, Phillipou G, Yen SS. Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab 1985; 61:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/6\">",
"      Hsueh AJ, Erickson GF, Yen SS. Sensitisation of pituitary cells to luteinising hormone releasing hormone by clomiphene citrate in vitro. Nature 1978; 273:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/7\">",
"      Kessel B, Hsueh AJ. Clomiphene citrate augments follicle-stimulating hormone-induced luteinizing hormone receptor content in cultured rat granulosa cells. Fertil Steril 1987; 47:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/8\">",
"      Eden JA, Place J, Carter GD, et al. The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Obstet Gynecol 1989; 73:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/9\">",
"      Dehbashi S, Parsanezhad ME, Alborzi S, Zarei A. Effect of clomiphene citrate on endometrium thickness and echogenic patterns. Int J Gynaecol Obstet 2003; 80:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/10\">",
"      Bonhoff AJ, Naether OG, Johannisson E. Effects of clomiphene citrate stimulation on endometrial structure in infertile women. Hum Reprod 1996; 11:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/11\">",
"      Sereepapong W, Suwajanakorn S, Triratanachat S, et al. Effects of clomiphene citrate on the endometrium of regularly cycling women. Fertil Steril 2000; 73:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/12\">",
"      Li TC, Warren MA, Murphy C, et al. A prospective, randomised, cross-over study comparing the effects of clomiphene citrate and cyclofenil on endometrial morphology in the luteal phase of normal, fertile women. Br J Obstet Gynaecol 1992; 99:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/13\">",
"      Thomson JL. Effect of two non-steroidal antifertility agents on pregnancy in mice. II. Effects on tubal transport rate and implantation. J Reprod Fertil 1968; 16:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/14\">",
"      Thompson LA, Barratt CL, Thornton SJ, et al. The effects of clomiphene citrate and cyclofenil on cervical mucus volume and receptivity over the periovulatory period. Fertil Steril 1993; 59:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/15\">",
"      Gelety TJ, Buyalos RP. The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles. Fertil Steril 1993; 60:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/16\">",
"      Roumen FJ. [Decreased quality of cervix mucus under the influence of clomiphene: a meta-analysis]. Ned Tijdschr Geneeskd 1997; 141:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/17\">",
"      Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in women. Fertil Steril 2003; 80:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/18\">",
"      Gorlitsky GA, Kase NG, Speroff L. Ovulation and pregnancy rates with clomiphene citrate. Obstet Gynecol 1978; 51:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/19\">",
"      Gysler M, March CM, Mishell DR Jr, Bailey EJ. A decade's experience with an individualized clomiphene treatment regimen including its effect on the postcoital test. Fertil Steril 1982; 37:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/20\">",
"      Kousta E, White DM, Franks S. Modern use of clomiphene citrate in induction of ovulation. Hum Reprod Update 1997; 3:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/21\">",
"      Glasier AF. Clomiphene citrate. Baillieres Clin Obstet Gynaecol 1990; 4:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/22\">",
"      Imani B, Eijkemans MJ, te Velde ER, et al. Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligoamenorrheic infertility. J Clin Endocrinol Metab 1999; 84:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/23\">",
"      Brown J, Farquhar C, Beck J, et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 2009; :CD002249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/24\">",
"      Guzick DS, Sullivan MW, Adamson GD, et al. Efficacy of treatment for unexplained infertility. Fertil Steril 1998; 70:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/25\">",
"      Reindollar RH, Regan MM, Neumann PJ, et al. A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial. Fertil Steril 2010; 94:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/26\">",
"      Glazener CM, Coulson C, Lambert PA, et al. Clomiphene treatment for women with unexplained infertility: placebo-controlled study of hormonal responses and conception rates. Gynecol Endocrinol 1990; 4:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/27\">",
"      Deaton JL, Gibson M, Blackmer KM, et al. A randomized, controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril 1990; 54:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/28\">",
"      Arici A, Byrd W, Bradshaw K, et al. Evaluation of clomiphene citrate and human chorionic gonadotropin treatment: a prospective, randomized, crossover study during intrauterine insemination cycles. Fertil Steril 1994; 61:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/29\">",
"      Hughes E, Collins J, Vandekerckhove P. Clomiphene citrate for unexplained subfertility in women. Cochrane Database Syst Rev 2000; :CD000057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/30\">",
"      Bohnet HG, Kato K, Trapp M, et al. Different hormonal patterns in human menopausal gonadotropin-treated, clomiphene citrate-treated, and untreated conception cycles. Fertil Steril 1986; 45:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/31\">",
"      Wu CH, Winkel CA. The effect of therapy initiation day on clomiphene citrate therapy. Fertil Steril 1989; 52:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/32\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists number 34, February 2002. Management of infertility caused by ovulatory dysfunction. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002; 99:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/33\">",
"      Lobo RA, Gysler M, March CM, et al. Clinical and laboratory predictors of clomiphene response. Fertil Steril 1982; 37:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/34\">",
"      Rostami-Hodjegan A, Lennard MS, Tucker GT, Ledger WL. Monitoring plasma concentrations to individualize treatment with clomiphene citrate. Fertil Steril 2004; 81:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/35\">",
"      O'Herlihy C, De Crespigny LJ, Robinson HP. Monitoring ovarian follicular development with real-time ultrasound. Br J Obstet Gynaecol 1980; 87:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/36\">",
"      Miller PB, Soules MR. The usefulness of a urinary LH kit for ovulation prediction during menstrual cycles of normal women. Obstet Gynecol 1996; 87:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/37\">",
"      Smith YR, Randolph JF Jr, Christman GM, et al. Comparison of low-technology and high-technology monitoring of clomiphene citrate ovulation induction. Fertil Steril 1998; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/38\">",
"      Rossing MA, Daling JR, Weiss NS, et al. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994; 331:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/39\">",
"      Homburg R. Clomiphene citrate--end of an era? A mini-review. Hum Reprod 2005; 20:2043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/40\">",
"      Shoham Z, Borenstein R, Lunenfeld B, Pariente C. Hormonal profiles following clomiphene citrate therapy in conception and nonconception cycles. Clin Endocrinol (Oxf) 1990; 33:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/41\">",
"      Macgregor AH, Johnson JE, Bunde CA. Further clinical experience with clomiphene citrate. Fertil Steril 1968; 19:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/42\">",
"      Scialli AR. The reproductive toxicity of ovulation induction. Fertil Steril 1986; 45:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/43\">",
"      Kurachi K, Aono T, Minagawa J, Miyake A. Congenital malformations of newborn infants after clomiphene-induced ovulation. Fertil Steril 1983; 40:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/44\">",
"      Dickey RP, Taylor SN, Curole DN, et al. Incidence of spontaneous abortion in clomiphene pregnancies. Hum Reprod 1996; 11:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/45\">",
"      S&oslash;rensen HT, Pedersen L, Skriver MV, et al. Use of clomifene during early pregnancy and risk of hypospadias: population based case-control study. BMJ 2005; 330:126.",
"     </a>",
"    </li>",
"    <li>",
"     REPROTOX: An information system on environmental hazards to human reproduction and development. Agent #1242 www.reprotox.org (Accessed on August 20, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/47\">",
"      Reefhuis J, Honein MA, Schieve LA, et al. Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997-2005. Hum Reprod 2011; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/48\">",
"      Dickey RP, Matis R, Olar TT, et al. The occurrence of ectopic pregnancy with and without clomiphene citrate use in assisted and nonassisted reproductive technology. J In Vitro Fert Embryo Transf 1989; 6:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/49\">",
"      Hack M, Brish M, Serr DM, et al. Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy. JAMA 1972; 220:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/50\">",
"      Lambalk CB, van Hooff M. Natural versus induced twinning and pregnancy outcome: a Dutch nationwide survey of primiparous dizygotic twin deliveries. Fertil Steril 2001; 75:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/51\">",
"      Olivennes F, Rufat P, Andr&eacute; B, et al. The increased risk of complication observed in singleton pregnancies resulting from in-vitro fertilization (IVF) does not seem to be related to the IVF method itself. Hum Reprod 1993; 8:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/52\">",
"      Pregnancies and births resulting from in vitro fertilization: French national registry, analysis of data 1986 to 1990. FIVNAT (French In Vitro National). Fertil Steril 1995; 64:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/53\">",
"      K&auml;ll&eacute;n B, Olausson PO, Nygren KG. Neonatal outcome in pregnancies from ovarian stimulation. Obstet Gynecol 2002; 100:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/54\">",
"      Gaudoin M, Dobbie R, Finlayson A, et al. Ovulation induction/intrauterine insemination in infertile couples is associated with low-birth-weight infants. Am J Obstet Gynecol 2003; 188:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/55\">",
"      Jones GS, De Moraes-Ruehsen M. Induction of ovulation with human gonadotropins and with clomiphene. Fertil Steril 1965; 16:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/56\">",
"      Purvin VA. Visual disturbance secondary to clomiphene citrate. Arch Ophthalmol 1995; 113:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/57\">",
"      Racette L, Casson PR, Claman P, et al. An investigation of the visual disturbances experienced by patients on clomiphene citrate. Fertil Steril 2010; 93:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/58\">",
"      Keenan JA, Herbert CM, Bush JR, Wentz AC. Diagnosis and management of out-of-phase endometrial biopsies among patients receiving clomiphene citrate for ovulation induction. Fertil Steril 1989; 51:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/59\">",
"      Althuis MD, Moghissi KS, Westhoff CL, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 2005; 161:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/60\">",
"      Palomba S, Falbo A, Giallauria F, et al. Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial. Hum Reprod 2010; 25:2783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/61\">",
"      O'Herlihy C, Pepperell RJ, Robinson HP. Ultrasound timing of human chorionic gonadotropin administration in clomiphene-stimulated cycle. Obstet Gynecol 1982; 59:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/62\">",
"      Deaton JL, Clark RR, Pittaway DE, et al. Clomiphene citrate ovulation induction in combination with a timed intrauterine insemination: the value of urinary luteinizing hormone versus human chorionic gonadotropin timing. Fertil Steril 1997; 68:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/63\">",
"      Zreik TG, Garc&iacute;a-Velasco JA, Habboosh MS, et al. Prospective, randomized, crossover study to evaluate the benefit of human chorionic gonadotropin-timed versus urinary luteinizing hormone-timed intrauterine inseminations in clomiphene citrate-stimulated treatment cycles. Fertil Steril 1999; 71:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/64\">",
"      Kosmas IP, Tatsioni A, Fatemi HM, et al. Human chorionic gonadotropin administration vs. luteinizing monitoring for intrauterine insemination timing, after administration of clomiphene citrate: a meta-analysis. Fertil Steril 2007; 87:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/65\">",
"      Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 2008; 89:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/66\">",
"      Badawy A, Gibreal A. Clomiphene citrate versus tamoxifen for ovulation induction in women with PCOS: a prospective randomized trial. Eur J Obstet Gynecol Reprod Biol 2011; 159:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/67\">",
"      de Paula Guedes Neto E, Savaris RF, von Eye Corleta H, et al. Prospective, randomized comparison between raloxifene and clomiphene citrate for ovulation induction in polycystic ovary syndrome. Fertil Steril 2011; 96:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/25/9626/abstract/68\">",
"      S&ouml;nmez AS, Yasar L, Savan K, et al. Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. Hum Reprod 2005; 20:175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7400 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9626=[""].join("\n");
var outline_f9_25_9626=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISMS OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Hypothalamus and pituitary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ovary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Uterus and cervix",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Oligoovulation or anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Controlled superovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      HOW TO USE CLOMIPHENE CITRATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pretreatment evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Initiation of therapy and dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1121988288\">",
"      - Ovarian enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1121988228\">",
"      Number of cycles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RESULTS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Pregnancy and perinatal outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      General",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Luteal phase defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Uterine cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUPPLEMENTARY AND ALTERNATIVE TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H461342\">",
"      Hypocaloric diet and exercise training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Modified regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Human chorionic gonadotropin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dopamine agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Infertility in PCOS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Metformin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Dexamethasone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Ovarian drilling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H461387\">",
"      - Tamoxifen and raloxifene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Alpha-glucosidase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Gonadotropins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/15/29947\" title=\"table 1\">",
"      WHO Classification of anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/43/6843\" title=\"table 2\">",
"      Fecundity with clomiphene treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/47/2811\" title=\"table 3\">",
"      Tests of anovulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/36/4684\" title=\"table 4\">",
"      Multistep approach treatment infertility PCOS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/0/3078?source=related_link\">",
"      Alpha-glucosidase inhibitors and lipase inhibitors for treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16490?source=related_link\">",
"      Clinical manifestations of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/27/18874?source=related_link\">",
"      Endometrial carcinoma: Epidemiology and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/6/26724?source=related_link\">",
"      Evaluation of the menstrual cycle and timing of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=related_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=related_link\">",
"      Management of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/34/41510?source=related_link\">",
"      Management of lactotroph adenoma (prolactinoma) during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/56/17287?source=related_link\">",
"      Overview of infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13482?source=related_link\">",
"      Overview of ovulation induction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/6/4201?source=related_link\">",
"      Ovulation induction with aromatase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/2/27685?source=related_link\">",
"      Physiology of the normal menstrual cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16487?source=related_link\">",
"      Strategies for improving the efficacy of clomiphene induction of ovulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3610?source=related_link\">",
"      Treatment of male infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25496?source=related_link\">",
"      Unexplained infertility",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_25_9627="Physical findings ETOH abuse";
var content_f9_25_9627=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82583&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical findings in alcohol abuse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Abdominal wall collaterals (caput medusa)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous telangiectasias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Digital clubbing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Disheveled appearance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dupuytren's contractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gynecomastia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jaundice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palmar erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Splenomegaly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Testicular atrophy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9627=[""].join("\n");
var outline_f9_25_9627=null;
var title_f9_25_9628="Acidosis and K distribution";
var content_f9_25_9628=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F68866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F68866&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ion redistribution after acid load",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 275px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of an HCl load on the distribution of Cl, Na, and K. As H enters the cells to be buffered, intracellular Na and K leave the cells and move into the extracellular fluid, tending to raise the plasma potassium concentration. These ion shifts are reversed when H ions are removed from the extracellular fluid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9628=[""].join("\n");
var outline_f9_25_9628=null;
var title_f9_25_9629="Polyglandular autoimmune syndromes";
var content_f9_25_9629=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F67520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F67520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of endocrine and nonendocrine autoimmune syndromes associated with adrenal insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Polyglandular autoimmune syndrome type I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypoparathyroidism",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        89",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic mucocutaneous candidiasis",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Adrenal insufficiency",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Primary hypogonadism",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypothyroidism",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Type 1 diabetes mellitus",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Hypopituitarism",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diabetes insipidus",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Nonendocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Malabsorption syndromes",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Alopecia totalis or areata",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pernicious anemia",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chronic active hepatitis",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vitiligo",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Polyglandular autoimmune syndrome type II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Endocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Adrenal insufficiency",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Autoimmune thyroid disease",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Type 1 diabetes mellitus",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Primary hypogonadism",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        5 to 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Diabetes insipidus",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        &lt;1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"2\">",
"        Nonendocrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Vitiligo",
"       </td>",
"       <td class=\"sublist_other_start_centered\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Alopecia, pernicious anemia, myasthenia gravis, immune thrombocytopenia purpura, Sjogren's syndrome, rheumatoid arthritis",
"       </td>",
"       <td class=\"sublist_other_centered\">",
"        &le;1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Leshin M. Polyglandular autoimmune syndromes. Am J Med Sci 1985; 290:77.",
"      </li>",
"      <li>",
"       Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine (Baltimore) 1981; 60:355.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9629=[""].join("\n");
var outline_f9_25_9629=null;
var title_f9_25_9630="Dyspnea post LVRS";
var content_f9_25_9630=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Respondent score changes in modified Medical Research Council dyspnea scale after LVRS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 282px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ciccone, AM, Meyers, BR, Guthrie, TJ, et al. Long-term outcome of bilateral lung volume reduction in 250 consecutive patients with emphysema. J Thor Card Surg 2003; 125:513.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9630=[""].join("\n");
var outline_f9_25_9630=null;
var title_f9_25_9631="Toddlers fracture tibia";
var content_f9_25_9631=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nondisplaced toddler's fracture of the distal tibia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This plain AP radiograph shows the characteristic faint fracture line indicating a nondisplaced spiral fracture (between black hash marks).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eglal Shalaby-Rana, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_25_9631=[""].join("\n");
var outline_f9_25_9631=null;
